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ABSTRACT

DISCOVERY OF PYRIMIDINE-BASED HETEROCYCLES AS SINGLE AGENTS WITH
COMBINATION CHEMOTHERAPY POTENTIAL AND AS INHIBITORS OF PURINE
NUCLEOTIDE BIOSYNTHESIS FOR THE TREATMENT OF CANCER

By
Rishabh Mohan
December 2017

Dissertation supervised by Professor Aleem Gangjee
This dissertation describes the design, synthesis and biological evaluation of monocyclic and
bicyclic pyrimidine-base heterocycles as single agents with combination chemotherapy potential
having both antiangiogenic effects and cytotoxic effects. This dissertation also describes selective
tumor targeting with 5-substituted pyrrolo[2,3-d]pyrimidines analogs with heteroatom bridge
substitution as GARFTase inhibitors.
The work in this dissertation is centered on identifying structural features that are necessary for
inhibition of tubulin polymerization as well as for inhibition of one or more of the receptor tyrosine
kinases (RTKs)- vascular endothelial growth factor receptor-2 (VEGFR2), platelet derived growth
factor receptor-β (PDGFRβ) and epidermal growth factor receptor (EGFR) in single entities.
Single agents with both antiangiogenic activities as well as cytotoxicity would afford agents that
circumvent pharmacokinetic problems of multiple agents, avoid drug-drug interactions, could be
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used at lower doses to alleviate toxicity, be devoid of overlapping toxicities, and delay or prevent
tumor cell resistance.
This work reviews the synthesis of substituted monocyclic pyrimidines as well as pyrrolo[2, 3d]pyrimidines. This work also reviews the synthesis of multi-transporter (PCFT and FR) selective
5-substituted pyrrolo[2, 3-d]pyrimidines as GARFTase inhibitors circumventing both doselimiting toxicity and tumor resistance associated with most prescribed antitumor agents like
pemetrexed.
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I.

BIOLOGICAL REVIEW

A. Microtubules
Cytoskeletal protein polymers which include microfilaments (actin proteins), intermediate
filaments (various proteins e.g. desmin, peripherin, keratin) and microtubules (tubulin
proteins) are crucial for cytoskeletal function and provide mechanical support and
resistance against physical stress. Microtubule targeting agents (MTAs) affect interphase
cells significantly by disrupting transcription, translation, axonal transport, mitochondrial
permeability, immune cell function, directional migration and centrosome clustering
(Figure 1).1 In interphase cells, MTA treatment perturbs microtubule dynamicity as well as
significantly disturbs interphase intracellular trafficking of protein and nucleic acid cargo
in various types of cancer cells.2 For this reason, MTAs that interfere with these processes
possess potent inhibitory activities against a wide variety of tumors.3 Drugs targeting
microtubules have been highly successful in the clinic and have been integrated into
therapeutic regimens against both solid tumors (e.g., breast, ovarian, non-small-cell lung
cancer, and Kaposi’s sarcoma) and hematological malignancies (non-Hodgkin's
lymphomas).4-5
Microtubules are assembled in polarized arrays during the G1-, S-, and G2-phases (Figure
2)2 with their (+) end pointing outward from the center and the (−) end is nucleated by the
centrosome. These move to the two opposite sides of the cell during the mitosis phase,
forming the mitotic spindle.

1

A.1 Structures of Microtubules
Microtubule/tubulin is one of the most important and promising targets in cancer therapy.6
Microtubules are tube-like protein filamentous fibers made of individual tubulin dimers.
The tubulin heterodimer consists of one α- and one β-tubulin subunit (molecular weight =
50 kDa).5 Tubulin dimers polymerize in a “head-to-tail” fashion between the α- and βtubulin to form protofilaments which further arrange in parallel to form a hollow cylindrical
microtubule

Figure 1. Interphase activities of MTAs (modified from ref. 1)

2

(a) Centrosome clustering. (b) voltage-dependent anion channel opening (c) disruption of
delivery of mRNA along interphase microtubule tracks to polysomes and (d) induce
mRNA release from polysomes. (e) improve MHC class I expression by cancer cells
(f) activation of dendritic cells, (g) cytotoxic T lymphocytes and (h) macrophages (i)
impede vesicular traffic to the cell front (j) timely endocytosis of focal adhesion
components (k) interference with transcription factor transport (l) up- or down-regulation
of tumor suppressor or oncogenes, respectively.

Figure 2. Microtubules organization during the cell cycle (modified from ref. 2).

3

structure (Figure 3). Each α- and β-tubulin heterodimer structure includes two GTP
molecules, one of which is tightly bound and the other bound GTP molecule is freely
exchangeable with unbound GTP. The non-exchangeable GTP is bound to α-tubulin,
whereas GTP and GDP are exchangeable on β-tubulin. GTP which is exchangable is highly
involved in the regulation of various functions of tubulin. Hydrolysis of GTP is necessary
for microtubule depolymerization and binding of GTP is required for microtubule
polymerization.7

Figure 3. A. Cervical cancer HeLa cell with individual microtubule filaments stained
green and nucleus stained red. B. and C. arrangement of 13 protofilaments. D. atomic-

4

resolution model of a 13 protofilament microtubule. E. apical side view of this model
(modified from ref. 7)
Microtubule associated proteins (MAPs) impact protein–microtubule interactions,
microtubule cross-linking and overall microtubule stability. The fast growing plus end
probes the cytoplasm in a search-and capture process to reach different targets but the slow
growing minus end is anchored at the microtubule organizing center.3

A.2 Microtubule Dynamics
Microtubule dynamics are responsible for the functional role of microtubules in cells
and are very tightly regulated.3 MAPs, kinases, phosphatases and nucleotides regulate these
dynamics. Microtubule dynamics, if disturbed, can have serious consequences on the fate
of a cell and therefore, disruption of microtubule dynamics is a very important strategy to
develop anticancer agents.8 Tubulin polymerization involves slow formation of a short
microtubule nucleus which is followed by a rapid phase of microtubule elongation through
reversible and non-covalent addition of αβ-tubulin heterodimers. GTP binding to β-tubulin
favors a dimer conformation that promotes polymerization.9 Upon the attachment of the
GTP-bound tubulin dimer to the ends of the microtubule, GTP hydrolysis occurs, which
further drives polymerization forming tubulin–GDP with the release of Pi which provides
energy for the addition of a dimer.

5

Figure 4. A. Treadmilling of a microtubule, whereby tubulin dimers are added to the
positive end of the microtubule. B. End view of atomic-resolution microtubule model. C.
a side apical perspective. (modified from ref.7)

The presence of a GTP cap i.e. GTP or GDP with unreleased phosphate (GDP-Pi). at the
end of the microtubule, stabilizes the open-sheet conformation of the growing microtubule
plus end, and thus lengthens the microtubule. The GTP cap prevents shrinkage of the
microtubule and the microtubule end shortens rapidly after loss of the GTP cap.10
Two major forms of non-equilibrium dynamics occur in vitro and in cells, namely dynamic
instability and treadmilling (Figure 4).4 Dynamic instability (Figure 5) is the switching of
microtubules between phases of lengthening and shortening, and is defined by some
factors:9, 11 1) the rate of growth and shrinkage 2) The transition from a growth or a pause
state to a shortening phase (“catastrophe”) 3) The transition from a shortening phase to a

6

growth or a pause state (“rescue”). Another kind of microtubule dynamics behavior is
treadmilling (Figure 6). This process is characterized by net growth at one end and balanced
equivalent shortening at the opposite end.

Figure 5. Microtubule growth and shrinkage (modified from ref. 12)

Figure 6. Microtubule treadmilling (modified from ref. 13)
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A.3 Microtubule Binding Agents: On the basis of their effects on microtubule stability
they are classified as follows.7, 14
1) Microtubule-destabilizing agents include natural products such as the Vinca alkaloids,
estramustine, colchicine and its analogs and combretastatin. They inhibit microtubule
polymerization and so, promote microtubule disassembly.7
2) Microtubule-stabilizing agents include paclitaxel, docetaxel, epothilones and
discodermolide. These agents induce microtubule polymerization and so, promote
microtubule assembly.

Microtubule binding agents can also be classified by their binding sites on tubulin.14
1) The Vinca alkaloids including vinblastine, vincristine, vindesine, and vinorelbine and
bind to the β-subunit of soluble tubulin heterodimers (Figure 7)15 and have been widely
used in cancer chemotherapy for the treatment of leukemias, lymphomas, small cell lung
cancer, and other cancers. The rapid and reversible binding of vinblastine to soluble tubulin
induces a conformational change that prevents integration of the dimer into the
microtubule.16

8

Figure 7. Vinca binding site and representative vinca alkaloids (modified from ref. 14)
2) Taxanes and Epothilones

Figure 8. Taxane binding site and representative taxanes (modified from ref. 14)

9

The second class of antimitotics, the taxanes, are exemplified by paclitaxel and
docetaxel which bind poorly to soluble tubulin, but bind strongly to tubulin along the length
of the microtubule.17 The binding site for paclitaxel is on the inside surface of the β-subunit
of the microtubule (Figure 8).15,

18

Paclitaxel induces an increase in microtubule

polymerization, thereby interfering with spindle microtubule dynamics and are termed as
microtubule-stabilizing agents or polymerizing agents.19 The taxanes are widely used for
breast cancer, ovarian cancer, non-small cell lung cancer, and Kaposi`s sarcoma.
Ixabepilone was approved for the treatment of drug-refractory metastatic breast cancer in
2007.18
3) Colchicine binding site agents
The third class is typified by colchicine binding site agents include podophyllotoxin,
combretastatins and flavonols. Colchicine produces toxicity at doses that produce
antimitotic effects, and so, is not used clinically in cancer treatment.20 The colchicine
binding site is on β-tubulin at the interface between α- and β- tubulins (Figure 9).15

Figure 9. Colchicine binding site and combreatastatins (modified from ref. 14)
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Combretastain A4 (CA4) is a potent vascular-disrupting agents (VDA) in addition to
microtubule targeting agent (MTAs).21-22 CA4 and CA4P have been developed as
antivascular agents for clinical trials. Combretastatins also inhibit angiogenesis, and so,
have been used to target target tumor vasculature selectively as an alternative to the
conventional chemotherapy.7
4. Additional binding sites: Several MTAs such as discodermolide,23 noscapine,24
laulimalide,25 and estramustine7 show potent microtubule inhibitory effects but do not bind
to the above mentioned three sites on tubulin.15, 18

A.4 Resistances to microtubule-binding agents- overexpression of Pgp and increased
levels of βIII-tubulin.
Multiple-drug resistance (MDR) is a one of the biggest causes of cancer chemotherapy
failure, which includes the failure of microtubule-binding agents.5, 17, 26 Among different
resistance mechanisms for this category of drugs, the most clinically significant are
structural alteration of the microtubules and drug efflux by ATP binding cassette (ABC)
proteins.27-28 The increased efflux of hydrophobic cytotoxic drugs that is mediated by one
family of energy-dependent transporters (e.g., P-glycoprotein (Pgp)).29 In Pgpoverexpressing SK-OV-3 MDR-1-6/6 cell lines, it is observed that the potency of paclitaxel
was reduced by 800-fold versus parental cell lines.30 Interestingly, the combination of
microtubule-binding agents with Pgp inhibitors failed to reverse resistance in clinical
trials.31 Another concern is increased levels of βIII-tubulin which is a major cause of
clinical resistance against taxanes in lung, breast and ovarian cancers.32-33 The potency of

11

paclitaxel decreases by five-fold in HeLa cells when they were adapted to express βIIItubulin.34 βIII-tubulin also causes resistance against a wide range of drugs with different
mechanisms of action.35
B. Angiogenesis
Agiogenesis is the process of formation of new blood vessels from existing vascular beds.36
It involves a complex cascade of cellular events that are tightly regulated by proangiogenic
factors including several growth factors and antiangiogenic factors.37 An upregulated
angiogenesis has been observed as one of the hallmarks of cancer, playing an essential role
in tumor growth, invasion, and metastasis.
During the early stages of development of a tumor, blood supply to the tumor tissue comes
from the vasculature supplying the surrounding normal healthy cells. But, as the tumor
grows beyond 2 mm in diameter, it requires its own blood supply to support its growth.38
It becomes increasingly hypoxic, and triggers the release of vascular endothelial growth
factor (VEGF), epidermal growth factor (EGF), and platelet derived growth factor (PDGF)
among others. These growth factors act as proangiogenic signals to initiate angiogenesis.
(Figure 10).36, 39-40 The new blood vessels grow and infiltrate into the tumor which results
in tumor progression and metastases.41 The sustained growth of solid tumors is highly
dependent on angiogenesis. Thus, antiangiogenesis is a potential approach and has been
widely used in the treatment of cancer.42-43
The growth of tumor tissue vasculature is chaotic and leaky. Therefore, tumor
vasculature differs from normal tissue vasculature in several aspects including the
hierarchy of organization and nature of endothelium.44
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Figure 10. The angiogenic process (modified from ref. 45)

B.1 Receptor Tyrosine Kinases (RTKs):
The pro-angiogenic growth factors bind to transmembrane receptors of the protein kinase
family identified as RTKs, and initiate signal transduction which initiates angiogenesis.
These RTKs, namely vascular endothelial growth factor receptor (VEGFR), epidermal
growth factor receptor (EGFR), and platelet derived growth factor receptor (PGFR) consist
of an extracellular domain, a transmembrane domain and an intracellular kinase catalytic
domain.46 Binding of the growth factor to the extracellular domain results in receptor homo
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or heterodimerization and autophosphorylation of tyrosine residues within the catalytic
domain.

Figure 11. Representative RTK inhibitors approved for clinical use in USA.
This triggers a cascade of events through phosphorylation of intracellular proteins that
ultimately transmit the extracellular signal to the nucleus, eventually leading to
angiogenesis. Dysregulation of these signaling pathways has been linked to malignancy
and is designated as a hallmark of cancer.47 Inhibition of these RTKs offers a key
therapeutic strategy for targeted cancer therapy.48 Several RTKs targeting small molecular
inhibitors (Figure 11) including erlotinib, imatinib, gefitinib, sorafenib, sunitinib have

14

been approved as "targeted agents" for the clinical treatment of various types of cancer.4849

A number of RTKs have been recognized to be involved in tumor induced angiogenesis.
The key RTK families in cancer include the platelet derived growth factor receptor
(PDGFR), epidermal growth factor receptor (EGFR), and the VEGFR families of RTKs
VEGFR
The VEGF family consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placenta
growth factor (PLGF). Three types of VEGFRs have been identified, VEGFR1, VEGFR2
and VEGFR3. VEGFR-2 (FlK-1/KDR) has been recognized as the principal receptor that
mediates VEGF stimulation which is one of the most important growth factors that is
involved in angiogenesis and vasculogenesis.50 Targeted VEGFR2 inhibition or disruption
of produces an abrogation of angiogenesis, and decreased tumor growth.50-51 Sunitinib and
semaxanib are some of the inhibitors of VEGFR2 which have displayed antiangiogenic
activity.42, 52
EGFR
The EGFR family of receptors contain four members: EGFR-1, also identified as
human EGF receptor HER-1), HER-2, HER-3, and HER-4. Among these, HER-2 lacks a
known endogeneous ligand and HER-3 lacks kinase activity. The EGF family is comprised
of eleven known members that bind to one of these four EGFR family receptors.53
Overexpression of EGFR, and its growth factors lead to increased tumor cell proliferation,
survival and invasiveness.54 EGFR signaling if inhibited, could promote selective apoptosis
in tumor endothelial cells.55 Abnormal activity through overexpression or constitutive
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action, has been linked to a number of cancers, including prostate, lung, and breast
cancers.56
PDGFR
It is comprised of four structurally related polypeptides namely -AA, -BB, -CC, -DD,
and -AB that exist as five different homodimers and heterodimer ligands.57 PDGF can bind
to and activate two of its receptors PDGFRα and PDGFRβ54 which are expressed on
pericytes, smooth muscle cells and provide mechanical support to vasculature. By
stimulating the formation of microvascular pericytes, and stabilizing the newly formed
blood

vessels,

PDGFR

plays

an

important role in angiogenesis.38

B.2 ATP Binding Site of RTKs
The site that has been has been indicated as a promising target for rational drug design is
the ATP binding site of RTKs. Diversity and homology among the ATP-binding sites of
kinases has allowed the building of pharmacophore models for rational drug design in
cancer chemotherapy.58-59 A twisted β-sheet of five antiparallel β-strands and one α-helix
make up the N-terminal lobe. The C-terminal lobe is made up of four β-strands and eight
α-helices.
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Figure 12. ATP-binding site of RTKs (modified from ref. 60)
RTK Catalytic Cleft: The catalytic cleft consists of two regions, the front cleft and the back
cleft.61 The front cleft of the catalytic domain is occupied by the ATP-binding site, while
the back cleft is comprised of elements responsible for the regulation of phosphorylation
of peptide substrates.

A. The Front Cleft: The front cleft consists of the ATP binding site and small, non-ATP
contact regions. The ATP site is divided into the following subregions depending on the
binding mode (Figure 12).59
1. Adenine region: This region is predominantly hydrophobic and is bordered by the hinge
region and the gatekeeper. Two key hydrogen bonds are formed by the interaction of the
N1 and N6 amino nitrogens of the adenine ring with the NH and carbonyl groups of the
peptide backbone of the hinge region residues of the RTKs.
2. Ribose binding region: This pocket is adjacent to a hydrophilic, solvent exposed region
and accommodates the sugar moiety of ATP. The ribose pocket accommodates the sugar
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moiety of ATP and is adjacent to a hydrophilic, solvent exposed region. This pocket
includes three hydrophobic and hydrophilic residues. These hydrophobic residues (Ile, Val
and Leu) have traditionally been exploited in developing EGFR inhibitors. Our group has
published many papers exploiting the hydrophobic residues of the sugar binding pocket of
the ATP site.
3. Phosphate binding region: This pocket is flexible, hydrophilic and solvent exposed, and
is covered by Asp, Lys and Asn residues and the DFG motif. Being highly flexible and
solvent exposed, this region is considered less important in improving inhibitor affinity and
potency.
4. Hydrophobic region II: This pocket serves as an entrance for ligand binding as it is not
utilized by ATP, and so variation in the residues and conformation of this pocket has been
reported for various kinase targets. To gain selectivity in the design of kinase inhibitors,
this region has highly ben been used.

B. The Back Cleft: The back cleft provides important binding regions for various kinase
inhibitors. ATP does not bind in the pockets in the back cleft.60-61 The hydrophobic pocket
in the back cleft adjacent to the adenine pocket is called Hydrophobic region I. This pocket
has highly been explored in the design of inhibitors to gain selectivity for kinase targets
with small gatekeeper residues.62
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C. Combination Chemotherapy
In order to bypass inhibition of a single biological target, cancer cells often find
alternative compensatory signaling routes. These findings provide the rationale for the use
of drugs able to target multiple unrelated proteins. It is not surprising that this strategy has
found utility in complex disease states such as cancer with remarkable clinical success.63
The concept of using a combination of drugs each with activity against a different
biological target has been used in the treatment of several diseases.66 The central idea of
combination chemotherapy is that by modulating multiple pathways simultaneously, the
utilization of alternate survival pathways that allow tumor cells to evade the therapy can
be prevented.64
Antiangiogenic RTK inhibitors are cytostatic agents that prevent further growth of the
tumor and are required to be used in combination with cytotoxic agents for complete
abrogation of tumors.64-65 Of significant interest is the remarkable clinical success of
combinations of antiangiogenic agents and cytotoxic agents.66-69 Sorafenib (5 µM)
significantly enhanced the anti-cancer effect (25% growth inhibition compared to control)
of low dose paclitaxel (125 pM) in microvascular endothelial cells, producing an additive
effect on inhibition of cell growth.
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D. Vascular Normalization Theory

Antiangiogenic agents target endothelial cell-mediated angiogenesis, and indirectly stop
growth of tumor cells by depriving them of nutrients, while cytotoxic agents kill cancer
cells directly. However, destroying the tissue vasculature is expected to severely
compromise the delivery of the cytotoxic agent to the solid tumor and render these
compounds inactive. Surprisingly, synergistic antitumor effects via the use of
antiangiogenic and cytotoxic drug combinations lead to the proposal of the "vascular
normalization" theory.70-71
Under healthy physiological conditions, a balance between endogenous proangiogenic
and antiangiogenic factors maintains normal vessels. These vessels are arranged in a
hierarchical manner (i.e., arteries, capillaries, and veins) forming an orderly distributed
compact network, whereas tumor vasculature is disorganized and morphologically
abnormal with a leaky endothelium.. In tumor environments, an abundance of
proangiogenic growth factors results in vascular growth being vigorous and random in all
possible directions at all junctures. Consequently, the difference in pressure between the
arterioles and venules is reduced, resistance to blood flow is increased, and blood supply
to the tumor is impaired.72 The vascular network appears haphazard with high vascular
density in certain regions of the tumor and lack of vasculature in others.73 Inefficient tumor
blood flow due to abnormal vasculature can negatively affect the delivery of cytotoxic
drugs and also cause systemic toxicities. However, as the targets of antiangiogenic agents
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are located in contact with the bloodstream, these drugs are considered to suffer less from
delivery obstacles than drugs targeting tumor cells in the extravascular space.

Figure 13. Antiangiogenic therapy and vessel normalization (modified from ref. 70)

The effect of antiangiogenic agents is twofold: first, they prune some of the abnormal
vessels and second, due to their antiangiogenic nature, these agents can balance the effect
of proangiogenic factors and result in a transient normalized vasculature (Figure 13). This
transient normalization is both structural and functional. The normalized vasculature is
central for blood flow with the least obstruction and blood supply to the tumor. As a result,
there is improved delivery of the cytotoxic agent to the tumor thereby explaining, in part,
the synergy observed in the use of antiangiogenic and cytotoxic drug combinations.
Anti-VEGF treatment induces a transient normalization process that leads to pruning
of immature vessels, and improvement of the integrity and function of the remaining
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vasculature by enhancing perivascular cell and basement membrane coverage.74-75
Normalization of tumor vasculature increases uptake and delivery of cytotoxic antitumor
drugs.76-77 However, enhancement in the delivery of cytotoxic agents to the tumor is both
dose- and time-dependent. The cytotoxic agent should be delivered to the tumor during the
"window of normalization" in order to maximize the intratumoral cytotoxic drug levels. As
a result, optimal scheduling of antiangiogenic therapy with chemotherapy and/or radiation
therapy requires knowledge of the timing window during which the vessels transiently
become normalized, and an understanding of the duration of the normalized vasculature.
Improper understanding could cause the chemotherapeutic agent to miss the therapeutic
window, and suboptimal effects or no effect of combination chemotherapy could result.
E. Multiple target inhibition with single agents
Multitargeted drugs are defined as rationally designed single chemical entities capable
of selectively targeting two or more biological targets or processes.78 If the
pharmacophores for the respective targets overlap, the common structural features of the
lead compounds can be "merged" resulting in a designed multiple ligand. As with
combination chemotherapy, targeting different pathways in tumor cells using multitargeted
agents can increase therapeutic effectiveness, as this strategy may prevent cancer cells from
developing resistance, which is the principal cause of chemotherapy failure.79 Other
advantages include a lower risk of drug-drug interactions in vivo and improved patient
compliance resulting from reduction in the number of medications required. At the level of
biochemical response, a single agent with multiple targets would be less prone to interact
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with anti-targets compared to multiple separate agents which would be more prone to
produce off-target toxicities. So, a single agent would have less adverse effects, if any,
compared to multiple agents. Optimizing the pharmacokinetics of the lead compound while
retaining a balanced target profile (i.e., optimizing the ratio of activities at the different
targets and the effects of metabolism to ensure a therapeutic, but non-toxic, effect at each
of these targets) is one of the challenges of the multitargeted agents.78 Several multitarget
strategies have been studied in cancer therapy.80-81 A clinical strategy that has been
successful is the combination of antiangiogenic and cytotoxic agents. 82-85
F. Folic acid (FA)
A p-aminobenzoic acid (PABA), a hetero-bicyclic pteridine, and a glutamic acid are the
three structural units of folic acid (FA) (Figure 14). FA, an oxidized synthetic compound
is used in dietary supplements. The word folate refers to the various reduced derivatives of
FA naturally found in food. Folates occur in several reduced states of the pteridine ring
(oxidized, 7,8-H2, and 5,6,7,8-H4).

Figure 14. Structure of folic acid with the three principal moieties of the molecule.
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1. Folate metabolism:
Folic acid metabolism cycle in mammals is a crucial process for the transfer of one-carbon
units to amino acids, nucleotides, and other biomolecules. The proton coupled folate
transporter (PCFT) in the intestines plays a major role for the folic acid uptake. Folates
have to be reduced to tetrahydrofolate (THF) to act as a cofactor. The first step is the
intracellular reduction of the folic acid, in presence of reductant nicotinamide adenine
dinucleotide phosphate (NADPH) to the intermediate 7,8-dihydrofolate (DHF). This is
followed by a similar reduction of DHF to THF.

Figure 15. De novo synthesis of purines
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β-Glycinamide-ribonucleotide

transformylase

(GARFTase)

and

amino-

imidazolecarboxamide ribonucleotide transformylase (AICARFTase) are two folate
related enzymes required for the de novo synthesis of purines, that utilize the cofactor N10formyltetrahydrofolate (N10-CHO-THF) to transfer one carbon units (Figure 15). N10CHO-THF and glycinamide ribosyl-5-phosphate (GAR) are converted to THF and formylglycinamide ribosyl-5-phosphate (fGAR) respectively in the presence of glycinamideribonucleotide formyl transferase (GART). The fGAR formed is then converted to aminoimidazolecarboxamide ribosyl-5-phosphate (AICAR) in five steps. The enzyme
AICARFTase then transforms AICAR to formyl-AICAR (fAICAR). THF is also released
in this process. The term antifolates is a class of antiproliferatives that closely resemble
FA, and so, interfere with the biosynthesis, utilization or metabolism of normal cellular
folate cofactors involved in folate metabolism.86
The fAICAR formed continues along the purine biosynthetic pathway leading to the
formation of inosine-5’-monophosphate (IMP), the precursor of adenosine-5’-triphosphate
(ATP) and guanosine-5’-triphosphate (GTP) necessary for ribonucleic acid (RNA)
synthesis and of 2’-deoxyadenosine-5’-triphosphate (dATP) and 2’-deoxyguanosine-5’triphosphate (dGTP) necessary for DNA synthesis.87
Folates are hydrophilic anionic molecules, and so, cannot passively diffuse across
biological membranes. Several sophisticated membrane transport systems are evolved in
mammals to facilitate membrane translocation of these essential cofactors. A folate
molecule is transported into the cell in its monoglutamate form and then, is metabolized
by folyl-γ-glutamate synthetase (FPGS) by adding L-glutamic acid units to the γ-carboxylic
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acid (up to eight glutamate moieties).88 The polyglutamate cofactor form is termed
folypoly-γ-glutamate and this process is described as polyglutamylation. This leads to (i)
increased intracellular retention of folates through metabolic trapping; (ii) enhanced
binding of polyglutamylated tetrahydrofolate (THF)

Figure 16. Representative examples of classical antifolates with principal targets.

to folate-dependent enzymes at low concentrations; (iii) increased retention of folate
cofactors in mitochondria.89-91 γ-Glutamyl hydrolase (GGH), present in the lysosome,
catalyzes the hydrolysis of

polyglutamates back to their monoglutamate form.92

Antifolates which contain L-glutamic acid at the side chain such as methotrexate (MTX),
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aminopterin, pemetrexed (PMX, Alimta), raltitrexed (RTX, ZD1694, Tomudex),
pralatrexate (PDX) (Folotyn, 10-propargyl-10-deazaaminopterin, N-(4-(1-((2,4-diamino6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid), lometrexol etc. are known as
classical antifolates (Figure 16).

2. Membrane transport of folates: Mammalian cells have evolved genetically distinct
systems to facilitate membrane transport of folates. Three major folate uptake systems, the
reduced folate carrier (RFC), folate receptor (FRs) and the proton-coupled folate
transporter (PCFT) have been described.88 Each plays a unique role in mediating folate
transport across epithelia and into tissues.

2.1. The Reduced Folate Carrier (RFC)
RFC is the major cellular and tissue folate transporter in mammalian cells. It is
ubiquitously expressed in mammals. RFC is also a major transporter of antifolate drugs
used in therapy for several illnesses and for cancer chemotherapy. The effectiveness of
chemotherapy with agents such as MTX, PMX, and RTX (Figure 18) is closely linked to
levels and activity of RFC in both tumors and normal tissues. 93-94

2.1.1. Structure of RFC
RFC is the major membrane transporter of circulating folate cofactors94 and belongs
to the major facilitator superfamily of hRFC. It is comprised of 591 amino acids and is 6466% conserved with rodent RFC. RFC is characterized by 12 transmembrane domains
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(TMDs) and is N-glycosylated at Asn58 in the extraloop domain connecting TMDs 1 and
2. A large loop domain connects TMD6 and TMD7, and is poorly conserved between
species. The major role for the TMD6–7 loop domain is to provide appropriate spacing
between the TMD1–6 and TMD7–12 segments for optimal membrane transport.88

2.1.2. RFC distribution
In liver and placenta, high levels of RFC transcripts have been detected, with
significant levels in other tissues, including leukocytes, kidneys, lungs, bone marrow,
intestines, and portions of the CNS and brain. RFC was also detected at the basolateral
membrane of the renal tubule epithelium, the apical brush-border membrane of the small
intestine and colon, hepatocyte membranes, the apical surface of the choroid plexus, and
the apical membrane of the cells lining the spinal canal.95 Low levels of RFC result in
pathologic conditions such as cardiovascular disease, fetal abnormalities, neurological
disorders, and possibly cancer.96 RFC is important for development since inactivating both
RFC alleles in mice by targeted homologous recombination is embryonic lethal.97

2.1.3. Transport mechanism of RFC
RFC transports reduced folates via counter-transport with organic phosphate
anions. The major circulating form of folate, 5-methylTHF, is its physiological substrate.
RFC has high affinity (~50-100-fold) for reduced folates (Ki ~1-5 µM) and a low affinity
for folic acid (Ki ~200 µM) as it is an integral transmembrane protein.98 RFC transport is
characterized by a neutral pH optimum and so, it has significantly decreased transport
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activity below pH 7. As folates are negatively charged, RFC actually produces a substantial
electrochemical potential difference for folates across cell membranes.99 RFC-mediated
transport is highly sensitive to the transmembrane anion gradient, in particular, the organic
phosphate gradient. So, asymmetrical distribution of organic phosphates across cell
membranes provides the driving force for RFC-mediated uphill transport of folates into
cells.97

2.1.4. RFC in antifolate chemotherapy
The classical antifolates MTX, RTX, and PMX (Figure 16) are all actively
transported into mammalian cells by RFC.100 However, RFC is ubiquitously expressed in
mammalian cells and, is a major folate transporter for normal tissues and tumors. These
elevated extracellular antifolate concentrations always result in dose limiting toxicity due
to a lack of RFC transport selectivity for tumor cells over normal cells.

2.2. The folate receptors (FRs)
The FRs represent another mode of folate uptake into mammalian cells, and are a
family of high affinity folate binding proteins.

2.2.1. Structure of FRs
The FRs are encoded by three distinct genes, designated α and β localized to
chromosome 11q13.3-q13.5.101 Another FR gene, designated γ, maps at chromosome
11q14.102 FRs α, β and γ are highly homologous proteins (68-79% identical amino acid
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sequence) and contain from 229 to 236 amino acids with two (β, γ) or three (α) Nglycosylation sites. In contrast to RFC, hFRα and hFRβ are anchored at the plasma
membrane via a glycosyl-phosphatidylinositol (GPI) anchors, whereas FRγ is secreted
due to the lack of a signal sequence for GPI anchor attachment.

Figure 17. a. Two views of the FRα-folic acid complex, with FRα in green, folic acid in
grey, N-acetylglucosamine in orange and the disulphide bonds depicted as yellow
sticks.(modified from ref.103)

Recently, the crystal structures of both FRα and FRβ were published. The crystal structure
of FRα with folic acid at 2.8 Å resolution was reported by Karsten Melcher and co-workers
(Figure 17).103 FRα has a globular structure stabilized by eight di FRa has an overall
globular structure, consisting of four long α-helices (α1, α2, α3, α6), two short α-helices
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(α4, α5), four short b-strands (β1–β4) and multiple loop regions. The tertiary structure of
FRα is stabilized by eight disulphide bonds formed by 16 conserved cysteine residues. It
also contains a deep open folate-binding pocket comprised of residues that are conserved
in all folate receptor subtypes.103
Charles E. Dann III and coworkers104 reported six different conformations of FRβ at neutral
and acidic pH. The results suggest that the pH of the receptor environment plays a crucial
role in the rearrangements of the structure that at neutral pH, folate binding cleft is poised
in an open conformation and at the acidic pH which is experienced in the endosome, it is
occluded which means that transport is most efficient at neutral pH and least efficient at
acidic pH.104

2.2.2. FRs distribution
FRα is generally localized on the apical surface of polarized epithelial cells,
particularly in the proximal tubule cells of the kidney, choroid plexus, retina, uterus and
placenta. FRα is not in contact with circulating folate as it is predominantly expressed on
the apical surface. This unusual polarized expression of hFRα protects normal tissues from
FR-targeted therapies in the blood circulation. hFRβ is expressed in the placenta, spleen,
and thymus and in the latter stages of normal myelopoiesis. hFRγ is secreted from
lymphoid cells in the spleen, thymus, and bone marrow at low levels. The restricted
distribution of FRs, the transcytosis mechanism used by hFRα, and the generally low
expression levels of hFRβ play a crucial role in limiting toxicities in normal tissues with
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FR-targeted therapeutics. Therefore, such agents circumvent the dose limiting toxicities
exhibited by currently used non-selective antifolates, that are also transported by RFC.105

2.2.3. Transport mechanism of FRs

Figure 18. Endocytosis of FRs.

When a folate molecule binds to a folate receptor on the cell surface, the process of
internalization by FRs is initiated, which leads to conformational change and invagination
of the plasma membrane at that site followed by the formation of vesicles (endosome) that
migrate to the cytoplasm. This process is known as endocytosis (Figure 18). The interior
of endosome becomes acidic (pH = 6.0-6.5) once it enters the cytoplasm. This decrease in
pH leads to another conformational change of the FR complex resulting in the dissociation
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of the folate from the complex. The endosome then migrates back to the cell surface, gets
fused with the cell membrane and the same FRs is recycled.106-107

2.2.4. FRs and antifolate chemotherapy
FRα is overexpressed in up to 90% of ovarian cancers.108-109 Unlike tumor cells,
FRα in normal tissues is inaccessible to the blood circulation.110 FRβ is expressed in a wide
range of myeloid leukemia cells. FRβ in normal hematopoetic cells differs from that in
leukemia cells in its inability to bind folate ligand.111 Unfortunately, for most classical
folate-based therapeutics (including MTX, RTX and PMX), since substrates are shared
between FRs and the ubiquitously expressed RFC, tumor selectivity is not present. That is
why, if a FR-targeted ligand were itself cytotoxic without RFC activity, selective tumor
targeting would ensue.112

2.3. The proton-coupled folate transporter (PCFT)
PCFT is a member of the superfamily of solute transporters. The gene encoding
PCFT is located on chromosome 17q11.2. The major physiological role of PCFT is
absorption of dietary folates through upper gastrointestinal tract where it functions
optimally at acidic pH-5.5. It functions by coupling the flow of protons down an
electrochemical concentration gradient to the uptake of folates into cells.113 Its activity at
the low pH and the structural specificity (high affinity for folic acid, and low affinity for
PT523, a non-polyglutamable analog of aminopterin) distinguishes itself functionally from
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the RFC (optimal activity at pH 7.4, very low affinity for folic acid and very high affinity
for PT523).114

2.3.1. Structure of PCFT

Figure 19. Structure of PCFT (modified from ref.113).
hPCFT consists of 459 amino acids with a molecular mass of 49.8 kDa. It is predicted to
include 12 TMDs with N- and C-termini towards cytoplasm (Figure 19). The loop
domain between the first and second TMDs must be extracellular because the two
putative N-glycosylation consensus sites in this region are glycosylated. N-glycosylation
does not appear to be required for either PCFT trafficking or function.113
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2.3.2. PCFT expression patterns in human tissue
PCFT is expressed in the apical membrane of the proximal jejunum and in many
normal tissues including retina, brain liver, kidney and placenta,.115 The highest PCFT
levels within the intestine are found in the proximal jejunum and duodenum. Here, it serves
as the primary means of intestinal uptake of dietary folates at the acidic pH characterizing
the upper small intestine.116

2.3.3. Transport mechanism of PCFT
The uphill flow of folates into cells is coupled with the downhill flow of protons
via PCFT, and so, PCFT functions as a folate-proton symporter. Consistent with a protoncoupled process, a transvesicular pH gradient results in an increased unidirectional
transport of folate and substantial transmembrane folate concentration gradients from the
low-pH to the high-pH compartment. One of the unique characteristics of PCFT involves
its acidic pH optimum i.e. transport is maximal at pH 5-5.5, but as the pH increases above
5.5, transport decreases significantly and above pH 7, there is no activity.117

2.3.4. PCFT and antifolate chemotherapy
The interstitial pH of solid tumors favors PCFT transport as it is acidic. A prominent
low-pH transport route was identified in a substantial cohort of solid human tumors, and
high levels of hPCFT transcripts were reported in a broad range of human tumors.118
Whereas the role of tumor selectivity and PCFT in antifolate activity is still evolving,
transport of classical antifolates by PCFT has been described previously,117 although
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classical antifolate PMX shows high affinity for the carrier at both acidic and neutral
pHs.119 PMX is transported by both PCFT as well as RFC, and so its transport into normal
tissues via RFC could be the major reason behind its lack of selectivity for tumor cells over
normal cells. Thus, this provides a strong rationale for designing and developing folatebased therapeutics that are substrates for transporters with limited transport in normal cells
compared with tumors. Thus, both FRs and PCFT can be used for targeted cancer
therapy.86,120
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3. Glycinamide-ribonucleotide formyltransferase (GARFTase)

Figure 20. Proposed mechanism for GARFTase catalysis of GAR to Fgar.121
GARFTase, involved in purine synthesis, is one of the most important trifunctional
enzymes.122 As mentioned above, it catalyzes the transfer of the formyl group from N10CHO-THF to the primary side-chain amino group of GAR to yield FGAR and THF (Figure
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20). It ultimately incorporates C-8 into IMP. Inhibition of de novo purine biosynthesis via
GARFTase inhibition is a viable approach for cancer chemotherapy.86, 123-124

3.1. Structure of GARFTase
The structure of hGARFTase has been reported at pH 4.2 (1.7 Å), pH 8.5 (2 Å), pH
8.5 in the binary complex with the substrate β-GAR (2.2 Å) and at pH 7 in a binary complex
with the co-substrate analog inhibitor 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8tetrahydrofolic acid (10-CF3CO-DDACTHF) (2 Å)125 and folate inhibitors.126 Crystal
structure of hGARFTase with pemetrexed and 6-substituted pyrrolo[2,3-d]pyrimidine
antifolate with β-GAR substrate was reported recently.120

3.2. Catalytic Mechanism of GARFTase
The formyl group is transferred by a nucleophilic attack of the GAR amino group
on the formyl carbon of the co-substrate leading to the formation of a tetrahedral
intermediate. Kinetic studies of the E. coli enzyme127 and of the human enzyme128 and
murine enzyme129 GARFTase domains suggested this mechanism. It isproposed that a
“fixed” water molecule mediates the required proton transfer between substrate and
cofactor, though, it has not been verified experimentally.130 A proposed mechanism for
GARFTase is shown in Figure 20. The cofactor binds to the active site, and Asp144 forms
a salt bridge with the imidazolium of His108. The formyl group is positioned to form
hydrogen bonds with the protonated imidazolium group of His108 and Asn106.
Tetrahedral intermediate is formed when the free base form of the amino group of GAR

38

attacks the activated formyl group. Catalytic water molecule mediates a proton transfer
from GAR to the N10 of folate, followed by breakdown of the tetrahedral intermediate to
form products. The positioning of this water molecule may be assisted by a hydrogen bond
to the carboxylate of Asp144.121

3.3. Binding of Inhibitors
Zhang et al.125 reported a 1.98 Å crystal structure of hGARFTase in a binary
complex with the co-substrate analog inhibitor 10-CF3CO-DDACTHF (Table 2) at pH 7
(PDB ID = 1NJS). The cofactor binding pocket of GARFTase is located at the interface
between the the C-terminal of the structure and the N-terminal mononucleotide binding
domain. The binding site for the folate cofactor moiety consists of three parts: the pteridine
binding cleft, the benzoylglutamate region, and the formyl transfer region.

Figure 21. Crystal structure of hGARFTase. (PDB:4ZZ1 and PDB:4ZZ2)120
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Gangjee and coworkers120 published the crystal structure of hGARFTase with
pemetrexed and 6-substituted pyrrolo[2,3-d]pyrimidine antifolate (Figure 21) and β-GAR
substrate recently. According to the crystallographic models, antifolates form six hydrogen
bonds via the pyrrolo[2,3-d]pyrimidine moiety with hGARFTase peptide backbone.
Moreover, two hydrogen bond interactions with the peptide backbone, a bidentate polar
interaction with Arg871, and three charge–charge interactions with Arg897 and Lys844
are mediated via the glutamate tail of the antifolates.120

Microtubules - Summary
Microtubules are important for various functions like transcription, translation,
permeability, centrosome clustering etc. in interphase cells. Microtubules is also important
for trafficking of protein and nucleic acid cargo in cancer cells, and so MTAs are highly
successful anticancer agents. These drugs disrupt microtubule dynamics leading to
microtubule polymerization or depolymerization, and thus classified as microtubule
stabilizing agents like Taxanes, and destabilizing agents like Vinca alkaloids or colchicine
site agents. The problem with current agents is multidrug resistance caused by structural
alteration of the microtubules and drug efflux by ATP binding cassette (ABC) proteins.
The MTAs can be combined with antiangiogenic agents. Agiogenesis is the process of
formation of new blood vessels from existing vascular beds. Release of the pro-angiogenic
growth factors lead to their binding with transmembrane receptors of the protein kinase
family identified as RTKs, namely, vascular endothelial growth factor receptor (VEGFR),
epidermal growth factor receptor (EGFR), and platelet derived growth factor receptor
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(PGFR). These initiates signal transduction and angiogenesis.
Tumor vessels are often dilated, and have a haphazard distribution of vessels. The
heterogeneity of tumor vasculature can be caused due to the excessive vessel leakiness
leading to escape of plasma. This heterogeneity leads to hypovascular and hypervascular
areas in tumor with sluggish blood flow in some regions and excessive in others. The
heterogeneous blood perfusion occurs spatially as well as temporally. These static regions
also lead to the hypoxic conditions in the cell as well as low extracellular pH. Due to this,
the administered cytotoxic drugs cannot penetrate well in these static regions of a tumor
cell. According to vascular normalization hypothesis formulated by Jain and coworkers,
the antiangiogenic agent transiently normalizes this vasculature by pruning the abnormal
vessels and remodeling the remaining ones which leads to reduction in hypoxia and
interstitial fluid pressure. As a result, there is improved delivery of the cytotoxic agent to
the tumor thereby explaining, in part, the synergy observed in the use of antiangiogenic
and cytotoxic drug combinations. Using multitargeted agents also increase therapeutic
effectiveness, preventing cancer cells from developing resistance, which is the principal
cause of failure of current chemotherapy. Other advantages include a lower risk of drugdrug interactions in vivo and improved patient compliance resulting from reduction in the
number of medications required. At the level of biochemical response, a single agent with
multiple targets would be less prone to interact with anti-targets compared to multiple
separate agents which would be more prone to produce off-target toxicities. So, a single
agent would have less adverse effects, if any, compared to multiple agents.
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Folates- Summary
The lack of tumor selectivity for all the currently clinically used antifolates reflects their
cellular uptake by the reduced folate carrier (RFC) expressed ubiquitously by both normal
tissues as well as tumors. In contrast, folate receptor (FR) α and β, and the proton-coupled
folate transporter (PCFT) exhibit selective tumor tissue expression, and serve specialized
physiological roles.113 FRs on normal cells are inaccessible to circulating folates or are
non-functional in normal tissues. PCFT is expressed in the upper gastrointestinal tract
where it functions only at acidic pH as the major intestinal transporter for absorption of
dietary folates.131 Given this requirement of acidic pH for activity, PCFT transport is
limited in normal tissues that are not at acidic pH (<6.9). A substantial cohort of solid
tumors (eg. ovarian, non-small cell lung cancer) express PCFT, often in concert with FRs.
FRα is accessible on tumors, thus, allowing tumor targeting by this mechanism. FRβ is
expressed in hematological malignancies and in white blood cells of the myeloid lineage,
including tumor-associated macrophages (TAMs). FRβ-positive TAMs may play an
important role in the tumor microenvironment in reaction to tumor metastasis and
angiogenesis by releasing proangiogenic factors suggesting that TAMs may constitute an
additional potential therapeutic target in cancer for FRβ-targeted agents.132 There are no
tumor targeted cytotoxic agents in clinical use, thus, all cytotoxic agents display doselimiting toxicity. New cytotoxic agents are needed which can target tumor cells selectively
by virtue of their specificities for FRs and /or PCFT and thus, afford agents that do not
suffer from dose-limiting toxicities.133
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II. CHEMICAL REVIEW
The chemistry related to the work described in this dissertation is reviewed in this
section.
1. Iodination
2. Cyanation
3. Trifluromethylation
4. Pyrrolo[2,3-d]pyrimidines ring system formation
1. Iodination
•

Using sodium iodide

Scheme 1. Exchange of chlorides with iodides using sodium iodide and
trimethylsilyl chloride.

Reactions and conditions: a) NaI, TMS-Cl, MeCN, 180 °C, MW
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Yang et al.134 and Lemoine et al.135 exchanged the chlorides in 11 and 13 respectively
with iodides with NaI and TMS-Cl in acetonitrile at 180 °C in a microwave reactor
(Scheme 1).
•

Using iodotrimethylsilane
Scheme 2. Exchange of chlorides with iodides using iodotrimethylsilane.

Reactions and conditions: iodotrimethylsilane, MeCN, 81 °C, 4 h, 79%
Zehnder et al.136 added iodotrimethylsilane to the suspension of 15 in MeCN to get to
the 2-amino-4-iodo-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine 16 (Scheme 2).
•

Using hydroiodic acid
Scheme 3. Exchange of chlorides with iodides using aqueous hydroiodic
acid.
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Reactions and conditions: aq. HI, MeCN, 0 °C- rt
Hughes et al.137 treated 4-chloro-1-methyl-6,8-dinitropyrrolo[4,3,2-de]quinolin-2(1H)-one
17 with hydroiodic acid to yield iodo 18 (Scheme 3). Yields were not mentioned.

2. Cyanation
•

Using copper cyanide
Scheme 4. Formation of 3-nitropicolinonitrile

Reactions and conditions: CuCN, fusion 150 °C, 2 h, 68%

Loidreau et al.138 reacted 2-bromo-3-nitropyridine 19 with copper cyanide to 3nitropicolinonitrile 20 (Scheme 4).
Scheme 5. Transformation of iodide into the nitrile moiety using copper cyanide.
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Reactions and conditions: CuCN, pyr, 80 °C
ughes et al.137 transformed N,N'-(4-iodo-1-methyl-2-oxo-1,2-dihydropyrrolo[4,3,2de]quinoline-6,8-diyl)bis(2,2,2-trifluoroacetamide) 21 into the nitrile 22 employing copper
cyanide in pyridine (Scheme 5).
3. Trifluoromethylation
Wang et al.139 used a novel strategy for aromatic trifluoromethylation by converting
aromatic amino group into a trifluoromethyl group. It was the trifluoromethylation
variation of the classic Sandmeyer reaction.
Scheme 6. Treatment of iodide with copper and diphenyl-(trifluoromethyl)sulfonium
trifluoromethanesulfonate

Reactions and conditions: CF3SO3-+S-(CF3)(Ph)2, Cu, DMF, 60 °C, 18 h, 80%

Georgsson et al.140 generated the trifluoromethyl-substituted pyrrolo[2,3-c]pyridine 24 by
treating ethyl 5-iodo-1H-pyrrolo[2,3-c]pyridine-2-carboxylate 23 with copper and
diphenyl-(trifluoromethyl)sulfonium trifluoromethanesulfonate in DMF (Scheme 6).
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Stout et al.141 attempted trifluoromethylation of 8a-hydroxy-8-methyl-octahydroimidazocyclopenta[1,2-e]pyrrolo[1,2-a]pyrazinedione 25 following the protocol of Baran and coworkers142 (tBuOOH, aqueous NaSO2CF3, or ZnSO2CHF2, respectively) which smoothly
converted the starting material to the trifluorinated analogue 26.
Scheme 7. Trifluoromethylation using NaSO2CF3

Reactions and conditions: NaSO2CF3, tBuOOH, H2O, rt, 46 h, 49%

4. Synthesis of 5-substituted pyrrolo[2,3-d]pyrimidines
The synthetic procedures for substituted pyrrolo[2,3-d]pyrimidines are already well
established as published by Gangjee and coworkers.
a.

From Pyrroles

Pyrimidine is the primary precursor in the literature for the synthesis of pyrrolo[2,3d]pyrimidines (Figure 22) and the formation of bonds between atom 4a, 5 and atom 6 and
7 is described in the literature.143-144
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Figure 22. pyrrolo[2,3-d]pyrimidine
Scheme 8. Synthesis of pyrrolo[2,3-d]pyrimidines 30 and 34 and furo[2,3-d]pyrimidines
31.

Reactions and conditions: a. DMF, 60 °C, 48 h, 20-45%

Secrist and Liu145 reacted 2,6-diamino-4-hydroxypyrimidine 27 with various a-halo
aldehydes and ketones (Scheme 8). Cyclization occurred via two modes to produce either
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the pyrrolo[2,3-d]pyrimidine and/or the furo[2,3-d]pyrimidine. Thus a-halo ketones,
chloroacetone 28 and 3-bromo-2-butanone 29, yielded both the furo[2,3-d]pyrimidine 30
and the pyrrolo[2,3-d]pyrimidine 31, whereas 32 produced only the pyrrolo[2,3d]pyrimidine 34 on reaction with 33.
Scheme 9. Synthesis of pyrrolo[2,3-d]pyrimidines 38.

Reactions and conditions: a. guanidine HCl, HCl solution b. heat, 120 °C, 5 h

Seela and Luepke143 reported 6-substituted 2-amino-3,7-dihydropyrrolo[2,3-d]pyrimidin4-one 38 synythesis from 1,3-dioxolane-2-propanoic acid, α-cyano-2-methyl-ethyl ester 35
and guanidine 36 (Scheme 9).
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Scheme 10. Synthesis of pyrrolo[2,3-d]pyrimidines 41 and 43

Reactions and conditions: 55-60 °C, 30 min, 35-89%

Noell and Robins146 reported the synthesis of unsubstituted pyrrolo[2,3-d]pyrimidines 41
(Scheme 10) and 43 by the reaction of chloroacetaldehyde 40 with 2-amino-6-alkylamino4-hydroxypyrimidines 39 and 6-amino-1,3-dimethyluracil, 42 respectively.
Scheme 11. 5-substituted, and 5,6-disubstituted pyrrolo[2,3-d]pyrimidine.

50

Reactions and conditions: a) NaOAc, H2O, 50 °C, 20 h, 83% b) NBS, DMF, rt, 6 h , 88%
Gibson et al.147 reported the synthesis of 5,6-disubstituted-pyrrolo[2,3-d]pyrimidine. 2Chloro-2-cyanoethanal 45 (Scheme 11) was reacted with 44 to furnish 7-yano-7deazaguanine 46. Substituents at C-5 and C-6 were obtained by brominating deazaguanine
46 with N-bromosuccinimide in DMF to yield 7-cyano-8-bromo derivative 47.
Taylor et al.148 reported synthesis of PMX (Scheme 12) involving cyclization of sodium 4[3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-4-nitrobutyl]benzoate 49. Acid 50 was
converted to PMX and involved peptide coupling with diethyl L-glutamate using 2-chloro4,6-dimethoxy-1,3,5-triazine as the coupling agent in presence of N-methylmorpholine and
final saponification.
Scheme 12. Synthesis of pyrrolo[2,3-d]pyrimidine 50 from 6-amino-5pyrimidylacetaldehydes.

Reactions and conditions: a. i) aq. NaOH, rt, 2 h ii) HOAc, overall 57% b. i) L-Glu.HCl,
NMM, CDMT, rt, 62% ii) I N NaOH, H2O, rt, 73%
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Scheme 13. Synthesis of pyrrolo[2,3-d]pyrimidines via Fischer indole cyclization.

Reactions and conditions: a. HCl, reflux, 1 h or 98% HCOOH, rt, 1 h

Wright, G. E. et al.149 reported acid-catalyzed (Fisher indole) cyclization of 6(phenylhydrazino)uracils 51 (Scheme 13) to 9H-pyrimido[4,5-b]indole-2,4-diones 52.
Several

authors150-154

have

employed

the

Fischer

indole

cyclization

of

4-

pyrimidinylhydrazones 53 (Scheme 13) to afford the pyrrolo[2,3-d]pyrimidine ring system
54.
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Scheme 14. Synthesis of pyrrolo[2,3-d]pyrimidine 60.

Reactions and conditions: a. Pd(OAc)2, b. NaN3, EtOH, reflux, 12 h; c. 180 °C, 10 h, 6290%
Kondo and coworkers155 synthesized pyrrolo[2,3-d]pyrimidine 60 (Scheme 14) via thermal
cyclization of 4-azidopyrimidines 59 containing an olefinic moiety at the 5-position.
Intermediates 58 were obtained by a palladium catalyzed cross-coupling between the 5iodopyrimidine 55 and appropriate stannanes 56 or 57, followed by nucleophilic
displacement of the 4-chloro in pyrimidine 58 with sodium azide. Yields were only
mentioned for the final step.
Gangjee and co-workers156 reported the synthesis of 2-amino-4-methylpyrrolo[2,3d]pyrimidine (Scheme 15). Compound 61 and guanidine carbonate were refluxed with
absolute ethanol in the presence of triethylamine or sodium methoxide to afford 62 which
was converted to 63 under reflux conditions with phosphorus oxychloride. Condensation
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of benzylamine with 63 in the presence of triethylamine under reflux in n-BuOH afforded
the bicyclic compound 64. Compound 64 was oxidized to aromatic compound 65 using
MnO2. Sodium in liquid ammonium at -78 °C afforded the debenzylation of 65 to 66.
Scheme 15. Synthesis of pyrrolo[2,3-d]pyrimidine 66.

Reactions and conditions: a. guanidine carbonate, EtOH, Et3N, reflux, 1 h , 69%; b.
POCl3, reflux, 2 h, 68%; c. benzylamine, Et3N, n-BuOH, 90 °C, 3 days, 50%; d. MnO2,
dioxane, reflux, 24 h, 45% e. Na/liq. NH3, -78 °C, 65%.

Legraverend and coworkers157 reported the synthesis of pyrrolo[2,3-d]pyrimidines 71
(Scheme 16) from 2-amino-4,6-dichloro-5-(2,2-diethoxyethyl)pyrimidine 68. 5-allyl-2-
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amino-4,6-dihydroxypyrimidine was prepared by the reaction of guanidine hydrochloride
with diethyl allylmalonate, and then converted to the 4,6-dichloro derivative by treatment
with POCl3.The (2-amino-4,6-dichloropyrimidin-5-yl)acetaldehyde 67 was obtained by
ozonolysis of the allyl group. The acetal 68 was cyclized to 2-amino-4-chloro-7-alkyl-7Hpyrrolo-[2,3-d]pyrimidine 70 by treatment with dilute aqueous HCl at room temperature.
Compound 71 was then obtained by hydrolysis of the 4-chloro group of 70 using 1N HCl
at 100 °C.
Scheme 16. Synthesis of pyrrolo[2,3-d]pyrimidines 71.

Reactions and conditions: a. Et3N, BuOH, 100 °C, 2 days, 42%; b. 0.2N HCl, rt, 3 days,
69%; c. 1N HCl, 100 °C, 6 h, 85%
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Scheme 17. Synthesis of pyrrolo[2,3-d]pyrimidines 74.

Reactions and conditions: a. Et4NCl, Pd(PPh3)2Cl2, MeCN, reflux, 2 h, 11-71%; b. Conc.
HCl, MeOH, reflux, 20-40 min, 71-96%.

Sakamoto et al.158 synthesized pyrrolo[2,3-d]pyrimidines 74 (Scheme 17) by
intramolecular cyclization of protected 5-acetaldehyde pyrimidines 73. Compounds 73
were in turn synthesized by palladium(0) catalyzed coupling of the appropriate 2,4disubstituted-5-bromo-6-acetamido

pyrimidines
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with

(Z)-1-ethoxy-2-

(tributylstannyl)ethane 75.
b. From Pyrroles
Taylor et al.144 reported the synthesis of 4-amino-5-carboxylic acid-pyrrolo[2,3d]pyrimidine 78 (Scheme 18). Tetracyanoethylene 75 was converted by the action of
hydrogen sulfide to 2,5-diamino-3,4-dicyanothiophene 76, which was rearranged to 5amino-3,4-dicyano-2-mercaptopyrrole 77 as described by Middleton, et al.159 Treatment
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of 77 with methyl orthoformate followed by alcoholic ammonia afforded 4- amino-5cyano-6-methylmercaptopyrrolo[2,3-d]pyrimidines 78. Raney nickel desulfurization of 78
then yielded 79. Exact yields and reaction conditions were not provided for the
intermediates.
Scheme 18. Synthesis of 4-amino-5-carboxylic acid-pyrrolo[2,3-d]pyrimidine 79.

Reactions and conditions: a. H2S; b. Alkali c. Orthoformate, NH3 in ethanol d. 1N
NaOH, 35%.
In another report, Taylor et al.160 synthesized 4-amino-5-methyl-pyrrolo[2,3-d]pyrimidine
84 (R = CH3) (Scheme 19) from 2-amino-3-cyano-5-substituted pyrroles 82 which in turn
were obtained from malononitrile and the appropriate a-aminoketones 80. Treatment of
pyrrole 82 with triethylorthoformate followed by ammonia resulted in the imidine
intermediates 83 which underwent cyclization with sodium methoxide in pyridine to afford
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the pyrrolo[2,3-d]pyrimidine 84.
Scheme 19. Synthesis of 4-amino-5-substituted pyrrolo[2,3-d]pyrimidines 84.

Reactions and conditions: a. malonitrile, EtOH, reflux, 67%; b. i. triethyl orthoformate,
reflux, 5 h, ii. NH3; c. i. triethyl orthoformate, reflux, 5 h, ii. NH3, 34-78 %; d. NaOMe,
pyridine, reflux, 1 h, 91%
Taylor and coworkers161 reported the synthesis of a 5,6-dihydro-pyrrolo[2,3d]pyrimidine analog of PMX by a novel route (Scheme 20). A manganic triacetate
dehydrate-mediated radical cyclization of racemic methyl N-crotyl-N-[1-(3,4-phenyl)-eth1-yl)malonamide 89, afforded a diastereomeric mixture of the 3-carbomethoxy-2pyrrolidinone 90.162 Compound 87 was in turn obtained by alkylation of racemic 1-(3,4dimethoxy-phenyl)-ethylamine 84 with crotyl bromide 86 followed by a DMAP catalyzed
acylation with methyl malonyl chloride 88. The pyrrolidinone 90 was converted to the
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thiolactam 91 with P2S5 followed by cyclocondensation with guanidine to afford the N7protected 5,6-dihydro-5-allyl-pyrrolo[2,3-d]pyrimidine 92. Palladium catalyzed cross
coupling with diethyl-4-iodobenzoyl-L-glutamate fortuitously afforded the ethano-bridged
derivatives, and not the expected vinyl-bridged derivatives, by double bond migration. This
compound was then elaborated to analogs of PMX.
Scheme 20. Synthesis of N7-substituted analogs of PMX.

Reactions and conditions: a. NaH, TBAI, THF, 0 °C-rt, 10 h, 82%; b. DMAP, Et3N,
EtOAc, 0 °C-rt, 2 h, 88%; c. Mn(OAc)3. H2O, Cu(OAc)2, Acetic acid, rt, 18 h, 97%; d.
P2S5, THF, reflux, 3 h, 68%; e. guanidine HCl, MeOH, rt, 30 min, 50%.
Barnett et al.163 reported the synthesis of a 2-amino-4-oxo-5,6-dihydropyrrolo[2,3d]pyrimidine 98 (Scheme 21) via a guanidine cyclization of a preformed 3-carbethoxy-2-
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thiopyrrolidine intermediate 97 as the key step This intermediate was in turn prepared in
several steps from 4-propionaldehyde benzoic acid tert-butyl ester 93. Compound 98 was
reduced to the pyrrolo[2,3-d]pyrimidine intermediate 99, which was then elaborated to
PMX in several steps. Reaction conditions are not provided in the publication.
Scheme 21. Synthesis of pyrrolo[2,3-d]pyrimidine 99 and PMX.

Reactions and conditions: a. diethyl malonate, TiCL4/Py, THF; b. MeNO2, DBU, 72%
over 2 steps; c. H2, Pd/C, 42%, d. P2S5, 77% e. TFA, guanidine, 64%; f. L-Glu, NMM,
CDMT, DMF, 52%; g. IN NaOH, 92%
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Girgis, Jørgensen, and Pedersen164 reported the synthesis of 2-methyl- pyrrolo[2,3d]pyrimidines 101 (Scheme 22). Compounds 101 were obtained in a one-step cyclization
of the corresponding 2-acylamino-3-cyanopyrrole derivatives 100. The reaction was
carried out by heating compound 100 in a mixture of phosphorus pentaoxide, N-Ndimethylcyclohexanamine, and water. It is believed that the formation of 101 proceeds
through the intermediacy of the amides 102 resulting from hydrolysis of the cyano function
in 100 followed by intramolecular cyclodehydration under reaction condition. Yields were
not mentioned in the publication for the intermediates.
Scheme 22. Synthesis of 7-deazahypoxanthines 101.

Reactions and conditions: a. 85% H3PO4. 130 °C; b. 50 °C, 3-5 min c P2O5/DMCA/H2O.
180 °C, 2 h, 43%
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Chen et al. 165 reported an efficient synthesis of pyrrolo[2,3-d]pyrimidine 112 (Scheme 23).
Knoevenagel condensation of malononitrile 103 and excess acetone in refluxing toluene or
benzene gave 105. Bromination of 105 using NBS and benzoyl peroxide in chloroform
afforded 106 as a major component contaminated with undesired dibromo derivative 107
and starting material which were separated using column chromatography. Cyclization of
106 with aryl amine 110 afforded the substituted pyrrole intermediate 111. Compound 111
was then cyclized to the pyrrolo[2,3-d]pyrimidine 112 using 85% phosphoric acid.
Scheme 23. Synthesis of 2,5,-dimethyl-N7-substitutedpyrrolo[2,3-d]pyrimidine 112.

Reactions and conditions: a. NaOAc, AcOH, benzene, reflux, 4 h, 70.1% b. NBS,
benzoyl peroxide, CHCl3, reflux, 15 h, 77%; c. rt, 15 h, 60%; d. 85% phosphoric acid,
130 °C, 30 min, 81.1%
c. From Furans
Scheme 24. Synthesis of 2,5,6-trisubstituted pyrrolo[2,3-d]pyrimidines 115.
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Reactions and conditions: NaSO2CF3, tBuOOH, H2O, rt, 46 h
Taylor and coworkers166 (Scheme 24) reported that 2-amino-3-cyanofurans 113 on
cyclization with amidines 114 afforded the corresponding pyrrolo[2,3-d]pyrimidines 115
by an unexpected ring transformation/ring annulation sequence.
Several plausible mechanisms for the above amidine-mediated ring transformation
during annulation reactions have been proposed. Michael addition of the amidine to the 2position of the furan ortho-aminonitrile 113 (Scheme 25) followed by furan ring cleavage
generates an open-chain carbonyl derivative 116, which recyclizes to pyrrole, thus
incorporating the 2-amino group of the furan aminonitrile starting material as the pyrrole
NH. Subsequent intramolecular addition of the amidino substituent to the ortho-substituted
nitrile group then completes the pyrimidine ring annulation to afford 115. Alternatively,
deprotonation of the acidic 2-amino group of the furan O-aminonitrile 116 by the strongly
basic amidine could be followed by C-O bond cleavage to generate an intermediate
ketenimine which would lead to the substituted malononitrile 116. Further reaction with
the amidine in the usual way would lead to a 2-substituted-4,6-diaminopyrimidine carrying
a β-carbonyl substituent at C-5, and fused pyrrole ring would then be formed with a final
ring closure.
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Scheme 25. Plausible mechanisms for amidine-mediated ring transformation

Various iodination reactions were reviewed in this section and electrophilic iodinating
agents did not work well with pyrimidine systems, and the reason could be that the
pyrimidine ring is an electron poor system. Various nucleophilic iodinating agents like
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sodium iodide, iodotrimethylsilane, hydroiodic acid have also been reviewed. 57 %
Hydroiodic acid in water worked successfully. One of the reasons might be the lower
temperature (0 °C – rt) this reaction was attempted at. Other nucleophilic reactions were
high temperature reactions at 80-180 °C. For the synthesis of pyrrolo[2,3-d]pyrimidines,
the biggest concern was the formation of side product furo[2,3-d]pyrimidine. Solvent plays
a major role for these kinds of reactions. For e.g., it was found that with DMF, both
products pyrrolo[2,3-d]pyrimidine, and furo[2,3-d]pyrimidine are formed but with
methanol-water mixture, only former product pyrrolo[2,3-d]pyrimidine is formed.
Although many methods were tried as mentioned in the chemical review section, it was
decided that using 2, 6-diamino-4-hydroxypyrimidines as starting material, it will not lead
to any production of 6-substituted pyrrolo[2,3-d]pyrimidine with bromo-aldehyde
intermediates. Taylor145 used the similar method for the synthesis of PMX as mentioned
earlier. Fischer Indole cyclization has been specifically employed for the synthesis of 6substituted or 5,6 substituted products. Gangjee and co-workers156 synthesized 2-amino-4methylpyrrolo[2,3-d]pyrimidine with guanidine carbonate as starting material. The method
works very well for synthesis of N-benzylated products with 4-methyl. Although synthesis
of pyrrolo[2,3-d]pyrimidine is less popular, various reactions were reviewed and described
earlier in the chemical review section. Taylor also synthesized pyrrolo[2,3-d]pyrimidine
from 2-amino-3-cyano-5-substituted pyrroles. This reaction led to the formation of 5substitued product but without any substitution at 2-position. Same product was also
formed from tetracyanoethylene which led to formation of 2,5-diamino-3,4dicyanothiophene which was rearranged to 5-amino-3,4-dicyano-2-mercaptopyrrole.
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These reactions used basic conditions as well but took two more steps for the formation of
the product
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III. STATEMENT OF THE PROBLEM

Antiangiogenic agents
Beyond 2 mm3, a tumor requires additional oxygen and nutrients for maintenance
and growth, and initiates the process of developing a blood supply system.37 Under hypoxic
conditions, several proangiogenic factors are secreted, of which VEGF is the key mediator
of angiogenesis.167 VEGF binds to its receptor VEGFR2, and stimulates the process of
angiogenesis which supports rapid tumor growth and metastases.50 Developing VEGFR2
kinase inhibitors is one of the key strategies to obtain antiangiogenic effects.168 These
inhibitors arrest tumor growth, and cause tumor shrinkage.169 However, resistance to
VEGFR2 inhibitors results in increased invasion and metastases.170 At the onset of
VEGFR2 inhibition there are two effects:
1. Regression of tumor vessels
2. Transient normalization of surviving vessels.70-71

Normalization
Tumor vessels are often dilated, and have a haphazard distribution of vessels. The
heterogeneity of tumor vasculature can be caused due to the excessive vessel leakiness
leading to escape of plasma. This heterogeneity leads to hypovascular and hypervascular
areas in tumor with sluggish blood flow in some regions and excessive in others. The
heterogeneous blood perfusion occurs spatially as well as temporally. These static regions
also lead to the hypoxic conditions in the cell as well as low extracellular pH. Due to this,

67

the administered drugs cannot penetrate well in these static regions of a tumor cell.73
According to vascular normalization hypothesis formulated by Jain and coworkers, the
antiangiogenic agent transiently normalizes this vasculature by pruning the abnormal
vessels and remodeling the remaining ones which leads to reduction in hypoxia and
interstitial fluid pressure. The treatment with bevacizumab (anti-VEGF antibody) and
DC101 (anti-VEGFR2 antibody) reduced the size and length as well as permeability of
these abnormally dilated and tortuous vasculature in human colon cancer and glioma
xenografts as well as murine breast cancers so that it more closely resembled the normal
vasculature. Bevacizumab also reduced the intratumoral microvessel density (MVD), but
not the density of mature vessels which are pericyte-covered MVD). This indicates that
during normalization, only immature vessels, which lack pericytes are pruned, and not
mature vessels.171
Therefore, the ‘normalized’ vasculature with bevacizumab treatment has greater
perivascular cells coverage with thicker and normal vasculature resembling basement
membrane in breast cancers, squamous cell carcinomas and gliomas. It also leads to the
normalization of tumor microenvironment characterized by reduced interstitial fluid
pressure due to the decrease in the vessel leakiness. Pressure gradient is also restored across
wall of the blood vessels as well as tumor interstitium. Overall antiangiogenic agents lead
to increased drug penetration in tumors.
Investigations into the combined use of VEGFR2 inhibitors with cytotoxic
therapies have yielded more promising results than VEGF-targeting monotherapy.71, 172
Combinations of cytotoxic agents and VEGFR2 inhibitors have shown synergistic effects
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suggesting that there is improved delivery of the cytotoxic agent during this transient phase
of vessel normalization.172
Yoshizawa et al.76 reported that paclitaxel (cytotoxic) in combination with the
VEGFR2 inhibitor semaxanib (cytotoxic) enhanced tumor penetration and in vivo
antitumor activity in Colon-26 solid tumor-bearing mice. Semaxanib treatment increased
the distribution of paclitaxel in the core region of the tumor, and hence, decreased (the ratio
of) its peripheral distribution. Thus, utilizing VEGFR2 inhibition-based vascular
normalization afforded transient enhanced blood supply to the tumor and allowed the
delivery of the cytotoxic agent.76
Scheduling of the cytotoxic agent
The effects of the antiangiogenic agent on the tumor and the intratumoral levels of the
cytotoxic agent affect the outcome of combination chemotherapy.173 To maximize the
intratumoral levels of the cytotoxic agent, administration of the cytotoxic agent needs to
be appropriately scheduled to ensure that it is used during the period of transient vessel
normalization by the antiangiogenic agent.174 Tumor-targeted drug delivery has the
potential to improve cancer treatment by reducing off-target toxicities and increasing the
efficacy of the cytotoxic agent.175 Judicious scheduling is an influential and critical factor
because of the impact on intratumoral cytotoxic drug levels.169, 174, 176, 177 Hence, if not
appropriately scheduled, the cytotoxic agent may miss the timing window of transient
normalization.178 Also, administering separate antiangiogenic and cytotoxic agents may
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not alleviate the issues of dose limiting toxicities of cytotoxic agents that are not tumor
selective.
Compounds with antiangiogenic and cytotoxic activities in single agents
Single agents with both antiangiogenic and cytotoxic activities have several advantages:
1. Antiangiogenic and cytotoxic activities in a single agent would allow the cytotoxicity
to be manifested as soon as the antiangiogenic effects are operable. These
multitargeted agents could exert their cytotoxic action as soon as, or even during
transient tumor vasculature normalization due to the antiangiogenic effects. Several
literature reports indicate the success of using antiangiogenic agents with metronomic
doses of cytotoxic agents.66-69, 179
2. These multitargeted single agents would circumvent the pharmacokinetic problems of
two or more agents dosed separately, would avoid drug-drug interactions at receptor
as well as chemical level, could be devoid of overlapping toxicities, and could delay
or prevent tumor cell resistance.180
3. Reduced cost and increased patient compliance are some of the other advantages of
such single agents which are sometimes as significant contributors to chemotherapy
failure as resistance, toxicity, and lack of efficacy.180
4. Dose-limiting toxicity is one of the major issues with conventional cytotoxic
chemotherapeutic agents. These single agents should avoid these toxicities since they
do not need to be as potent as conventional chemotherapeutic agents.180
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Gangjee et al.181-184 have reported the discovery of single agents with dual antiangiogenic
and cytotoxic activities. The antiangiogenic effects of these compounds were due to
inhibition of RTKs, and the cytotoxic effects were due to inhibition of dihydrofolate
reductase181 or thymidylate synthase183 or an unknown target.184 For cytotoxic effects,
tubulin was chosen as the main target as several clinical and preclinical combinations of
tubulin inhibitors and VEGFR2 inhibitors have been successful.185-187 For a variety of
different cancers including colorectal, breast, lung among others, several clinical trials are
ongoing that involve FDA-approved antiangiogenic agents as well as those in
development, and cytotoxic chemotherapeutic agents, and include microtubule targeting
agents (MTAs) CA4P, paclitaxel, docetaxel, vincristine, vinblastine with antiangiogenic
agents bevacizumab, axitinib, sorafenib, sunitinib, cediranib, pazopanib, vandetanib and
vatalanib.188 Additionally, half of all human tumors have mutations in the p53 gene, and
p53 status effects vulnerability of tumor cells to chemotherapy via cell cycle arrest. The
most effective drugs in cell lines with p53 gene mutations are MTAs.189-190
Several highly potent MTAs have failed in the early stage clinical trials due to
toxicities. Discodermolides and cryptophycin 52 (LY355703) are recent examples of such
agents.191-192 All clinically used MTAs share neurological toxicity as the most prominent
dose-limiting side effect.5 Other common toxicities of microtubule-binding agents include
myelosuppression and neutropenia. Neutropenia was observed in several combination
chemotherapy clinical trials with other drugs and was mostly manageable.193-195 The
myeloid toxicity, which is usually reversible, is seen with vinca alkaloids and taxanes.196-
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Thus, new agents are needed which are safe and effective, and have both antiangiogenic

and cytotoxic activities in a single agent.

Figure 22. Hybrid design from lead compounds
7-Benzyl-pyrrolo[2,3-d]pyrimidines with general structure 122 (Figure 22) have been
reported by Gangjee et al.198 as antiangiogenic, antimetastatic and antitumor agents. To
engineer RTK inhibitory activity in 121·HCl, without loss of MTA activity, hybrid
129·HCl was designed that
incorporates the 7-benzyl group of 122 onto the pyrrolo[3,2-d]pyrimidine scaffold of
121·HCl. This analog 129 was reported recently by Gangjee et al.180
Compound 129·HCl maintained cytotoxic antitubulin activity of 121·HCl, and improved
activity against VEGFR2 by 9-fold for antiangiogenic effects over 121·HCl (Figure 22).
Compound 129·HCl has an inhibitory potency against VEGFR2 comparable with the
clinically used sunitinib and clinically evaluated semaxinib. The cytotoxic effect, mediated
by the microtubule targeting, was independent of overexpression of Pgp and βIII-tubulin
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(two clinically relevant tumor resistance mechanisms). Thus, 129·HCl has combination
chemotherapeutic potential in a single agent.180, 199

The general RTK pharmacophore model consists of an Adenine region, a Sugar binding
pocket and a Phosphate binding region which binds the adenine ring, the sugar moiety and
the triphosphate moiety of ATP respectively. Additionally, there are two hydrophobic
regions I and II, neither of which are used by ATP for binding. The 7-benzyl group in
129·HCl could access the Sugar binding pocket as shown in binding mode 1 (Figure 23).
Alternatively, the pyrrolo[3,2-d]pyrimidine compounds could adopt mode 2 in which the
compounds are rotated around the 2-CH3-C2 bond. In this mode, the 7-benzyl group and
the 4-anilino groups could occupy Hydrophobic region I and Sugar binding pockets
respectively. These compounds could also adopt binding mode 3 in which the molecule is
rotated by 60o (from mode 2). In this mode, the 7-benzyl group could orient towards the
Hydrophobic region I and the 4-anilino groups could occupy Hydrophobic region II.
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Figure 23. Predicted binding modes of 129·HCl in VEGFR2 [pdb: IYWN]200
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Design of single agents with combination chemotherapy and multiple RTK inhibitory
potential
The complexity of the angiogenic pathways implies that disrupting only a single
mechanism of angiogenesis may not result in long term clinical success. Multiple RTKs
are co-activated in tumors and redundant inputs drive and maintain downstream signaling,
thereby limiting the efficacy of therapies targeting single RTKs.54, 201 Resistance to antiVEGF treatment is associated with increased PDGFR expression within the tumor,
increased recruitment of pericytes to tumor vasculature, and increases in other
proangiogenic factors.202 Preclinical models suggest that PDGF-mediated recruitment of
pericytes may contribute to resistance to VEGF blockade. EGFR inhibition can lead to
VEGFR2 up-regulation which subsequently promotes tumor growth signaling independent
of EGFR and thus contributes to the resistance of EGFR inhibitors.203-204 The effect of
EGFR inhibition can also be partially overcome by activation of PDGFR signaling and the
subsequent transactivation of HER-3 (EGFR family) signaling to promote alternate tumor
growth signaling.53,

203

Hence, targeting multiple RTKs maximizes the proportion of

angiogenic signaling that is effectively targeted.201,

203

Moreover, high intratumoral

heterogeneity has been reported with different subpopulations producing distinct growth
factors. 205-207 Targeting a single RTK could be ineffective due to subpopulations of cells
that are either not affected by the drug mechanism and possess or acquire a greater drug
resistance.208 Hence, it was of interest to explore the effect of structural variation and its
effect on activity against the RTKs VEGFR2, PDGFRβ and EGFR in addition to having
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cytotoxic antitubulin effects. The aim of this work was to identify single agents with
antitubulin and multiple RTK inhibitory potential.
Thus, it was of interest to elucidate the effect of conformational flexibility on
antiangiogenic/ MTA activities to achieve multikinase inhibition. Therefore, Series I
(Figure 24) was designed as dual antiangiogenic and microtubule targeting agents with
multikinase inhibition potential.

Figure 24. Series I
Compounds 130 and 131 were designed as open chain analogs of 129·HCl. Compounds
130 and 131 would be conformationally flexible compared to lead 129·HCl, and so will
have more freedom to bind in different binding modes to different targets which could
afford multikinase inhibition. Compound 132 would be a more rigid structure than 130 or
131, and was designed to determine the effect of conformational restriction on the
inhibitory activity of 130 and 131.
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Figure 25. Distances between pyrimidine and phenyl (between carbons a and b, Figure 24)
for 129·HCl and 130-132.
Figure 25 shows analogs 130-132 in their minimized forms using MOE2016.08.183
Distances between the pyrimidine and the side-chain phenyl (between carbons a and b,
Figure 25) for 129·HCl and 130-132 were calculated. Compounds 131 and 132 could
extend further in the binding pocket of multiple RTKs, and access the hydrophobic residues
of RTKs better than 129·HCl as shown in Figures 27a-c.
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Figure 26. Docked pose of 130 (green) overlaid with 129 (brown) in the colchicine site
(PDB ID 4O2B).
Docking studies: Compound 130 was docked in the colchicine site of tubulin (PDB: 4O2B,
2.3 Å)209 using MOE2016.08183 (validated by re-docking the crystal structure ligands) to
predict the potential binding of these analogs (Figure 26). The docked conformation of 129
in the colchicine site of tubulin is based on its similarity to the bound conformation of
colchicine210 (not shown in the model). It was observed that 130, open chain
conformationally flexible analog of 129, binds in a similar manner as 129. The 4′-OMe
phenyl group of 130 is oriented towards the triOMe containing A-ring of colchicine and
interacts with Cys241 and HOH615. The N-Me of 130 is involved in hydrophobic
interactions with Leu255 and Ala250. 2-Me is involved in hydrophobic interactions with
Ala354 and Ala316. The 6-benzyl moiety makes hydrophobic interactions with Val181
and Phe404. Compound 130 has a docked score of -6.34 kcal/mol, similar to that of the
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lead 129 = -6.57 kcal/mol. This suggested that 130 should retain activity against tubulin as
129 did.

Figure 27a. Docked pose of 130 (green) overlaid with 129 (brown) in the ATP site of
VEGFR-2 (PDB ID 1YWN).211
Compound 130 was also docked in the ATP site of VEGFR2 (PDB: 1YWN, 1.75 Å).211
using MOE2016.08.183 Figure 27a shows the docked pose of 130 and 129 in the ATP site
of VEGFR2. In the best pose of 130 (docked score of -7.02 kcal/mol), the phenyl 4′-OMe
is observed in the same location as the benzyl moiety of 129, and interacts with Leu1047
and Ala1048. The benzyl moiety of 130 is oriented towards Val897 and Ile1042. It was
observed that 130, because of its extra flexibility, could bind in multiple poses and, could
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provide multikinase inhibition. Compound 129 because of the constraint imposed by the
second ring, did not afford multiple poses.
Due to the issues with the MOE server in the chemistry department of Duquesne University
during the final parts of the dissertation writing, rest of the modeling in EGFR and
PDGFRβ modeling was done using LeadIT2.1.3 and images were taken directly from there.

Figure 27b. Docked pose of 130 in the ATP site of EGFR (PDB ID 4WKQ). 212
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Figure 27c. Docked pose of 130 in the ATP site of homology model of PDGFRβ.

Compound 130 was docked in the ATP site of EGFR (PDB: 4WKQ, 1.85 Å)212 and
PDGFRβ (homology model) using LeadIT2.1.3 (Figures 27b and 27c). In the EGFR crystal
structure, the phenyl 4′-OMe is observed interacting with Ala743 and Ile 744. The benzyl
moiety of 130 is oriented towards the long side chain of Lys745. 2-Me is oriented towards
Ser70. The best docked pose of 130 had a score of −16.12 kJ/mol. In the PDGFRβ
homology model (docked pose of −15.56 kJ/mol.), the aniline is observed interacting with
Val631 and Lys630. The anilino moiety of 130 is flipped in this case compared to that in
EGFR or VEGFR. The benzyl moiety of 129 is oriented towards Val615 and 2-Me towards
Ala632.
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Figure 28. Compound 122 was synthesized as an intermediate.
Table 1. Effects of 122 on tubulin, and inhibition of colchicine binding compared to
121·HCl.

R

CA4
121·HCl
122

Inhibition of
tubulin assembly
IC50 (µM) ± SD

0.96 ± 0.07
10 ± 0.6
µ

Inhibition of colchicine
binding
(% Inhibition ± SD)
1 µM
inhibitor
89 ± 0.6

5 µM
inhibitor
99 ± 0.4

-

-

63 ± 1

81 ± 0.3

Compound 122 was an important intermediate in the synthesis of 130. Because 122 is an
open chain, conformationally flexible analog of 121·HCl, docking studies were done to
predict its potential binding modes.
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Figure 29a. Docked pose of 122 (green) overlaid with 121 (brown) in the colchicine site
(PDB ID 4O2B).
Docking studies: Compound 122 and 121 were then docked in the colchicine site of
tubulin (PDB: 4O2B209, 2.3 Å) using MOE2016.08183 (validated by re-docking the crystal
structure ligands) to predict potential binding of these analogs for docking studies (Figure
29a). The docked conformation of 121 in the colchicine site of tubulin is based on its
similarity to the bound conformation of colchicine, not shown in Fig. 29a. It was observed
that 122 binds in similar fashion as 121. The 4′-OMe phenyl group of 122 is oriented
towards the triOMe containing A-ring of DAMA-colchicine and interacts with Cys241 and
HOH728. The N-Me of 122 is involved in hydrophobic interactions with Leu255 and
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Ala250. The 2-Me is involved in hydrophobic interactions with Ala354 and Ala316.
Compound 122 has a docked score of -6.62 kcal/mol, which is similar to the docked score
of 121: -6.95 kcal/mol.

Figure 29b. Docked pose of 122 in the ATP site of EGFR (PDB ID 4WKQ).212
Compound 122 was also docked in the ATP site of EGFR (PDB: 4WKQ, 1.85 Å)212 and
PDGFRβ (homology model) using LeadIT2.1.3 (Figures 29b and 29c). In the EGFR crystal
structure, the anilino moiety is observed interacting with Leu792 and Pro794. The 4N-Me
of 122 is oriented towards the long side chain of Gly796 and Phe795. The best docked pose
of 122 had a score of −5.25 kcal/mol.In the PDGFRβ homology model, the aniline is
observed interacting with Tyr683 and Lys630. The 2-Me is oriented towards Gly616 and
Val615. The best docked pose of 130 had a score of −5.94 kcal/mol.
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Figure 29c. Docked pose of 122 in the homology model of PDGFRβ.
Because 122 is an open chain, conformationally flexible analog of 121·HCl (Figure 28),
its effects on the polymerization of purified bovine brain tubulin was evaluated (Table 1),
and compared with CA4 and 121·HCl. CA4 is the active metabolite of the water soluble
prodrug combretastatin A-4 phosphate (Zybrestat, Fosbretabulin), which has orphan drug
status for ovarian cancer. Interestingly, 122 was found to be a potent inhibitor of bovine
tubulin assembly with about 5-fold greater inhibitory activity than the parent 121·HCl, and
only 2-fold less inhibitory activity than CA4. The best docked pose of 122 and 121 had
scores of −15.99 kJ/mol and -15.61 kJ/mol.
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Table 2. RTK and CAM inhibitory activities (IC50 ± SD)
Kinase inhibition
IC50 ± SD (nM)

Compd.
EGFR
121·HCl
122

29.5 ± 3.1

0.21 ± 0.002

SU5416

-

Erlotinib

2

250.2 ±

20.6

43.0

12.9

172.1 ± 19.4 18.9 ± 2.7
1.2 ± 0.2

PDGFR-β

182.3 ±

415.4 ± 50.1 33.2 ± 4.1

PD153035

Sunitinib

VEGFR-

124.7 ±
18.2

CAM
angiogrenesis
inhibition
IC50 ± SD
(µM)
ND

183.2

20.6 ± 3.1

-

0.041 ± 0.009

83.1 ± 10.1

1.3 ± 0.07

-

29.1 ± 1.9

Although, 122 was not initially designed as an antiangiogenic agent, its potent activity
against bovine tubulin assembly prompted us to evaluate its antiangiogenic effects in
keeping with our aim of providing multitargeted agents. In VEGFR2 expressing cell line,
it was determined that 122 was 5-fold more inhibitory compared to 121·HCl with 2-fold
less potency than the standard sunitinib (Table 2). These results are remarkable as VEGFR2
is the principal mediator of angiogenesis. In PDGFRβ inhibitory assay, 122 was 1.5-fold
more active than 121·HCl. These results indicated that the open chain monocyclic, flexible
pyrimidines not only preserve but increase dual potency against both targets tubulin and
multiRTK.
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Figure 30. Series II
Compound 122 (with 6-Cl) was an intermediate in the process of synthesizing 130 (6benzyl). The compound turned out to be an active compound in tubulin depolymerization
assays as well as kinase inhibition assays. To further increase the activity by utilizing
hydrophobic interactions with the hydrophobic residues in the active site, homologation of
N5 of 122 was done, and 123-127 were designed.
The discovery of 122 as a dual tubulin and RTK inhibitor prompted a SAR study, and
Series II (Figure 30) was designed to address the effect of homologation at N5 of 122
(compounds 123, 125-127) and chain branching (124,128) on potency at both tubulin and
RTK sites.
1. With this series, optimum chain length of the N5-substituent could be determined.
This would effectively mimic the pyrrole ring of 121·HCl.
2. The biological activities of Series II will allow a determination of the effect of
increased hydrophobicity on tubulin, EGFR, VEGFR2 and PDGFRβ inhibition,
and provide a SAR of N5-substituents for inhibition of tubulin and multiple RTKs.
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3. Chain branching as in iBu makes the alkyl chain more compact, and cause less
disruption of hydrogen bonding network of water, and can cause major changes in
pharmacological activity.213
4. Increased lipophilicity of the molecule due to the increased chain length may also
permit better penetration into the cell membranes, and might be leading to better
activities in cell assays.

5. With compounds 123-127, we are utilizing these hydrophobic interactions:
Hydrophobic residues in tubulin site - Ala316, V al315, V al181 and Ile378.
Hydrophobic residues in VEGFR site Leu840 and Leu1035. Hydrophobic
residues in EGFR site Ala719. Hydrophobic residues in PDGFR homology
model Val665 and Phe845.
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Figure 31. Docked pose of 125 (green) overlaid with 121·HCl (brown) in the colchicine
site (PDB ID 4O2B).
Compound 123-128 were docked in the colchicine site of tubulin (PDB: 4O2B209, 2.3 Å)
using MOE2016.08183 (validated by re-docking the crystal structure ligands) to predict
potential binding of these analogs for docking studies. The docked conformation of
121·HCl (Figure 31) in the colchicine site of tubulin is similar to colchicine. It was
observed that 125 binds in a similar fashion as 121·HCl, and mimics the pyrrole ring of
121·HCl better than 122.
The N-ethyl chain extends to the hydrophobic pocket consisting of Ala316, Val315,
Val181 and Ile378. Compound 125 has a docked score of -7.29 kcal/mol, which is better
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than that of the lead 121·HCl: -6.95 kJ/mol, and 122: -6.62 kcal/mol because of the extra
hydrophobic interactions.

Figure 32a Docked pose of 125 (green) overlaid with 121·HCl (brown) in the ATP site
of VEGFR-2 (PDB ID 1YWN).211

Compound 123-128 were also docked in the ATP site of VEGFR2 (PDB: 1YWN, 1.75
Å).211 Figure 32a shows the docked pose of 125 in the ATP site of VEGFR2. The
pyrimidine scaffold of 125 forms hydrophobic interactions with Lys866, Val914 and
Cys1040. The N4-methyl forms hydrophobic interactions with Leu838 and Val846. The
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4′-OMe of 125 is oriented towards Leu1047 and Ala1048. The best docked pose of 125 had
a score of −6.85 kJ/mol.

Figure 32b. Docked pose of 127 (green) overlaid with 121·HCl (brown) in the ATP site
of VEGFR-2. PDB: 3BE2. 212

Figure 32b shows the docked pose of 127 in the ATP site of VEGFR2 (PDB: 3BE2212, 1.75
Å) using LeadIT2.1.8. The pyrimidine scaffold of 127 is oriented parallel to the hinge
region amino acids, and occupies the adenine binding region of the ATP site of VEGFR2.
The N1 nitrogen of 127 forms a hydrogen bond interaction with the hydroxy group of
Thr916. 2-methyl interacts with Ile1044. The 4′-OMe of 127 interacts with Phe845. The 4anilino ring interacts with Phe1047. The 4N-methyl is oriented towards the hydrophobic

91

site formed by Val848. The propyl chain at N5 of 127 is involved in hydrophobic
interactions with Leu840 and Leu1035. The best docked pose of 127 and 121 had scores
of −17.27 kJ/mol and -17.51 kJ/mol.

.
Figure 32c. Docked pose of 127 (yellow) overlaid with 121 (green) in the ATP site of
EGFR (PDB ID 1M17). 214

Figure 32c shows the docked pose of 127 in the ATP site of EGFR (PDB: 1M17 – 2.6Å).214
The pyrimidine scaffold of 127 forms hydrophobic interactions with Leu820, Leu694. The
N4-methyl forms hydrophobic interactions with Val702.The 4′-OMe of 127 is oriented
towards Lys721 and Phe832. The 5N-butyl chain is oriented towards Ala719, Thr830 and
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Thr766. The best docked pose of 127 and 121 had scores of −17.13 kJ/mol and -16.74
kJ/mol.

Figure 32d. Docked pose of 127 (yellow) overlaid with 121 (green) in the homology
model of PDGFRβ.

Figure 32d shows the docked pose of 127 in the homology model of PDGFRβ. The N4methyl forms hydrophobic interactions with Ala848 and Phe845.The 4′-OMe of 127 is
oriented towards Leu606. The 5N-butyl chain is oriented towards Val665 and Phe845. The
best docked pose of 127 and 121 had scores of −16.71 kJ/mol and -16.99 kJ/mol.
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Thus, the molecular modeling studies provided support for the synthesis and biological
evaluation of 123-128.

Results found:
So, in sum, with compounds 123-127, we are utilizing these hydrophobic interactions:
Hydrophobic residues in tubulin site - Ala316, V al315, V al181 and Ile378. Hydrophobic
residues in VEGFR site Leu840 and Leu1035. Hydrophobic residues in EGFR site
Ala719. Hydrophobic residues in PDGFR homology model Val665 and Phe845.
Replacement of 6-Cl of 122 with 6-Me was not tolerated and so 6-Cl was not replaced for
further target compounds. Compared to the pyrrolo[2,3-d]pyrimidine compound 121, the
lone pair of 5-NH2 in 122 is not part of the ring system and so available for hydrogen
bonding with residues in the active site of various targets as a hydrogen bond donor as well
as acceptor. Compound 121 doesn’t have a hydrogen bond acceptor due to the nitrogen
lone pair being part of the pi system. Compound 122 NH2 lone pair might be involved in
conjugation with the pyridine ring but still can form hydrogen bond with the residues at
the active site.
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Also, 123 with a 6-Cl might be more active than 121 because of the electron withdrawing
nature of the 6-chloro group in 122. Any electron donating group at 6-position like OH,
NH2 or alkyl groups were not tolerated. Replacement of Cl with similar bulk Me was also
not tolerated. But replacement with other electron withdrawing groups at 6-position like
trifluoromethyl was tolerated. So, we believe, it is because of the electron withdrawing
nature of the Cl, or 5-NH2 being involved in hydrogen bonding as a hydrogen bond acceptor
(although it is a hydrogen bond donor too), which is leading to the improved activity
compared to 121.
In molecular modelling studies, compound 122-128 bound better in the crystal structure of
target protein than the lead compound 121, and had better scores (about 1-2 units higher).

Design rationale for Series III

Figure 33. Series III
Table 3. tPSA and cLogP of 122 and 133-136.
Cmpd.
122
133
134
135
136

tPSA (Aº)
63.21
66.29
74.57
66.29
89
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CLogP
3.5
2.8
2.7
4.1
3.2

Series III was designed to determine the effects of electron withdrawing N-acetyl, Npivylyl, and nitro group in the 5 position of pyrimidine ring on the biological activity
(Figure 33). The polar amide bond in the acetyl and pivalic groups is capable of forming a
hydrogen bond because of the presence of both donor as well as acceptor moieties. Figure
34 shows pivalic carbonyl oxygen of 135 forming a water-mediated (HOH623) hydrogen
bond with the carbonyl of Thr353. Table 3 shows the calculated LogP as well as tPSA
(Topological Polar Surface Area) values of 133-136 (calculated using ChemBioDraw Ultra
15.1.0.144). Compound 133 with N-acetyl would be less lipophilic (Table 3), and 135 with
N-pivalic group would be more lipophilic than 122. The nitro moiety at the 5-position (136)
has highest tPSA.

Figure 34. Docked pose of 135 (green) in the colchicine site (PDB ID 4O2B). Surface:
black hydrophilic and red lipophilic.
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Table 4. Effects of 121·HCl on tubulin and VEGFR2 in cellular assays
Inhibition of
MDA-MB-435
VEGFR2 kinase
bovine tubulin
IC50 ± SD
inhibition
assembly
(nM)
IC50 ± SD (nM)
IC50 (µM) ± SD
121·HCl
10 ± 0.6
96.6 ± 5.3
183 ± 3.4
CA4

0.96 ± 0.07

3.47 ± 0.6

-

Sunitinib

-

-

18.9 ± 2.7

Table 5. Compound 121·HCl overcomes overexpression of Pgp and βIII-tubulin.

Compd.

IC50 ± SD
in HeLa
cells (nM)

IC50 ±
SD in
WTβIII
(nM)

IC50 ± SD in
SK-OV-3
cells (nM)

IC50 ± SD in
SK-OV-3
MDR1-M6/6
cells (nM)

Rr
value

121.HCl

179 ± 8.7

158 ± 13 0.8

219 ± 40

448 ± 110

2.1

CA4

5.6 ± 0.3

5.7 ± 0.4
32.9 ±
5.8

1.0

6.9 ± 0.1

3.0 ± 0.3

0.4

Paclitaxel

1.9 ± 0.3

17.3

6.3 ± 0.4

1,187.2 ± 265.2

188

Rr
value

Efforts to elucidate the plausible binding modes of multiple RTK-inhibitors led Gangjee et
al.215 to the discovery of a highly potent water-soluble antitumor pyrrolo[2,3-d]pyrimidine
121·HCl (Figure 22).216-217 It was discovered to be a colchicine site binding, microtubule
depolymerizing agent that inhibited the growth of cancer cells with IC50 in the nanomolar
range (Table 4). The effects of 121·HCl were evaluated in two pairs of multidrug resistant
cell lines (Table 5). Compound 121·HCl was evaluated in the parental HeLa cells and in
an engineered cell line overexpressing βIII tubulin (WTβIII). In addition, 121·HCl was
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evaluated for their ability to inhibit the growth of SK-OV-3 cells overexpressing Pgp in
comparison to the parental line.218-222

Figure 35. Series IV
It was of interest to identify the structural features that are crucial for tubulin and RTK
inhibition. Hence, 137-139, conformationally flexible, open chain analogs of 121·HCl
were designed to elucidate the minimal structural requirements to retain tubulin and RTK
inhibition (Series IV, Figure 35). The methyl and ethyl groups in the open chain analogs
138 and 139 mimic the pyrrolo ring of pyrrolo[3,2-d] pyrimidine 121·HCl .
Both pyrrolo[2,3-d]pyrimidine223 and pyrrolo[3,2-d]pyrimidine224 derivatives have been
reported to possess potent inhibitory activity against tubulin. Hence, 140 with amino at
both 5- as well as 6-position was designed.
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Figure 36. Docked pose of 140 (green) overlaid with 129·HCl (brown) in the colchicine
site (PDB ID 4O2B) showing the distance between 6-amino protons and Asn258 side
chain.
The amino protons at 6-position interact with Asn258 side chain amide oxygen with a
hydrogen bond (Figure 36, distance calculated using MOE2016.08 = 2.74 Aº).

Figure 37. Series V
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To determine whether the excellent tubulin/VEGFR-2 dual activity of compound 122 is
due to the electron withdrawing nature of the 6-chloro group in 122, Series V (Figure 37)
was designed to evaluate the effect of electron-withdrawing substituents at 6-position by
substituting the 6- chloro group in 122 with electron withdrawing groups, -CN, -I, and –
CF3, 141-143 respectively.
Table 6. tPSA and cLogP of 122 and 141-143
Cmpd.

cLogP

tPSA (Aº)

122

3.53

63.21

141

2.51
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142

3.64

63.21

143

3.73

63.21

In series IV, electron donating groups like alkyl and amino groups were designed but the
compounds turned out to be less active/ in active. 6-hydroxy has already been synthesized
in our group and was found to be inactive. Because of this reason, in series V, electron
withdrawing groups (lipophilic and hydrophilic) were designed.
The biological activities of compounds 141-143 will allow a determination of the effect of
electronics and size on EGFR, VEGFR2 and PDGFRβ as well as tubulin inhibition. Table
6 shows the calculated LogP as well as tPSA values of 141-143 (calculated using
ChemBioDraw Ultra 15.1.0.144). Compound 141 is less lipophilic compared to 122 with
a higher polar surface area (Table 6). The nitrile moiety is more electron withdrawing
compared to the chloro moiety in 122.213 Compound 142 would be more lipophilic and
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bulkier than 122. The iodo in 142 also has the potential to form a stronger halogen bond
compared to a chloro.225
Compound 143 with a lipophilic trifluromethyl moiety would be a stronger electron
withdrawing group than the chloro group due to the presense of three fluroine atoms,
thereby, altering the electronics of the pyrimidine ring system making it more electron
poor.

Figure 38. Series VI
To evaluate the importance of the 2-methyl of 122, Series VI (Figure 38) was designed
by replacing the 2-methyl with different groups. To determine, if the 2-methyl is
specifically required for hydrophobic interactions, compounds 144 (desmethyl) and 145147 (2-ethyl) were designed. These compounds would evaluate the steric effect at the 2position on biological activity.
Gangjee et al.226 have reported that a 2-amino group on fused pyrimidine ring systems
improves hinge region binding and provides multiple-RTK inhibition. Compounds 148150 (Figure 38) were designed by replacing the 2-methyl group in 122 with a 2-amino
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group which could potentially increase binding to the hinge region of EGFR or PDGFRβ
via hydrogen bonds, without loss of tubulin and VEGFR2 inhibitory activities.

Figure 39. Series VII
Series VII (Figure 39) addresses the effect of bioisosterism, conformational restriction and
flexibility on biological activity by introducing various substituted anilines in the 4position of the pyrimidine ring of 122 in place of the 4´-OMe aniline.

Figure 40. Design rationale and biological activity for 301.
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When the 4ʹ-methoxy group of 301 was replaced with a 4ʹ-thiomethyl group (Figure
40), it led to a 2-fold increase in activity against tubulin, and a 1.5-fold increase in
inhibition of cell proliferation. Therefore, 151 with a 4ʹ-thiomethyl group (Series VII) was
designed.

Figure 41. Dihedral angle α : C5-C4-4N-C1ʹ (bond rotation about bond a)

Figure 42. Dihedral angle β : C5-C4-C1ʹ-C2ʹ (bond rotation about bond b)
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Table 7. Dihedral angles of compounds 122, and 151-155
Dihedral

Dihedral

Compound

Dihedral

Dihedral

angle α

angle β

Compound
angle α

angle β

122

45.7

78.3

151

48.1

65.0

152

50.7

65.2

153

44.9

78.3

154

176.9

47.7

155

172.2

45.8

Bond rotations about 2 rotatable single bonds, b and c in the lead molecule 122
(Figure 39) were restricted in compounds 152 and 153 (Series VII), respectively, thus,
affording a much more rigid structure than 122 but still maintaining the phenyl and alkyl
substitutions on the N4 as in 122. This substitution could also restrict the rotation around
the N-phenyl bond, thus providing conformational rigidity and perhaps improved potency.
Diheredral angles α (Figure 41) and β (Figure 42) were calculated for 122 and
compounds 151-155 using MOE2016.08 in their energy minimized conformations. The
results clearly tell that compounds 154 and 155 without 4N-Me have a higher dihedral
angle α suggesting that phenyl is not on top of the 5-amino but on the other side.
Conformational restriction of the phenyland 4ʹ methoxy moieties in 152 and 153
respectively could lock the compound in a conformation that is conducive to selective RTK
(VEGFR2 or other) inhibition without loss of tubulin inhibitory activity. Conformational
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restriction of the flexible 4-anilino moiety of 122 would minimize the entropic loss
associated with the 4-anilinio moiety adopting the preferred conformation for binding to a
specific RTK. This could enhance potency for RTK and/or tubulin.227
Compounds 154 and 155 (Series VII) were designed to evaluate the importance of the 4NCH3, and to increase the free rotation about the 4-position C-N bond (bond a) as well as
the 1’-position C-N bond (bond b) in 122 and 151, respectively.
Rationale explained further: As phenyl ring of 122 can exist in multiple conformations,
this can result in unexpected entropic costs while binding to the colchicine bind site of
tubulin. High entropic cost would offset any possible enthalpic gains that may have been
achieved while binding to the active site. Hence, compounds 152 and 153 were designed
as conformationally restricted analogs of 122 restricting the rotation about the bonds b and
c respectively (Fig. 39, pg 87). A series of restricted analogs have already been designed
and synthesized for other scaffolds like thieno[2,3-d]pyrimidines and pyrrolo[2,3d]pyrimidines, and it is found that the replacement of 4’-methoxyaniline moiety with
bicyclic 6-methoxy-tetrahydroquinoline (152) and 4-N-methyl- 2'-3'-dihydrobenzofuran
moiety (153) are the most active as they maintain the phenyl and alkyl substitution at N4
of 122. Also, the 4-methoxy group of 152 and 153 maintained the hydrogen bonding
interaction with Cys241 in tubulin binding site.
Compound 151 was designed as a bioisostere of 122 by replacement of 4ʹ-methoxy group
with a 4ʹ-thiomethyl group to determine the bulk tolerance (O vs S) as well as the
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importance of hydrogen bonding. Sulfur being a bulkier hydrophobic group could increase
the activity by increasing the hydrophobic interactions at the colchicine site
The S-Me compound 151 was also designed because it showed improved activity in other
scaffolds. For instance, when the 4ʹ-methoxy group of 300 (Fig. 40) was replaced with a
4ʹ-thiomethyl group (301), it led to a 2-fold increase in activity against tubulin, and a 1.5fold increase in inhibition of cell proliferation. Therefore, 151 with a 4ʹ-thiomethyl group
was designed.
The N-Me of 122 is involved in hydrophobic interactions with Leu255 and Ala250 at the
colchicine binding site of tubulin. To gain the kinase inhibitory activity by improving
hydrogen bonding interactions with the hinge region, N-methyl at the 4-position of 122
was replaced with the N-H (compounds 154 and 155) that would provide additional Hdonor binding in RTK active sites. 4N of 154 and 155 would still maintain its hydrogen
bond acceptor capabilities. This in turn would make it possible to inhibit multiple RTKs.
Moreover, in RTK inhibitors, such as gefitinib, erlotinib, lapatinib, N-H is involved in
hydrogen bonding interaction with the kinase region in multiple RTKs. Same strategy has
been used while designing 154 and 155.

Omitted compoundsThe SAR for tubulin inhibition has already been established for other scaffolds in Dr.
Gangjee’s group. Meta and ortho compounds have already been designed and synthesized
before for other scaffolds. It was concluded with the biological results that only paramethoxy group is active for tubulin depolymerization as it can form a hydrogen bond
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interaction with Cys241 in the colchicine binding site of tubulin while meta and ortho
analogs cannot. A series of conformationally restricted analogs have already been designed
and synthesized for other scaffolds like thieno[2,3-d]pyrimidines and pyrrolo[3,2d]pyrimidines, and it is found that the replacement of 4’-methoxyaniline moiety with
bicyclic 6-methoxy-tetrahydroquinoline and 4-N-methyl- 2'-3'-dihydrobenzofuran moiety
lead to the most active analogs as they maintain the phenyl and alkyl substitution at N4 of
122. Also, the 4-OR of 152 and 153 maintained the hydrogen bonding interaction with
Cys241 in tubulin binding site.
Homologation of 4N has been reported for other scaffolds but it was found to be
detrimental for the inhibitory activity.

Design rationale for 4,6-disubstituted compounds

Figure 43. Design rationale for 156.
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The potent inhibitory activity of 129·HCl, a N4-,7-disubstituted analog, in cell lines
overexpressing VEGFR2 led to the design of 156 (Figure 43) with 4´-methoxy-Nmethylaniline in the 6-position to determine its effects on the cell lines overexpressing
multikinases. The 6-benzyl moiety in 129·HCl occupies hydrophobic region I or sugar
binding pocket in different modes (described above, Figure 23). Similarly, the 4´-methoxyN-methylaniline moiety at the N6-position of 156 could also access different pockets in the
ATP binding site to afford multikinase inhibition.

Figure 44. Docked pose of 156 (green) overlaid with 129·HCl (brown) in the ATP site of
VEGFR-2 (PDB ID 1YWN).211
Docking studies: Figure 44 shows the docked pose of 156 and 129·HCl in the ATP site of
VEGFR2 (PDB: 1YWN, 1.75 Å).211 In the best docked pose of 156 (docked score of -7.94
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kcal/mol), the 4´-methoxy-N-methylaniline at the 6-position occupies the site where the
benzyl moiety of 129·HCl binds, and interacts with Leu1047 and Ala1048. The 4′-OMe of
the N6 substitution of 156 is oriented towards Arg840 and could involve a hydrogen
bonding interaction.
Compound 156 was found to have single digit nanomolar inhibition in cell lines
overexpressing VEGFR2 and was greater than a 4-fold increase in activity compared to
lead 129·HCl albeit with loss of inhibition of tubulin activity.

Figure 45. Series VIII
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Because of the loss of tubulin activity in 156, Series VIII (Figure 45) with 157-160 was
designed to regain the lost tubulin inhibitory activity while retaining or further improving
the potent VEGFR2 inhibitory activity.

Compounds 157 and 158 without N-methyl can have hydrogen bonding interactions with
the tubulin protein in the colchicine binding site due to two additional hydrogen bond
donors, one at the N4 and the other at the N6. This might restore the tubulin inhibitory
activity.

Figure 46. General pharmacophore model of pyrimidines with potential binding mode of
157.
In addition, binding modes of 157 and 158 with N4-H and N6-H are proposed (Figure 46)
to enable inhibition of an increased spectrum of RTKs compared to 156. In an attempt to
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design similar multikinase inhibitors, a general RTK pharmacophore model was used as
opposed to a specific crystal structure of a specific RTK to approach multikinase
inhibition.183 It was envisioned that removing the N-methyl at the 4- and 6-positions would
provide additional hydrogen bond donors which could provide additional H-donor binding
in RTK active sites in multiple binding modes relative to the corresponding N-methyl
compounds. This in turn would make it possible to inhibit multiple RTKs. Compounds 159
and 160 were designed to regain the lost tubulin inhibitory activity by the replacement of
4´-OMe at 4- and 6-positions of 156 with 4´-SMe, and 4,6-bis-4´methoxyanilino moiety
with 4,6-bis-6´-methoxy-3,4-dihydroquinolino moiety respectively.

Design rationale for Series IX

Figure 47. Series IX
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Gangjee et al.228 reported the bicyclic pyrrolo[2,3-d]pyrimidine compound 161, with the
N-methyl-4’-methoxyaniline moiety at the 4-position, as a potent microtubule
depolymerizing agent (Figure 47).

Table 8. Disruptive effect on microtubule polymerization in A-10 cells, and inhibition of
proliferation of MDA-MB-435 cells for 161.
Compound

EC50 (nM) in A-10
cells

IC50 (nM) (MDA-MB435)

161

5.8 µM

183 nM

Inhibition of
colchicine binding
(% Inhibition ± SD)
70 %

In the preclinical screening program of the National Cancer Institute 60-cancer cell line
panel, 161 was found to inhibit the proliferation of most of the cancer cell lines with a GI50
of less than 500 nM. It also caused a dramatic reorganization of the interphase microtubule
network, which was similar to the effects of CA4-P (Table 7).228
Unlike paclitaxel, it maintained most of its potency against P-gp-overexpressing cell lines
and showed slightly better activities against β-III-tubulin-overexpressing cancer cell
lines.228 Moreover, it displaced 70% of the [3H] colchicine at a concentration of 5 µM.
Thus, it was determined to be a colchicine binding agent. Prior to this work,228 there were
sparse reports on pyrrolo[2,3-d]pyrimidine-based colchicine-site binding agents. This
discovery was an inspiration to explore the SAR of this class of compounds as MTAs.
Based on the above data, 161 was an excellent lead compound for further development and
Series IX (Figure 47) addresses the effect of substituting the N-methyl-4’-methoxyaniline
moiety with various anilines in the 4-position of the pyrrolo[2,3-d]pyrimidine ring of 161.
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Compound 162 (Figure 47), a conformationally restricted aniline with a fused bicyclic 4N-methyl-2'-3'-dihydrobenzofuran moiety at the 4-position of 2-methyl-7H-pyrrolo[2,3d]pyrimidine was designed. Bond rotation about rotatable single bond, b in the lead
molecule 161 was restricted in compound 162, thus, affording a much more rigid structure
than 161 but still maintaining the phenyl and alkyl substitutions on the N4 as in 161.
Conformational restriction of the flexible 4-anilino moiety would minimize the entropic
loss associated with the 4-anilinio moiety adopting a preferred conformation for binding to
tubulin. This could enhance potency for tubulin. Another advantage could be reduced drug
metabolism.227 The electron poor 4’-methoxypyridine moiety was designed in place of the
4’-methoxyaniline moiety of 161 in 163. Napthols 164 and 165 would determine if the 4’methoxy and 4N-methyl are necessary for activity. It was hypothesized that fusion of
another aromatic ring at the appropriate positions of the pyrrolo[2,3-d]pyrimidine 161
would improve tubulin inhibitory potency. Compound 166 with a 5’-methoxy-N-methyl2-naphthalenamine moiety would determine if additional bulk would lead to increase in
biological activity. Compound 167 was designed by replacing the 4'-methoxy of the lead
161 with a 4'-thiomethyl moiety as discussed earlier in Figure 40.
Rationale explained further: As phenyl ring of 161 can exist in multiple conformations this
can result in unexpected entropic costs while binding to the colchicine bind site of tubulin.
High entropic cost would offset any possible enthalpic gains that may have been achieved
while binding to the active site. Hence, compounds 162 were designed as conformationally
restricted analog of 161 restricting the rotation about bond b (Fig. 47, pg 94). A series of
restricted analogs have already been designed and synthesized for other scaffolds like
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thieno[2,3-d]pyrimidines and pyrrolo[2,3-d]pyrimidines, and it is found that the
replacement of 4’-methoxyaniline moiety with bicyclic 6-methoxy-tetrahydroquinoline
and 4-N-methyl- 2'-3'-dihydrobenzofuran moiety are the most active as they maintain the
phenyl and alkyl substitution at N4 of 161. 6-methoxy-tetrahydroquinoline replacement
has already been done by Dr. Lin in our group. Also, the 4-OR of 162 maintained the
hydrogen bonding interaction with Cys241 in tubulin binding site.
A series of compounds with electron withdrawing groups eg halogens, OCF3 at para
position were synthesized by Dr. Lin. Compound 163 with an electron poor 4’methoxypyridine moiety was designed to determine if an electron poor ring would be
beneficial for the inhibitory potency. 4’-methoxypyrimidine moiety has already been
synthesized by Dr. Lin.
Nitrogen containing heteroaromatic rings are ubiquitously present in drug-like molecules
and 59% of U.S. FDA approved small-molecule pharmaceuticals contain at least one
nitrogen heterocycle. Substituting a CH group with a N atom (as in 163) can lead to
improvements in functional activities such as biochemical potency, cellular potency, and
target selectivity. It redistributes electron density in the ring and introduces dipole moment
(µ= 2.2 D), hydrogen bond capability, and polarity into the molecule. Other students in our
group will be performing a systematic N atom scan (N-scan) by exchanging the trivalent
CH groups in the phenyl side chain of the ligand 161 with trivalent N atoms, one at a time,
to determine its optimal placement for desired pharmacological improvements.
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A series of compounds replacing phenyl with substituted naphthalenyl moiety has already
been synthesized by Dr. Lin in our group. Compounds 164-166 were designed to determine
the bulk tolerance in the colchicine site of tubulin. The increased bulk can form
hydrophobic interactions with hydrophobic residues Ala250, Leu248, Ile1042 and Val914.
The 4N-Me analog of 164 has already been synthesized by Dr. Lin. To determine the role
of N-Me in hydrophobic interactions and to also determine if N-H would be involved in
any hydrogen bonding interactions as a donor, 164 was designed.
The 4N-Me and 4’O-Me analog of 165 has been synthesized by Dr. Lin. To determine if
these methyl groups are conducive to microtubule depolymerization, 165 with 4NH and
4’OH were designed. These extra H groups can also lead to improved activity because of
extra hydrogen bonding interactions with the target as hydrogen bonding donors.
Compound 166 with a 5’-methoxy-N-methyl-2-naphthalenamine moiety was designed
because of the improved biological results in other scaffolds when 4’-methoxyaniline
moiety was replaced with a 5’-methoxy-N-methyl-2-naphthalenamine moiety. It was found
that position of 5’-methoxy group in the naphthalene ring plays a big role in the biological
activity against tubulin polymerization. 5’-methoxy group maintains the hydrogen bonding
interaction with Cys241.
The replacement of 4’-OMe with 4’S-Me in 167 was done to determine the bulk tolerance
(O vs S) as well as the importance of hydrogen bonding. Sulfur being a bulkier hydrophobic
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group could increase the activity by increasing the hydrophobic interactions at the
colchicine site of tubulin.
The S-Me compound 167 was also designed because it showed improved activity in other
scaffolds. For instance, when the 4ʹ-methoxy group of 300 (Fig. 40) was replaced with a
4ʹ-thiomethyl group (301), it led to a 2-fold increase in activity against tubulin, and a 1.5fold increase in inhibition of cell proliferation
Oxazolo[5,4-d]pyrimidines as microtubule targeting agents

Figure 48. Design rationale for Series X
Compounds 168 and 169 (Figure 48) were recently reported82-83, 180 by Gangjee et al. as
potent MTAs that bind in the colchicine site of tubulin. Compounds 170-171 were designed
as hybrids of these molecules to determine the effect of oxazolo compounds on tubule
polymerization.
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Pyrimido[4,5-g]pteridine as a potential MTA.

Figure 49. Design rationale for dimer 172
A number of tricyclics183, 229-230 have been reported by Gangjee et al. which act as MTAs.
The dimer 172 (Figure 49) was obtained via self-condensation of 122, and it was of interest
to evaluate its effects on tubulin polymerization.

Selective tumor targeting with 5-substituted pyrrolo[2,3-d]pyrimidines with
heteroatom bridge substitution

The lack of tumor selectivity for all the currently clinically used antifolates, including
methotrexate (MTX), pemetrexed (PMX), pralatrexate (PDX), and raltitrexed (RTX),
reflects their cellular uptake by the reduced folate carrier (RFC) expressed ubiquitously by
both normal tissues as well as tumors.231 In contrast, folate receptor (FR) α and β, and the
proton-coupled folate transporter (PCFT) exhibit selective tumor tissue expression, and
serve specialized physiological roles.113 FRs on normal cells are inaccessible to circulating
folates or are non-functional in normal tissues. PCFT is expressed in the upper
gastrointestinal tract where it functions only at acidic pH as the major intestinal transporter
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for absorption of dietary folates.131 Given this requirement of acidic pH for activity, PCFT
transport is limited in normal tissues that are not at acidic pH (<6.9). A substantial cohort
of solid tumors (eg. ovarian, non-small cell lung cancer) express PCFT, often in concert
with FRs. FRα is accessible on tumors, thus, allowing tumor targeting by this mechanism.
FRβ is expressed in hematological malignancies and in white blood cells of the myeloid
lineage, including tumor-associated macrophages (TAMs). FRβ-positive TAMs may play
an important role in the tumor microenvironment in reaction to tumor metastasis and
angiogenesis by releasing proangiogenic factors suggesting that TAMs may constitute an
additional potential therapeutic target in cancer for FRβ-targeted agents.132 There are no
tumor targeted cytotoxic agents in clinical use, thus, all cytotoxic agents display doselimiting toxicity. New cytotoxic agents are needed which can target tumor cells selectively
by virtue of their specificities for FRs and /or PCFT and thus, afford agents that do not
suffer from dose-limiting toxicities.133
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Figure 50. PMX, lead compound 302 and target compounds 173-176.
PMX is currently among the most prescribed antitumor agents used in the clinic.232 The
principal indications for PMX are malignant pleural mesothelioma (with cisplatin) and
non-small cell lung cancer. Neutropenia is the major dose-limiting toxicity associated with
PMX, and reflects in part, its nonselective uptake into normal cells, via RFC, expressed in
normal as well as tumor cells.233 Gangjee et al.
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previously reported a 5-substituted

pyrrolo[2,3-d]pyrimidine antifolate with a 5-carbon bridge and a phenyl L-glutamate side
chain, 302 (Figure 50). These compounds were part of a series of chain extension analogs
of clinically used PMX to improve tumor cell potency as well as specificities for FRs and
/or PCFT. Although, 302 was found to be 3.5-fold more potent in KB tumor cells than
clinically used PMX, and showed potent inhibition of CHO cells expressing FRα (IC50 =
33.5 nM), it had reduced activity toward CHO cells expressing PCFT, and high activity
toward CHO cells expressing RFC, thus, it lacked selectivity for FR and/or PCFT. Previous
studies of related 6-substituted pyrrolo[2,3-d]pyrimidines established that the nature and
length of the bridge plays an important role in determining tumor cell potency and
selectivity.124 Thus, it was of interest to insert heteroatom into the carbon bridge of 302 to
determine if O or S substitution of C would afford better activity. Compounds 173-176
(Figure 50) were designed and their impact on drug potency and transport selectivity was
determined. The novel analogs were tested as growth inhibitors against CHO cells
expressing human FRα (RT16), FRβ (D4), RFC (PC43-10), and PCFT (R2/PCFT4) as well
as KB tumor cells in culture.
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Molecular Modeling Studies

Figure 51. Superimposition of the docked poses of 174 (grey) and PMX (green) in the
folate binding site of human FRα (5IZQ) .124
Compounds 173-176 and PMX were docked in the folate binding cleft of FRα (PDB
5IZQ)124using MOE2013.0801183 software to predict potential binding of these analogs for
uptake by FRα. Figure 51 shows the superimposition of docked poses of 174 and PMX in
the human FRα active site. Compound 174 displayed similar interactions in the pocket,
maintaining important protein contacts between the bicyclic scaffolds and benzoyl Lglutamate tail, as also seen in the crystal structure ligand 6-substituted pyrrolo[2,3d]pyrimidine (not shown) and docked standard compound PMX.
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Figure 52. Superimposition of the docked poses of 173 (green) and 6-substituted
pyrrolo[2,3- d]pyrimidine 304 (grey) in the 10-formyl tetrahydrofolate binding site of
GARFTase (4ZZ1).120

In the docked pose of 174 (Figure 51), the 2-hydroxy of 174 interacts with Ser174. The 4oxo moiety forms hydrogen bonds with the side chain NH of Arg103 and the side chain
OH of Ser174. The pyrrolo[2,3-d]pyrimidine scaffold is stacked between the side chains
of Tyr60 and Trp171. The L-glutamate moiety of 174 is oriented similar to the
corresponding L-glutamate in PMX. The γ-carboxylic acid of 174 interacts with the
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protonated amine of Lys136 and the side chain OH of Ser101. The bridge of 174 forms
hydrophobic interactions with Tyr60, Phe62, Trp102, and His135. The docking score of
174 was −13.29 kJ/mol (rmsd = 1.68), somewhat better than the docked scores of PMX
(−12.36 kJ/mol, rmsd = 1.68), and suggests better or similar activity for 174 at FRα.
Figure 52 shows docked 173 in the crystal structure of human GARFTase (PDB
4ZZ1)120complexed with 6-substituted pyrrolo[2,3- d]pyrimidine 304. Compounds 173176 were docked into the X-ray crystal structure of human GARFTase to predict potential
activities for GARFTase inhibition.. The pyrrolo[2,3-d]pyrimidine scaffold of 173 binds in
the region occupied by the bicyclic scaffold of the bound molecule 304 in GARFTase.
Hydrogen bonds between the N1 nitrogen of 173 and the backbone of Leu899; 2-NH2 of
173 and the carbonyls of Glu948 and Leu899, N3 of 173and the backbone C=O of Ala947,
and 4-oxo of 173 and the backbone C=O of Asp951 stabilize the scaffold. The pyrrolo[2,3d]pyrimidine scaffold of 173 forms hydrophobic interactions with Leu892, Ile898 and
Leu899. The docking score of 173 was −14.18 kJ/mol. Similarly, compounds 174-176 had
similar docked scores indicating potent GARFTase inhibition. Thus, the molecular
modeling studies provided support for the synthesis and biological evaluation of 173-176.
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IV. CHEMICAL DISCUSSION

Figure 53. Retrosynthesis of target compound 130
Synthesis of 130 was envisioned to be accompished via a simple Suzuki coupling as benzyl
boronic esters/acids are easily avaliable (Figure 53). The intermediate 122 could be
synthesized via nucleophilic substitution reaction229 of 177 with N-methyl 4-methoxy
aniline.
Scheme 26. Formation of Meisenheimer complex235
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Synthesis of 122 and 156
With the above synthetic strategy for the synthesis of 130, key intermediate 122 was
synthesized by treating 177 with 1.1 equivalents of N-methyl-4-methoxyaniline and
catalytic amounts of hydrochloric acid. The reaction was also attempted without addition
of any HCl but leads to 25-30% less yields. Reactions with catalytic amounts of HCl
provided better yields as HCl protonates the pyridine nitrogen next to the C-Cl bond
(Scheme 26).236
Scheme 27. Synthesis of 156 and 122

Reagents and conditions: N-methyl-4-methoxyaniline, cat. HCl (conc.), 2 h, 150 oC, MW,
dioxane
The reactions were attempted in a microwave reactor at 150 ºC as described in the
literature.237 However, it was found that higher temperature afforded a disubstituted
product 156, and significantly reduced the yield (15 % product formation, Scheme 27).
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Table 9. Effect of variation in temperature
Equiv of Nucleophile used

Temperature

Major product formed?

1.1

150 ºC

Disubstituted product

1.1

120 ºC

Monosubstituted product

Scheme 28. Synthesis of 122

Reagents and conditions: N-methyl-4-methoxyaniline, cat. HCl (conc.), 2 h, 120 ˚C,
MW, dioxane
Lower temperatures (Table 8) were then used, and the reaction temperature was optimized
to significantly decrease formation of 156, affording 122 in 75% yield (Scheme 28).
A 1H NMR study was also done in DMSO-d6 to determine the conformation of 122.
According to the 1H NMR spectrum, the 5-NH2 protons of 122 are more shielded and come
at 4.0 ppm compared to the 5-NH2 protons of starting material 177 which come at 5.92
ppm. This suggested a nearby diamagnetic anisotropic cone. Due to the bulk of the 4N-Me
group, the conformation of 122 is restricted, and the phenyl ring of 122 positions itself on
the top of the 5-NH2 protons (as shown in Scheme 28) leading to the observed shielding
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effect.83
It was observed that lower temperature, less reaction time and less equivalents should be
used to produce monosubstituted reactions.

Synthesis of 130
Compound 122 was subjected to a Suzuki coupling using potassium benzyltrifluoroborate
to afford 130.238 The reaction was performed in a microwave for 5-10 min with palladium
triphenylphosphine as the catalyst and cesium carbonate as the base to afford benzyl
product 130. The reaction was carefully monitored by thin layer chromatography (TLC).
A new product (red spot) was observed on TLC with other side products, and after
extracting the product with ethyl acetate and drying under sodium sulfate, column
chromatography afforded the product. Purification of 130 required extensive column
chromatography. Variations in temperature, time, catalyst, solvent and boronic reagents
were carried to afford a pure product (Scheme 29).
Scheme 29. Variations in temperature, time, catalyst, solvent and boronic reagents

Reagents and conditions: Pd catalyst, Cs2CO3, MeCN : Water = 1 : 1, MW
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Table 10. Variations in temperature, time, catalyst, solvent and boronic reagents

After the pure product was isolated using conditions mentioned in entry 7 (Scheme 29).
1

H NMR analaysis of the isolated product showed the absence of any amino protons at the

5-position of 130. 1H NMR analysis also showed the absence of benzyl methylene protons
or the phenyl protons.
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Figure 54. 1H NMR of Suzuki coupling product which yielded 172 instead of 130.

Compound 178 was synthesized to determine whether its Rf was similar to the final product
but was found to be different, and so, one possibility was the formation of a dimer product
172 (Scheme 30).
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Scheme 30. Possible products with suzuki coupling

The pure isolated product was further analyzed for CHN and mass spectrometry which
proved the formation of a dimer product 172.The mass of 122 was 270.09 while the mass
of the dimer 172 was 482.55. The % of element C in the isolated product was found to
64.5% which confimed that 172 was formed. If it were 122, the % of element C wpuld
have been 56.3%.
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Scheme 31 Synthesis of 172

Reagents and conditions: a. Pd(PPh3)4, Cs2CO3, MeCN: Water = 1 : 1, 120 °C, 30 min,
MW b. Pd(PPh3)4, MeCN: Water = 1 : 1, Cs2CO3, MW, 120 °C,30 min
Scheme 32. Synthesis of 172 without palladium catalyst and boronic reagent was
unsuccessful

Reagents and conditions: acetonitrile/H2O, Cs2CO3, MW, 120 °C, 30 min.
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To evaluate 172 in biological assays, it was resynthesized. It was observed that the reaction
fails without addition of any palladium catalyst and/or boronic reagent (Schemes 31-32).
Interestingly, it was found that the boronic ester/salt is required for the formation of the
dimer.
Reason Suzuki coupling might have failed: Although the actual mechanism is still
unresolved, the boronic reagent and palladium could be involved in the oxidative addition
and transmetallation steps of the Suzuki coupling. But before reductive elimination occurs
to form 130, the 5-amino could attack and form the dimer 172.
Scheme 33. Failure of the protection of the 5-amino using pivalic anhydride.

Reagents and conditions: Pivalic anhydride, 130 oC, 12 h
The 5-amino of 122 was then protected using pivalic anhydride to prevent dimer formation
but the protection failed to afford 135 (Scheme 33).
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Figure 55. 1H NMR of pivalic protection isolated product yielded 171 instead of 135.

After the pure product was isolated (observed on TLC) , 1H NMRs of isolated product
showed absense of 5-NH. One possibility was formation of a bicyclic oxazolo[5,4d]pyrimidino compound 171 (Scheme 34). Elemental (CHN) analysis and mass
spectrometry confirmed the presence of the oxazole (Figure 55). The mass of product
formed was 326.17, which is the correct mass of 171 (with loss of one Cl and one H ),
while the mass of the 135 is 362.15. The % of element C was found to be 66% which
confirmed the formation of 171.
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Scheme 34. Synthesis of 171

Reagents and conditions: Pivalic anhydride, 130 oC, 12 h
Table 11. Effect of variation in temperature
Temperature

Product

105 ºC

N-pivylyl formation
oxazolo[5,4-d]pyrimidinyl

150 ºC
formation

Lower temperatures were then used, and the reaction temperature was optimized to
significantly decrease the formation of 171, and to afford 135 so that the target benzyl
compound 130 could be synthesized (Table 9).
It was observed that low temperatures lead to pivalyl protection (78% yield), and higher
temperatures lead to bicyclic oxazolo formation (60% yield).
Synthesis of 133
The reaction of 122 with acetic anhydride will serve two purposes:
1. Compound 170 (Scheme 35) could be synthesized at higher temperatures which
could function as a potent microtubule targeting agent. This would afford novel
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oxazolo[5,4-d]pyrimidinyl compounds that have not been reported as MTAs in the
literature.
2. At lower temperature, acetyl protection could be achieved which would prevent
dimer formation under Suzuki conditions.
Scheme 35. Synthesis of 133 and 134.

Reagents and conditions a. Acetic anhydride, 100 oC, overnight b. Acetic
anhydride, 150 oC, overnight

The 5-amino group in 122 was reacted with acetic anhydride at both lower and higher
temperatures (Scheme 35). Very interesting results were obtained.
Low temperatures, without basic conditions, afforded the N-acetyl product 133. Higher
temperatures without any base afforded N-acetyl-acetamide 134 instead of 170 (Table 10).
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Table 12. Effect of variation in temperature.
Reagent

Temperature

Product

No base

100 ºC

N-acetyl formation

No base

150 ºC

N-acetyl-acetamide formation

Base, CuI

110 ºC

Oxazole formation

Scheme 36. Synthesis of 170

Reagents and conditions: CuI, DMEDA, K2CO3, Toluene, reflux, 6 h, 55% yield
Finally, the synthetic method by Xu et al.239-240 which reported intramolecular C-O crosscoupling of the o-halogenopyrimidine amide 133 via Cu-mediated cyclization afforded
exclusively the oxazolo[5,4-d]pyrimidino 170 in 55 % yield (Scheme 36).
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Synthesis of 150
Scheme 37. Attempted Suzuki coupling with 133 and 135.

Reagents and conditions: a) acetonitrile/H2O, Cs2CO3, Pd(PPh3)4, MW, 120 oC, 30 min

Acetylated (133) (Scheme 37) and pivylated (135) products were subjected to Suzuki
coupling to afford 130. Unfortunately, the reactions under Suzuki conditions did not work.

Reasons for the failure of the Suzuki reaction with 133 and 135.
1. The bulk of the acetyl and pivylyl groups could make the attack of the boronic salt
difficult during the transmetallation step of the Suzuki coupling.
2. Chlorides are not good leaving groups for coupling reactions like the Suzuki. Better
groups like bromides or iodides are necessary.241-242
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Base plays a major role in the transmetallation step of the Suzuki coupling.242 The presence
of a base might also be the main reason for the formation of dimers in Suzuki coupling as
it makes the 5-amino a better nucleophile (Scheme 31). Hence, Negishi coupling was
attempted on 122 as this coupling does not require base and could prevent dimer formation
(Scheme 38).
Scheme 38. Attempted Negishi coupling with 122 was unsuccessful.

Reagents and conditions Pd(PPh3)4, THF, 60 oC, 2 h (inert)
Compound 122 was treated with 0.5 M solution of benzyl zinc bromide in THF under
Negishi conditions to yield 133.243 The reaction was carried out under inert conditions.
There was no sign of any product or side product formation. No base was used, and that
could be the reason for failure of products even dimer formation. The absence of a good
leaving group like a bromide/iodide might be the reason behind the failure of the Negishi
reaction.
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Scheme 39. Synthesis of 142 with sodium iodide was unsuccessful.

Reagents and conditions: a) N-methyl-4-methoxyaniline, cat. HCl (conc.), 2 h, 120 oC,
MW, dioxane b) NaI, TMS-Cl, MeCN, 180 °C, MW

Synthesis of 142 - Iodination
The next step was to introduce an iodo moiety at the 6-position. Yang et al. 134 and Lemoine
et al.135 introduced the iodo by reacting chloride with NaI and TMS-Cl in acetonitrile at
180 °C in a microwave reactor. The same method was followed but it failed for the
pyrimidine scaffold (Scheme 39).
Scheme 40. Synthesis of 142

Reagents and conditions: a) N-methyl-4-methoxyaniline, cat. HCl (conc.), 2 h, 120 oC,
MW, dioxane , 75 % yield b) 57 % HI (aq.), MeCN, 0 oC- rt, 48% yield
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Finally, the method used by Hughes et al.137 worked successfully for the substitution of the
chloro group with an iodo group with 57% aqueous hydroiodic acid in acetonitrile (Scheme
40). Compound 122 was treated with a 57% aqueous solution of hydroiodic acid at 0 ºC to
afford 142 in 48% yield.

Replacement of the chloro moiety with an iodo was a crucial step for the final synthesis
of the target 6-benzyl compound 130.

Synthesis of 130
Scheme 41. Synthesis of 130

Reagents and conditions: Pd(PPh3)4, THF, 60 oC, 2 h (inert), 35% yield

Compound 142 (Scheme 41) was treated with 0.5 M solution of benzylzinc bromide in
THF under Negishi conditions to afford 130 in 35% yield The reaction was carried out
under inert conditions.
Why Negishi coupling might have worked:
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1. The use of zinc metal could help in forming a coordination complex with nitogen
of pyrimidine leading to reduction in electrophilicity of C-Cl, and facilitating
coupling reaction. This coordination was not possible with Suzuki coupling.
2. No base was used, and that must be the reason for the lack of formation of any
side products like dimer formation.

Synthesis of 151
Scheme 42. Attempted synthesis of 131 under Suzuki conditions.

Reagents and conditions: acetonitrile/H2O, Cs2CO3, Pd(PPh3)4, MW, 120 oC, 30 min

Suzuki coupling for phenylethyl product formation
Attempted syntheses of 131 under Suzuki conditions (Scheme 42) were unsuccessful.
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Scheme 43. Attempted Negishi coupling for the synthesis of 131.

Reagents and conditions: Pd(PPh3)4, N2, 60 °C, THF

Negishi coupling for phenylethyl product 131 formation.
Although the treatment of 142 with 0.5 M solution of phenylethyl zinc bromide and
palladium catalyst worked, it led to side product formation which could not be isolated
using column chromatography (Scheme 43).

As both Suzuki and Negishi coupling reactions failed to afford 131, Sonogoshira coupling
was attempted.
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Scheme 44. Attempted Sonogoshira reaction with the chloropyrimidine 122.

Reagents and conditions: CuI, PdCl2(PPh3)2, NEt3, dry DCE, 100 °C, 2 h

Sonogoshira reaction for phenylethyl product formation.

The Sonogoshira reaction was not successful with the chloropyrimidine (Scheme 44).
However, the iodide 142 did afford 131 under the same cconditions.

Scheme 45. Synthesis of 131

Reagents and conditions: a) CuI, PdCl2(PPh3)2, NEt3, dry DCE, 100 °C, 2 h, 65 % yield b)
H2 (50 psi), 10 % Pd/C, rt, 35 % yield.
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Compound 142 was coupled with phenylacetylene under Sonogoshira coupling conditions
to afford 132 in 65% yield which was then catalytically hydrogenated at 50 psi using 10%
Pd/C to yield 131 (Scheme 45).

Synthesis of 154-159
Scheme 46. Synthesis of 123, 125-128

Reagents and conditions : a) N-methyl-4-methoxyaniline, cat. HCl (conc.), 2 h, 120 oC,
MW, dioxane , 75 % yield b) NaH, alkyl halide, DMF, 2 h, 0º C-rt, 35- 78% yields c)
Diethyl ether, HCl (g), 90 % yield.
2-Methyl-4,6-dichloropyrimidine 177 (Scheme 46) was subjected to nucleophilic aromatic
substitution using N-methyl-4-methoxyaniline and catalytic amount of conc. HCl in
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dioxane to afford 122.244 Reactions involving microwave irradiation afforded 15-25%
better yields than conventional bench-top conditions. Compound 122 was deprotonated
with sodium hydride, and treated with the appropriate alkyl halide to afford the
corresponding N5-alkylated compounds 123-128 in 35-78 % yields. Reactions involving
combinations of cesium carbonate or potassium carbonate and dimethylformamide with
microwave irradiation did not show complete consumption of starting material. The use of
excess base or alkyl halide did not afford the alkylated product exclusively. To increase
water solubility, the products were converted to the HCl salt using HCl gas and ether. The
composition

of

element

chloro

was

found

to

be

19.15%

for

127·HCl

(C17H23ClN4O.1.0HCl) which confirmed the formation of the HCl salt.
Synthesis of 124
Scheme 47. Synthesis of 124

Reagents and conditions: NaH, MeI, DMF, 2 h, 0º C- rt
Base equiv.

MeI equiv.

Ratio (% yield)

0.9

0.9

123:124 = 70:30

144

2.0

2.0

123:124 = 50:50

Deprotonation of 122 with 0.9 equiv. of sodium hydride, and treatment with 0.9 equiv. of
MeI afforded a mixture of yield of (70%) 123 and 30% of the N5-dialkylated 124 (Scheme
47). The products could be easily separated using column chromatography due to different
Rfs on TLC (Rf = 0.62 for 123 and 0.65 for 124). CHN elemental analysis confirmed the
formation and separation of both products with C = 58.06%, H = 5.97%, N = 18.76%, Cl
= 11.85% for 123 and C = 59.16%, H = 6.37%, N = 17.71%, Cl = 11.23% for 124. 1H
NMR analysis for 124 showed a sharp peak at 2.14 ppm which integrated for 6 protons
while for 123, the sharp peak at 2.26 ppm integrated for 3 protons only. Increasing
equivalents of base and alkylating agent from 0.9 to 2 equiv. increased yield of 124 to 50%
of the mixture.
Synthesis of 136
Scheme 48. Synthesis of 136

Reagents and conditions : N-methyl-4-methoxyaniline, cat. HCl (conc.), 3 h, 160 oC, MW,
dioxane, 82% yield.
2-Nitro-4,6-dichloropyrimidine 178 (Scheme 48) was subjected to a nucleophilic aromatic
substitution reaction using 4-methoxy aniline and catalytic amount of conc. HCl in dioxane
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to afford 136 in 82% yield.244 The higher yield was obtained due to the presence of a strong
electron withdrawing nitro group which makes the 4-position of 178 highly electrophilic.
Synthesis of 137
2-Methyl-4,6-dichloropyrimidine 177 (Scheme 49) was subjected to a nucleophilic
aromatic substitution using 4-methoxy aniline and catalytic amount of conc. HCl in
dioxane to afford 122.244 The use of Pd/C as for hydrogenation afforded 137 in 65 % yield.

2-Methyl-4,6-dichloropyrimidine 177 (Scheme 49) was subjected to a nucleophilic
aromatic substitution using 4-methoxy aniline and catalytic amount of conc. HCl in
dioxane to afford 122.244 The use of Pd/C as for hydrogenation afforded 137 in 65 % yield.
Scheme 49. Synthesis of 137

Reagents and conditions : a) N-methyl-4-methoxyaniline, cat. HCl (conc.), 2 h, 120 oC,
MW, dioxane, 75 % yield b) H2 (50 psi), 10 % Pd/C, rt, 65 % yield.
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Synthesis of 138-139
Scheme 50. Synthesis of 138-139

Reagents and conditions : a) N-methyl-4-methoxyaniline, cat. HCl (conc.), 2 h, 120 oC,
MW, dioxane b) Al(Me)3, Pd(PPh3)4, THF, 90 oC, 2 h, 65 % yield c) N-methyl 4methoxyaniline, cat. HCl (conc.), 2 h, 120 oC, MW, dioxane d) Al(Et)3, Pd(PPh3)4, THF,
90 oC, 2 h, 58 % yield.
2-Methyl-4,6-dichloropyrimidine 177 (Scheme 50) was subjected to a nucleophilic
aromatic substitution reaction using 4-methoxyaniline and catalytic amount of conc. HCl
in dioxane to afford 122 which was then coupled with the appropriate trialkyl aluminium
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reagent using palladium catalyst to afford 138 and 139

in 65% and 58 % yields

respectively.
Synthesis of 140

Table 13. Maximum temperature afforded with different types of ammonia solution .

Max. Temperatute
Ammonia type used

attained in microwave

Yield

(MW)
Aqueous (35 %)

120 oC

No product formed

Ammonia in MeOH (7 N)

140 oC

10%

Ammonia in EtOH (2 N)

160 oC

65%

Scheme 51. Synthesis of 140
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Reagents and conditions : a) NH3 in ethanol solution, 160 °C, 3 h , MW, 42% yield b Nmethyl N-methyl-4-methoxyaniline, cat. HCl (conc.), 2 h, 120 oC, MW, dioxane, 75 %
yield.

For the amination of 177 (Scheme 51) at the 6-position, it was treated with aqueous
ammonia solution at 100 ºC to afford 179 (Table 11). The reaction was unsuccessful, and
so ammonia in methanol and ethanol were attempted to achieve higher reaction
temperatures. Ammonia in ethanol afforded microwave tempeartures 20º to 40º higher and
also afforded better yields compared to ammonia in methanol (Table 11). Compound 179
(Scheme 51) was subjected to a nucleophilic aromatic substitution using 4-methoxyaniline
and catalytic amount of conc. HCl in dioxane to afford 140. However, this reaction
failed.244
Why reaction may have failed: The displacement of the 6-Cl of 177 with an amino group
makes the 4C-Cl of 179 less electrophilic which could be the reason of the failure of the
displacement reaction. The reverse sequence of addition was attempted which worked
successfully to afford 140. First, displacement with aniline was carried out to afford 122 in
75 % yield, followed by amination with a solution of ammonia in ethanol to afford 140 in
42 % yield.
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Synthesis of 141
Diazonium salt formation
Scheme 52. Synthesis of 181

Reagents and conditions : a) Pivalic anhydride, 120 °C, 3 h, 65 % yield b) NH3 in ethanol
solution, 160 °C, 3 h , MW, 42 % yield c) i. NaNO2, H2O, HCl, 0 °C ii. CuCN, H2O, 60
°C, 15 min.

Compound 135 (Scheme 52) was treated with an ethanol solution of ammonia to yield 180
which in turn was converted to a diazonium salt using sodium nitrite under acidic
conditions, and then converted to the nitrile using copper cyanide. The use of acid in this
reaction led to the cleavage of the methoxy group into the phenol (182 formation).
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Fusion method
Scheme 53. Attempted synthesis of 141 using fusion method

Reagents and conditions : a) N-methyl 4-methoxy aniline, cat. HCl (conc.), 2 h, 120 oC,
MW, dioxane b) CuCN, fusion, 150 °C, 2 h

The failure of the previous synthesis of 141 prompted Fusion method in which the
reaction of 122 and copper cyanide was performed in a sealed microwave vial at 150 °C
without the use of any solvent but it too failed to afford 141 (Schemes 53).138
Why the reaction may have failed: The lack of solvent might be the reason behind failure
of the reaction, as optimum collision between molecules is required to cause bond
formation.
Scheme 54. Attempted synthesis of 141 using CuCN-DMSO mixture.

Reagents and conditions : CuCN, DMSO, argon, 100 oC, 12
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Next, DMSO was added as a solvent to determine the effect of adddition of a high boiling
solvent, however this too failed to afford 141 (Scheme 54).

Scheme 55. Attempted synthesis of 141 using DABCO as base

Reagents and conditions : CuCN, DABCO, DMSO : H2O , 9:1, 65 °C, 30 h
Another reaction with DMSO-water mixture, and DABCO as base was attempted to afford
141 but was also unsuccessful (Scheme 55).

Rosenmund-von Braun reaction 137
Scheme 56. Attempted synthesis of 141 using Rosenmund-von Braun reaction.

Reagents and conditions : CuCN, DMF, 180 oC, 12 h
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Next, the Rosenmund-von Braun reaction with copper cyanide in a polar solvent like DMF
and NMM at higher temperatures (180 oC) was attempted but also failed to yield the desired
nitrile product 141 (Scheme 56).137
Why the reaction may have failed: The 6-Cl is not electrophilic enough for reaction to
occur. The high temperature and longer hours did not work successfully here.
Another reason: Rosenmund-von Braun reaction works better with iodides rather than
chlorides, so next iodides should be attempted

Scheme 57. Synthesis of 141

Reagents and conditions : CuCN, DMF, 180 oC, 12 h, 22 % yield.
Another high boiling solvent, NMP, was used instead of DMF but also failed to afford
141.The Rosenmund-von Braun reaction works better with iodides rather than chlorides,137
and so, 142 (Scheme 57) with a 6-I was treated with copper cyanide iwhich in a high boiling
solvent like DMF finally worked successfully with complete disappearance of the starting
material on TLC affording the desired nitrile 141.
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It was found that for the substitution reactions, it always better to do reactions on iodides
or bromides than chlorides as iodides/bromides are better leaving groups. Chlorides are
better for SNAr kind of reactions, where electrophilicity plays more important role.

Scheme 58. Attempted variation of the classic Sandmeyer reaction.

Reagents and conditions : a) Pivalic anhydride, 120 °C, 3 h b) NH3 in ethanol solution,
160 °C, 3 h , MW c) t-BuNO2, ACN, HCl, 0 °C, 15 min. d) AgCF3, -78 °C, 3 h
Synthesis of 143- Trifluromethylation reaction.
Wang et al.139 used a novel strategy for aromatic trifluromethylation by substituting an
aromatic amino group with a trifluromethyl. This was a trifluromethylation adaption of the
classical Sandmeyer reaction.
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To 180 (Scheme 58) dissolved in acetonitrile, was added dropwise a solution of tert-butyl
nitrite and HCl to afford the diazonium salt 183. The change in Rf on TLC confirmed the
presense of a new intermediate. To this, in situ generated AgCF3, which was formed by the
addition of silver fluoride into TMSCF3, was added, however the reaction failed to afford
183a (Scheme 58).
Trifluromethylation using Ruppert-Prakash reagent 139
Scheme 59. Synthesis of trifluoromethylcarbene 185

Scheme 60. Attempted synthesis of 143

Reagents and conditions : KF, CuI, TMSCF3, NMP, 70 °C, 12 h
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Then, trifluromethylation was attempted using spray-dried potassium fluoride and copper
iodide. TMSCF3 Compound 184 with potassium fluoride leads to the formation of
trifluoromethylcarbene 185 (Scheme 59) which then reacts with chloride 122 or iodide 142
but the reaction failed to afford 143 (Scheme 60).139
Reason behind failure of the reaction: As seen in the earlier case with nitrile formation,
chlorides are not good leaving groups, and so iodides were used this time. The reaction
might have failed as the 6-C position is not electrophilic enough. Also super-dry potassium
floride is required for this reaction, and spray drying was not possible in the lab conditions,
and that might have been the reason behind reaction failure. Radical reactions (single
electron transfer) could be tried next.
Scheme 61. Attempted synthesis of 143

Reagents and conditions : CF3SO3-+S-(CF3)(Ph)2, Cu, DMF, 60 °C, 18 h
Another trifluoromethylation method used by Georgsson et al.140 was attempted in which
copper

was

added

to

a

solution

of

diphenyl(trifluoromethyl)sulfonium

trifluoromethanesulfonate and 142 in DMF under N2 but was unsuccessful (Scheme 61).245
It was proposed (S)- (trifluoromethyl)diphenylsulfonium triflate is first reduced by copper
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via single electron transfer which then decomposes rapidly to produce the CF3 radical,
which further generates CuCF3.

Scheme 62. Attempted synthesis of 143

Reagents and conditions: NaSO2CF3, tBuOOH, H2O, rt, 46 h
Stout et al.141 attempted trifluoromethylation following the protocol of Baran and coworkers142 (tBuOOH, aqueous NaSO2CF3, or ZnSO2CHF2) which smoothly converted the
starting material to the trifluorinated analogues. However, when this method was attempted
on the pyrimidine scaffold 137, it failed to afford 143 (Scheme 62).
Reason behind reaction failure: Both radical reactions failed to work. One reason might be
that 6-C position is not electrophilic enough. As seen earlier in Suzuki or Negishi coupling
case, reactions worked well when metals were used which could coordinate with
pyrimidine nitrogen resulting in increased electrophilicity at 6-Cl.
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Scheme 63. Synthesis of 143

Reagents and conditions : phenanthroline/CuCF3 complex, DMF, 80 °C, 8 h , MW, 85 %
yield
Trifluoromethylation was finally achieved when iodide 142 (Scheme 63) was treated with
phenanthroline−CuCF3 complex reagent 186, and DMF as solvent using microwave
irradiation at 80 ºC for 8 hours.246
After attempting various aromatic substitution reactions, it was observed that1. Iodides or bromides should be used as they are better leaving groups compared to
chlorides
2. Fluorides/chlorides are better for SNAr reactions, as electrophilicity is more
important there.
3. If iodides do not work, radical reactions could be attempted. To make position more
electrophilic in pyrimidines, nitrogen could be coordinated with metals like zinc,
copper which form a complex with nitrogen, and decrease electrophilicity of
position next to it, facilitating substitution/coupling reactions.
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Synthesis of 144-147
Appropriate 4,6-dichloropyrimidine-5-amines 190 and 191 (Scheme 64) were treated with
4-methoxyaniline and catalytic amount of conc. HCl to afford the corresponding 144 and
145 in 70-75 % yields. Compound 145 was then deprotonated with sodium hydride and
treated with the appropriate alkyl halides to afford the corresponding N5-alkylated 146147 in 35-65% yield.
Scheme 64. Synthesis of 144-147

Reagents and conditions: a) N-methyl-4-methoxyaniline, cat. HCl (conc.), 2 h, 120 oC,
MW, dioxane b) NaH, MeI or EtI, DMF, 2 h, 0 ºC-rt, 35-65 % yield.
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Synthesis of 148-150
Scheme 65. Synthesis of 149

Reagents and conditions : a) N-methyl-4-methoxyaniline, cat. HCl (conc.), 2 h, 120 oC,
MW, dioxane, 72 % yield b) NaH, MeI, DMF, 2 h, 0 ºC-rt, 22 % yield

4,6-Dichloropyrimidine-2,5-diamine 187 (Scheme 65) was subjected to a nucleophilic
aromatic substitution244 using 4-methoxyaniline and catalytic amount of conc. HCl in
dioxane to afford 148 in 72 % yield. Reactions involving microwave irradiation rather than
bench top worked with 15-25% better yields. Compound 148 was deprotonated with
sodium hydride and treated with the appropriate alkyl hydride and treated with the
appropriate alkyl halides to afford the corresponding N5-alkylated compounds 149-150
(Schemes 65 and 66). Reactions involving combinations of cesium carbonate or potassium
carbonate and dimethylformamide with microwave irradiation did not show complete
consumption of starting material. The use of excess base or alkyl halide also did not afford
the alkylated product exclusively.
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Scheme 66. Synthesis of 150

Reagents and conditions : a) N-methyl-4-methoxyaniline, cat. HCl (conc.), 2 h, 120 oC,
MW, dioxane, 72 % yield

b) ethyl iodide, DMF, 2 h, 0º C-rt, 53 % yield

Two side products the 5-N,N-dimethylated 188 and the 2-N,5-N,N-trimethylated 189 were
formed when 148 was deprotonated and treated with the methyl iodide which were easily
isolated using column chromatography. The CHN elemental analysis confirmed the
presence of 149 with C = 54.83%, H = 5.86%, N = 22.55%, Cl = 11.36 %. The Rf of 149
was also 0.1-0.2 units lower than 188 and 189. In 1H NMR analysis, the 4-NH2 peak of 148
can be seen at 4.7 ppm integrating for 2 protons, and the 2-NH2 peak at 2.98 ppm (exact
peak positions known as they were compared with 2-methyl and 4-methyl compounds). In
149, the 4-NH2 gets methylated, and the peak shifts to 4.84 ppm integrating for only 1

161

proton. The 2-NH2 peak shifts to 2.92 ppm still integrating for 2 protons. This confirmed
that the methylation happened at 4-position.
Synthesis of 151-155 : Starting materials 193 and 196 were synthesized for the synthesis
of target compounds 151 and 153 respectively (Scheme 67). Compound 192 was first
deprotonated with sodium hydride and treated with methyl iodide to afford the alkylated
product 193 in 45% yield. However, an equal amount of dimethyl product 194 was formed
as well. To obtain pure monomethylated product (193), 192 was treated with formaldehyde
and sodium methoxide to yield the imine which was then reduced using sodium
borohydride to afford pure 193 in 90% yield.
Scheme 67. Synthesis of anilines 193 and 196.
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Reagents and conditions: a) NaH, MeI, DMF, 2 h, 0º C-rt b) i. (HCHO)n, NaOMe, MeOH
ii. NaBH4, 85-90 % yield.
Compound 195 (Scheme 67) was treated with formaldehyde and sodium methoxide to
yield imine which was then reduced using sodium borohydride to afford 196 in 85 %
yield.
Scheme 68. Synthesis of 151-155

Reagents and conditions: appropriate anilines, cat. HCl (conc.), 2 h, 120 oC, MW, dioxane,
20-85 % yield
Nucleophilic aromatic substitution reaction of 2-methyl-4,6-dichloro-5-aminopyrimidine
177 (Scheme 68) with appropriately substituted amines in dioxane afforded compounds
151-155 in 20-85% yields.229 Displacement reactions with bulky nucleophiles N-methyl2,3-dihydrobenzofuran-5-amine and 6-methoxy-1,2,3,4-tetrahydroquinoline required
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longer reaction times compared to the other amines for complete disappearance of starting
material estimated from TLC. Displacement reactions with 4-methoxyaniline and 4(methylthio)aniline afforded better yields than the methylated counterparts. Reactions
involving microwave irradiation afforded 15-25% better yields than conventional benchtop conditions.
Synthesis of 157-160
Scheme 69. Synthesis of 157-160

Reagents and conditions : appropriate anilines, cat. HCl (conc.), 5 h, 150 oC, MW,
butanol, 32-65% yields.
Table 14. Chemical shift of 5-NH2 protons using 1H NMR (DMSO-d6-400MHz)
Compound

Chemical shift

Compound

Chemical shift

122

3.99

155

5.18

151

4.32

156

3.04

152

4.50

159

3.5

153

3.98

160

3.72

164

154

5.11

177

5.92

A 1H NMR study was also done in DMSO-d6 to compare the conformation of 122 with
154. The N-C4 bond (‘a’ bond, Scheme 68) connecting the phenyl ring and the pyrimidine
ring in 164 is freely rotatable, while it is restricted in 122 due to the presence of 4N-Me
group. According to the 1H NMR spectrum, the 5-NH2 protons of 154 are less shielded
(chemical shift at 5.11 ppm) than
the 5-NH2 of 4N-methylated 122 (chemical shift at 3.99 ppm). This suggested a nearby
diamagnetic anisotropic cone in 122 which is missing in 154. Due to the bulk of the 4NMe group, the conformation of 122 is restricted, and the phenyl ring of 122 positions itself
on the top of the 5-NH2 protons (conformation shown in Scheme 28) leading to the
observed shielding effect. Due to the absence of 4N-Me group in 154, 4N-H places itself
on the top of the 5-NH2 protons, and so no shielding effect is observed as was found in the
case of 122.83
Some effects observed are1. The 5-NH2 protons of all the final products are more shielded compared to the 5-NH2
protons of the starting material 177 which come at 5.92 ppm. This suggested a nearby
diamagnetic anisotropic cone due to the placement of aniline on top of 5-NH2.
2. The 4-NMe compounds (122, 151-156, 159-160) are shielded compared to the 4N-H
compounds 154 and 155. Due to the bulk of the 4N-Me group, the conformation of the
final compounds (other than 154 and 155) is restricted, and so, the phenyl ring positions
itself on the top of the 5-NH2 protons leading to the observed shielding effect.83
3. The disubstituted compounds 159 and 160 with 4,6-N-diMe are much more shielded
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than their monosubstituted counterparts 122 and 151. This might have happened because
both aniline rings might position themselves on the top of the 5-NH2 leading to a greater
diamagnetic anisotropic cone, and hence a stronger shielding effect.
Synthesis of 162-167

Scheme 70. Synthesis of 198, 200 and 203a

Reagents and conditions: a) i. (HCHO)n, NaOMe, MeOH ii. NaBH4, 75-85 % yields b)
NaH, MeI, DMF, 2 h, 0º C-rt, 69%
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Starting materials 198, 200 and 203a were synthesized for the synthesis of 163, 164 and
166 respectively (Scheme 70). Compounds 197, 199 and 201 were treated with
formaldehyde and sodium methoxide to afford the imines which were then reduced using
sodium borohydride to afford corresponding 198, 200 and 202 respectively in 75-85%
yields. Compound 202 was then deprotonated with sodium hydride, and treated with the
methyl iodide to afford the corresponding alkylated product 203a in 79% yield.

Scheme 71. Synthesis of 206

Reagents and conditions: a) 1. NaOMe, MeOH, rt, 30 min, 2. DMF, 100 °C, 6 h, b) NaOEt,
EtOH, reflux, 4 h, Acetamidine HCl, c) H2SO4, EtOH, reflux, 2
To synthesize the pyrrolo[2,3-d]pyrimidine scaffold 206 (Scheme 71), the acidic proton of
ethyl cyanoacetate 203b was deprotonated using sodium methoxide and alkylated to afford
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204 which was then cyclized using acetamidine hydrochloride to yield 205. Under acidic
conditions, 205 cyclized to afford 206.228, 247
Scheme 72. Synthesis of 162-167

Reagents and conditions: appropriate anilines, Dioxane, HCl, 140 °C, 2 h, MW, 42-65%
yield.
Direct cyclization of 6-amino-2-methylpyrimidin-4(3H)-one was also attempted with
chloroacetaldehyde to afford 206 , but was unsuccessful.228
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2-Methyl-pyrrolo[2,3-d]pyrimidine was subjected to nucleophilic aromatic substitution
reaction using appropriate anilines and catalytic amount of conc. HCl in dioxane to afford
162-167 in 42-65% yields (Scheme 72).244
A 1H NMR study was done in DMSO-d6 to determine the conformation of 162-167 and
was compared with the starting material 206 as shown in Table 13.
Table 15. Chemical shift of aromatic 5-CH proton in 1H NMR (DMSO-d6-400MHz)
Compound

Chemical shift

Compound

Chemical shift

206

6.52

165

5.9

162

4.6

166

4.45

163

4.75

167

4.65

164

6.01

The aromatic 5-CH proton of all the final products is more shielded compared to the same
proton in the starting material 206 suggesting a nearby diamagnetic anisotropic cone. So,
that’s why, we believe that the phenyl ring positions itself on the top of the 5-CH proton
leading to the observed shielding effect.83

Synthesis of 173-174

Commercially available esters 207a-207b (Scheme 73) were alkylated with 6-bromo-1hexanol to afford alkylated intermediates 208a-208b. The intermediates were then
oxidized using Dess-Martin Oxidation to the respective aldehydes 209a-209b. α-
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Bromination of the aldehydes with bromine-dioxane mixture at 0 ºC afforded the
corresponding α-bromo aldehydes 210a-210b. The

Scheme 73. Synthesis of 173-174

Reagents and conditions: a) K2CO3, DMF, rt, 10 h b) Dess-martin reagent, DCM, rt, 5 h c)
Br2, dioxane, DCM, rt, 2 h d) H2O/MeOH 1:1, CH3COONa, 50° C, 5 h e) 1 N NaOH f)
NMM, CDMT, DMF, rt, 5 h g) 1 N NaOH

Commercially available esters 207a-207b (Scheme 73) were alkylated with 6-bromo-1hexanol to afford alkylated intermediates 208a-208b. The intermediates were then
oxidized using Dess-Martin Oxidation to the respective aldehydes 209a-209b. α-
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Bromination of the aldehydes with bromine-dioxane mixture at 0 ºC afforded the
corresponding

α-bromo

aldehydes

210a-210b.

The

5-substituted

pyrrolo[2,3-

d]pyrimidines 211a-211b were then synthesized by condensation of 210a-210b with 2,4diamino-6-hydroxypyrimidine at 45 °C in the presence of sodium acetate. Subsequent
hydrolysis with 3 N NaOH afforded key intermediates 2-amino-4-oxo-pyrrolo[2,3d]pyrimidin-5-yl-alkoxybenzoic acids 211a-211b, followed by coupling with (L)-diethyl
glutamate esters using N-methylmorpholine and 6-chloro-2,4-dimethoxytriazine as the
activating agents, to afford diesters 212a-212b. Final saponification of the diesters with 1
N NaOH yielded the target 5-substituted pyrrolo[2,3-d]pyrimidines 173-174.
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Synthesis of 175-176
Scheme 74. Synthesis of 215

Reagents and conditions: a) K2CO3, MeCN, rt, 10 h b) Dess-martin reagent, DCM, rt, 5 h
c) 1. oxalyl chloride, DMSO, THF 2. TEA d) 1. NaBr, TEMPO, DCM/H2O (4:1), 0 °C 2.
6% NaOCl, NaHCO3, 0 °C, 2 h..
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Scheme 75. Synthesis of 218

Reagents and conditions: a) EtOH, H2SO4, reflux, 6 h b) Cs2CO3, DMF, rt, 10 h c) Dessmartin reagent, DCM, rt, 5 h d) 1. NaBr, TEMPO, DCM/H2O (4:1), 0 °C 2. 6% NaOCl,
NaHCO3, 0 °C, 2 h e) PCC, DCM, 30 min, rt

For the synthesis of the target compound 175, compound 207a (Scheme 74) was alkylated
with 4-bromo-1-butanol to afford alkylated intermediates 214. The intermediate were then
oxidized using Dess-Martin Oxidation but failed to afford 215. Similarly, for the synthesis
of target compound 176, compound 207b (Scheme 75) was alkylated with 4-bromo-1-
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butanol to afford alkylated intermediates 217. Dess-Martin oxidation failed to afford 218
and so different oxidation methods were attempted for the oxidation of both 214 and 217
as summarized in Table 14
Table 16. Different oxidation methods used and their results.
Type

Reagents

Temperature

Product

DMP

DMP

rt

Multiple spots

Swern

DMSO, Oxalyl chloride,
TEA

- 78 ºC

Multiple spots

TEMPO

TEMPO, 6% NaOCl,
NaHCO3

0 ºC

215

PCC

PCC in DCM

rt

218

Swern oxidation afforded multiple products which were difficult to isolate using column
chromatography. TEMPO oxidation worked successfully to afford 215 (Scheme 74).
Compound 217 under TEMPO oxidation conditions cleaved to yield alcohol 216 (Scheme
75). PCC oxidation was attempted which worked successfully to afford 218 (Scheme 75).
With these reactions, it was observed that for heteroatoms, various kind of oxidation
reactions should be attempted. Different reaction conditions ranging from - 78 ºC to rt
should be tried. Different reactions could also range from partially acidic to basic
conditions. TEMPO recation is run under partial acidic conditions, DMP under neutral, and
Swern under basic conditions as TEA is used. Sulfur as a heteroatom could have formed a
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complex with DMP, and this might be the reason behind failure of the reaction. With PCC,
that complex did not form, and reaction worked successfully.

Synthesis of 175
α-Bromination of the aldehyde 215 (Scheme 76) with bromine-dioxane mixture at 0 ºC
afforded the α-bromo aldehydes 216 (Scheme 76). The 5-substituted pyrrolo[2,3d]pyrimidines 217 was then synthesized by condensation of 216 with 2,4-diamino-6hydroxypyrimidine at 45 °C in the presence of sodium acetate. Subsequent hydrolysis with
3 N NaOH afforded key intermediate 2-amino-4-oxo-pyrrolo[2,3-d]pyrimidin-5-ylalkoxybenzoic acid 218, followed by coupling with (L)-diethyl glutamate esters using Nmethylmorpholine and 6-chloro-2,4-dimethoxytriazine as the activating agents, to afford
diesters 219. Final saponification of the diesters with 1 N NaOH yielded the target 5substituted pyrrolo[2,3-d]pyrimidines 175.

175

Scheme 76. Synthesis of 175

Reagents and conditions: c) Br2, dioxane, DCM, rt, 2 h d) H2O/MeOH 1:1, CH3COONa,
50° C, 5 h e) 1 N NaOH f) NMM, CDMT, DMF, rt, 5 h g) 1 N NaOH
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V. EXPERIMENTAL
All evaporations were carried out in vacuum with a rotary evaporator. Analytical samples
were dried in vacuo in a CHEM-DRY drying apparatus over P2O5 at 50 °C. Melting points
were determined either using a MEL-TEMP II melting point apparatus with FLUKE 51
K/J electronic thermometer or using an MPA100 OptiMelt automated melting point system
and are uncorrected. Nuclear magnetic resonance spectra for proton (1H NMR) were
recorded on the Bruker Avance II 400 (400 MHz) or Bruker Avance II 500 (500 MHz)
NMR systems with TopSpin processing software. The chemical shift values (δ) are
expressed in ppm (parts per million) relative to tetramethylsilane as an internal standard:
s, singlet; d, doublet; dd, doublet of doublet; t, triplet; q, quartet; m, multiplet; br, broad
singlet; td, triplet of doublet; dt, doublet of triplet; quin, quintet. Thin-layer
chromatography (TLC) was performed on Whatman® PE SIL G/UV254 flexible silica gel
plates and the spots were visualized under 254 and 365 nm ultraviolet illumination.
Proportions of solvents used for TLC are by volume. All analytical samples were
homogeneous on TLC in at least two different solvent systems. Column chromatography
was performed on the silica gel (70 to 230 meshes, Fisher Scientific) column. Flash
chromatography was carried out on the CombiFlash® Rf systems, model COMBIFLASH
RF. Pre-packed RediSep® Rf normal-phase flash columns (230 to 400 meshes) of various
sizes were used. The amount (weight) of silica gel for column chromatography was in the
range of 50-100 times the amount (weight) of the crude compounds being separated.
Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, GA. Element
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compositions are within ± 0.4% of the calculated values. Fractional moles of water or
organic solvents frequently found in some analytical samples could not be prevented
despite 24 to 48 hours of drying in vacuo and were confirmed where possible by their
presence in the 1H NMR spectra. High Perfomance Liquid Chromatography (HPLC) was
performed on Waters® 600E Multisolvent Delivery System, components: Waters® 600
Controller (model code: 600), 600E Pump (model code: 60F), Waters® 2487 Dual λ
Absorbance Detector. Mobile phase was an aqueous blend of water with a miscible, polar
organic solvent acetonitrile.
6-chloro-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (122)
2-Methyl-4,6-dichloropyrimdine (2g, 11.23 mmol, 1 equiv) and the N-methyl-4methoxyaniline (13.48 mmol, 1.2 equiv) were dissolved in dioxane (15 mL). To this
solution, was added 37 % HCl (cat.). The mixture was heated at 120 ºC in microwave and
stirred for 1.5 h. Then the reaction mixture was cooled to room temperature. Neutralization
was done by the addition of aq. NH4OH. The butanol is then stripped off. Silica gel was
added and the solvent evaporated to obtain a plug. Purification by column chromatography
using hexanes and ethyl acetate (10:1 to 1:2) afforded a brown solid in 75 % yield. TLC Rf
0.5 (EtOAc: Hex; 1:1), 1H NMR (CDCl3, 400MHz): δ 2.55 (s, 3H, 2CH3), 3.44 (s, 3H,
4NCH3), 3.84 (s, 3H, 4’OCH3), 2.55 (s, 2H, NH2), 6.90-6.92 (d, 2H, J = 8.8 Hz), 7.06-7.08
(d, 2H, J = 8.8 Hz), Anal. calcd. for C13H15ClN4O: C = 56.02%, H = 5.42%, N = 20.10%,
Cl = 12.72%, Found C = 56.29%, H = 5.51%, N = 20.00%, Cl = 12.55%, M.P.= 109-110º
C.
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6-chloro-N4-(4-methoxyphenyl)-N4,N5-2-trimethylpyrimidine-4,5-diamine (123)
Sodium hydride (29 mg, 1.1 equiv, 1.18 mmol) was added to a 3-neck flask. DMF (10 mL)
was added under inert conditions. The N-methyl-4-methoxyaniline (300 mg, 1 equiv, 1.08
mmol) compound is then added at 0 ºC. After 20 minutes when the nucleophile is
generated, methyl iodide (260 mg, 1.5 equiv, 1.84 mmol) is added dropwise and reaction
was run at room temperature for 2 hours. DMF is then stripped off and the reaction mixture
was neutralized to pH 8. The compound was then extracted in the organic layer using ether
and dried under sodium sulfate. Silica gel was added and the solvent evaporated to obtain
a plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to
1:2) afforded a light brown solid in 35 % yield. TLC Rf 0.62 (EtOAc: Hex; 1:1), 1H NMR
(400 MHz, DMSO-d6): δ 2.26 (s, 3H, 5-NHCH3), 2.39 (s, 3H, 2CH3), 3.31 (s, 3H, 4NCH3),
3.74 (s, 3H, 4’OCH3), 6.87-6.89 (d, 2H, J = 8.8 Hz), 6.98-7.00 (d, 2H, J = 8.8 Hz), Anal.
calculated for C14H17ClN4O . 0.08C6H14: C = 58.03%, H = 6.09%, N = 18.69%, Cl =
11.83%, Found C = 58.06%, H = 5.97%, N = 18.76%, Cl = 11.85%, M.P. = 67-68º C.
6-chloro-N4-(4-methoxyphenyl)-N4,N5,N5,2-tetramethylpyrimidine-4,5-diamine
(124)
Sodium hydride (29 mg, 1.1 equiv, 1.18 mmol) was added to a 3-neck flask. DMF (10 mL)
was added under inert conditions. The N-methyl-4-methoxyaniline (300 mg, 1 equiv, 1.08
mmol) compound is then added at 0 ºC. After 20 minutes when the nucleophile is
generated, the alkyl halide (252 mg, 1.5 equiv, 1.61 mmol) is added dropwise and reaction
was run at room temperature for 2 hours. DMF is then stripped off and the reaction mixture
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was neutralized to pH 8. The compound was then extracted in the organic layer using ether
and dried under sodium sulfate. Silica gel was added and the solvent evaporated to obtain
a plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to
1:2) afforded a brown solid in 50 % yield. TLC Rf 0.65 (EtOAc: Hex; 1:1), 1H NMR
(CDCl3, 400MHz): δ 2.14 (s, 6H, 5-N-diCH3), 2.54 (s, 3H, 2CH3), 3.37 (s, 3H, 4NCH3),
3.83 (s, 3H, 4’OCH3), 6.87-6.89 (d, 2H, J = 8.8 Hz), 7.08-7.10 (d, 2H, J = 8.8 Hz). Anal.
calculated for C15H19ClN4O. 0.08C6H14: C, 59.27; H, 6.46; N, 17.86; Cl, 11.30, Found C =
59.16%, H = 6.37%, N = 17.71%, Cl = 11.23%, M.P. = 71-73º C.
6-chloro-N5-ethyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine
(125)
Compound 122 (100 mg, 0.25 mmol) was taken in a 3-neck round bottom flask covered
with a septum, an adapter and a stopper. NaH (9.47 mg, 1.1 equiv) was added quickly and
was diluted with 3 mL of DMF. The reaction is kept under argon for the entire time. After
10 min, ethyl iodide (84 mg, 1.5 equiv, 0.54 mmol) was added and remaining DMF (2 mL)
was added quickly after that. The reaction was allowed to run under argon for 4 hrs at room
temperature. DMF was stripped off using high pressure. The product was then extracted
using ethyl acetate and dried under sodium sulfate for half an hour. Ethyl acetate was then
evaporated using rotary evaporator at 36 ºC. Silica gel was added and the solvent
evaporated to obtain a plug. Purification by column chromatography using hexanes and
ethyl acetate (10:1 to 1:2) afforded a light brown solid in 68 % yield. TLC Rf 0.72 (EtOAc:
Hex; 1:1), 1H NMR (400 MHz, DMSO-d6): ∂ 0.64 (t, 3H, CH3), 2.40 (s, 3H, 2-CH3), 2.622.64 (q, 2H, 5-N-CH2), 3.74 (s, 3H, NCH3), 3.32 (s, 3H, OCH3), 6.88-6.90 (d, 2H, J = 8.8
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Hz), 7.02-7.04 (d, 2H, J = 8.8 Hz), Anal. calculated for C15H19ClN4O: C, 58.73; H, 6.24;
N, 18.26; Cl, 11.55; Found C = 58.70%, H = 6.22%, N = 18.38%, Cl = 11.46%, M.P. = 8485◦ C.
6-chloro-N4-(4-methoxyphenyl)-N4,2-dimethyl-N5-propylpyrimidine-4,5-diamine
(126·HCl)
Sodium hydride (29 mg, 1.1 equiv, 1.18 mmol) was added to a 3-neck flask. DMF (10 mL)
was added under inert conditions. The N-methyl-4-methoxyaniline (300 mg, 1 equiv, 1.08
mmol) compound is then added at 0 ºC. After 20 minutes when the nucleophile is
generated, propyl iodide (252 mg, 1.5 equiv., 1.61 mmol.) is added dropwise and reaction
was run at room temperature for 2 hours. DMF is then stripped off and the reaction mixture
was neutralized to pH 8. The compound was then extracted in organic layer using ether
and dried under magnesium sulfate. Silica gel was added and the solvent evaporated to
obtain a plug. Purification by column chromatography using hexanes and ethyl acetate
(10:1 to 1:2) afforded a brownish semi solid in 78 % yield. The product was converted into
a HCl salt using HCl gas in ether solution. TLC Rf 0.88 (EtOAc: Hex; 1:1), 1H NMR
(DMSO-d6, 400MHz): δ 0.65(t, 3H,CH3, J = 7.6 Hz), 0.98-1.02 (m, 2H, CH2), 2.40 (s, 3H,
2-CH3), 2.52-2.55 (m, 2H, CH2, J = 7.6 Hz), 3.33 (s, 3H, 4’OCH3), 3.45 (s, 1H, 5-NH),
3.74 (s, 3H, 4NCH3), 6.87-6.89 (d,2H, J = 8.8 Hz), 6.99-7.01 (d,2H, J = 8.8 Hz), Analysis
calculated for C16H21ClN4O.0.4H2O.1.0HCl, C = 52.72%, H = 6.31, N = 15.37%, Cl =
19.45%, Found C = 53.04%, H = 5.92, N = 15.34%, Cl = 19.13%, M.P. for 126·HCl = 107
◦

C.
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N5-butyl-6-chloro-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine
(127·HCl)
Sodium hydride (29 mg, 1.1 equiv, 1.18 mmol) was added to a 3-neck flask. DMF (10 mL)
was added under inert conditions. The aniline (300 mg, 1 equiv, 1.08 mmol) compound is
then added at 0 ºC. After 20 minutes when the nucleophile is generated, butyl iodide (252
mg, 1.5 equiv, 1.61 mmol) is added dropwise and reaction was run at room temperature for
2 hours. DMF is then stripped off and the reaction mixture was neutralized to pH 8. The
compound was then extracted in organic layer using ether and dried under magnesium
sulfate. Silica gel was added and the solvent evaporated to obtain a plug. Purification by
column chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded a brownish
semisolid in 62 % yield. The product was converted into a HCl salt using HCl gas in ether
solution. TLC Rf 0.90 (EtOAc: Hex; 1:1) 1H NMR (CDCl3, 400MHz): δ 0.80-0.84 (t, 3H,
CH3, J = 7.6 Hz), 1.05-1.17 (m, 4H, CH2), 2.56(s, 3H, CH2), 2.65-2.67 (m, 2H, CH2), 2.84
(s, 1H, NH), 3.43 (s, 3H, 4NCH3), 3.83 (s, 3H, 4’OCH3), 6.87-6.89 (d,2H, J = 8.8 Hz),
6.99-7.01 (d, 2H, J = 8.8 Hz). Analysis calculated for (C17H23ClN4O.1.0HCl) C = 55.14%,
H = 6.26, N = 15.13%, Cl = 19.15%., Found C = 54.86%, H = 6.52, N = 15.08%, Cl =
18.92%, M.P. for 127·HCl = 119-123 ◦ C.
6-chloro-N5-isobutyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine
(128)
Sodium hydride (29 mg, 1.1 equiv, 1.18 mmol) was added to a 3-neck flask. DMF (10 mL)
was added under inert conditions. The aniline (300 mg, 1 equiv, 1.08 mmol) compound is
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then added at 0 ºC. After 20 minutes when the nucleophile is generated, isobutyl iodide
(252 mg, 1.5 equiv, 1.61 mmol) is added dropwise and reaction was run at room
temperature for 2 hours. DMF is then stripped off and the reaction mixture was neutralized
to pH 8. The compound was then extracted in organic layer using ether and dried under
magnesium sulfate. Silica gel was added and the solvent evaporated to obtain a plug.
Purification by column chromatography using hexanes and ethyl acetate (10:1 to 1:2)
afforded a light brown semi solid in 65 % yield. TLC Rf 90 (EtOAc: Hex; 1:1) 1H NMR
(CDCl3, 400MHz): δ 0.72 (s, 3H,CH3), 0.74 (s, 3H,CH3), 1.25-1.33 (m, 1H, CH), 2.492.52 (t, 2H, CH2), 2.55(s, 3H, CH2), 2.96 (m, 1H, NH), 3.44 (s, 3H, 4NCH3), 3.82 (s, 3H,
4’OCH3), 6.87-6.89 (d,2H, J = 8.8 Hz), 6.99-7.01 (d, 2H, J = 8.8 Hz). HPLC –98.47% pure,
LRMS calculated for C17H23ClN4O = 334.85, found 334.85.
6-benzyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (130)
0.5 M solution of benzyl zinc chloride (5.7 mL, 4 equiv, 2.87 mmol) and
tetrakis(triphenylphosphine)palladium (0.05 equiv, 36 µmol) was added to a sloution of
iodopyrimidine (1equiv, 540 µmol) in dry THF at 60 ºC for 12 h under inert conditions.
The reaction was stopped and THF was stripped off. Silica gel was added and the solvent
evaporated to obtain a plug. Purification by column chromatography using hexanes and
ethyl acetate (10:1 to 1:2) afforded a brown semisolid in 35 % yield. TLC Rf 0.20 (EtOAc:
Hex; 1:1) 1H NMR (DMSO-d6, 400MHz): δ 2.57 (s, 3H, 2CH3), 3.49 (s, 3H, 4NCH3), 3.79
(s, 3H, 4’OCH3), 4.08 (s, 2H, CH2), 4.23 (s, 2H, NH2), 6.99-7.01 (d, 2H, aromatic), 7.22-
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7.32 (m, 7H, aromatic). HPLC –97.23% pure, HRMS calculated for C20H23N4O [M + H]+
335.1874, found 335.1862.
N4-(4-methoxyphenyl)-N4,2-dimethyl-6-phenethylpyrimidine-4,5-diamine (131)
The aniline 152 (1g, 2.9 mmol, 1 equiv) was hydrogenated using 5% Pd/C (200 mg, 20%
w/w) in 15 mL methanol for 7 h under 50 psi. Palladium was then filtered using Celite®
and washed several times with methanol. Methanol was then striped off. Silica gel was
added and the solvent evaporated to obtain a plug. Purification by column chromatography
using hexanes and ethyl acetate (10:1 to 1:2) afforded 131 in 35 % yield as a brownish
semisolid. TLC Rf 0.35 (EtOAc: Hex, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 2.41(s, 3H),
2.80-2.84 (dd, J = 6.0Hz, J = 9.6Hz, 2H), 2.92-2.96 (dd, J = 6.1Hz, J = 10.2Hz, 2H), 3.25
(s, 3H), 3.73 (s, 3H), 3.85 (s, 2H), 6.88 (m, 4H), 7.18 (m, 1H), 7.26 (s, 2H), 7.27 (s, 2H),
HPLC –96.9% pure, HRMS calculated for C21H25N4O [M + H]+ 349.2031, found
349.2030.
N4-(4-methoxyphenyl)-N4,2-dimethyl-6-(phenylethynyl)pyrimidine-4,5-diamine
(132)
Copper iodide (0.16 equiv, 3.38 mmol) and bis(triphenylphosphine)palladium chloride
(0.05 equiv, 67.5 mmol) were added to a solution of iodopyridine (1 equiv, 1.35 mmol) in
10 mL trimethylamine under nitrogen gas and the resulted compound was stirred for 30
min. Then phenylacetylene (2.5 equiv, 3.38 mmol) was added dropwise to the solution,
and was stirred for 30 minutes. Silica gel was added and the solvent evaporated to obtain a
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plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to 1:2)
afforded 132 in 65% yield as a dark brown solid. TLC Rf 0.50 (EtOAc: Hex, 1:1); 1H NMR
(400 MHz, DMSO-d6) δ 2.41 (s, 3H), 3.34 (s, 3H), 3.76 (s, 3H), 4.19 (s, 2H), 6.95-6.97 (d,
J = 8.9Hz, 2H), 7.07-7.09 (d, J = 8.9Hz, 2H), 7.42 (d, J = 1.3Hz, 1H), 7.44 (d, J = 2.3Hz,
1H), 7.63-7.66 (m, 2H) Anal. calcd. for C21H20N4O: C, 73.23; H, 5.85; N, 16.27; Found C
= 73.13%, H = 5.90, N = 16.11%.
N-(4-chloro-6-((4-methoxyphenyl)(methyl)amino)-2-methylpyrimidin-5yl)acetamide (133)
Compound 122 (50 mg, 0.18 mmol) was dissolved in 6 mL acetic anhydride and the
reaction was run at 120 ºC for 5 h. The solvent was stripped off. Silica gel was added and
the solvent evaporated to obtain a plug. Purification by column chromatography using
hexanes and ethyl acetate (10:1 to 1:2) afforded a white solid in 75 % yield. TLC Rf 0.25
(EtOAc: Hex; 1:1),

1

H NMR (DMSO-d6, 400MHz): δ 1.6 (s, 3H, NAc.), 2.61 (s, 3H,

2CH3), 3.42 (s, 3H, 4NCH3), 3.82 (s, 3H, 4’OCH3), 5.70 (s, 1H, NH), 6.94-6.96 (d, 2H, J
= 8.8 Hz), 7.22-7.25 (d, 2H, J = 8.8 Hz) Analysis calculated for C15H17ClN4O2 : C =
56.16%, H = 5.34, N = 17.47%, Cl = 11.05%; Found C = 56.33%, H = 5.52, N = 17.37%,
Cl = 10.88%, M.P. = 158-159 ºC.
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N-acetyl-N-(4-chloro-6-((4-methoxyphenyl)(methyl)amino)-2-methylpyrimidin-5yl)acetamide (134)
Compound 122 (50 mg, 0.18 mmol) was dissolved in acetic anhydride (6 mL) and the
reaction was run at 150 ºC for 5 h. The solvent was stripped off. Silica gel was added and
the solvent evaporated to obtain a plug. Purification by column chromatography using
hexanes and ethyl acetate (10:1 to 1:2) afforded a white solid in 45 % yield. TLC Rf 0.75
(EtOAc: Hex; 1:1), 1H NMR (CDCl3, 400MHz): δ 1.99 (s, 6H, NPiv.), 2.61 (s, 3H, 2CH3),
3.42 (s, 3H, 4NCH3), 3.82 (s, 3H, 4’OCH3), 6.94-6.96 (d, 2H, J = 8.8 Hz), 7.22-7.25 (d,
2H, J = 8.8 Hz). Analysis calculated for C17H19ClN4O3: C, 56.28; H, 5.28; N, 15.44; Cl,
9.77; Found C = 56.37%, H = 5.33%, N = 15.41%, Cl = 9.59%, M.P. = 179-181 ºC.
N-(4-chloro-6-((4-methoxyphenyl)(methyl)amino)-2-methylpyrimidin-5yl)pivalamide (135)
Compound 122 (50 mg, 0.18 mmol) was dissolved in pivalic anhydride (6 mL) and the
reaction was run at 120 ºC for 2 h. The solvent was stripped off. Silica gel was added and
the solvent evaporated to obtain a plug. Purification by column chromatography using
hexanes and ethyl acetate (10:1 to 1:2) afforded a grey solid in 78 % yield. TLC Rf 0.28
(EtOAc: Hex; 1:1); 1H NMR (DMSO-d6, 400MHz): δ 1.39 (s, 9H, CH3), 2.55 (s, 3H,
2CH3), 3.78 (s, 3H, 4NCH3), 3.87 (s, 3H, 4’OCH3), 6.94-6.96 (d, 2H, J = 8.8 Hz), 7.227.25 (d, 2H, J = 8.8 Hz). Analysis calculated for C18H23ClN4O2: C, 59.58; H, 6.39; N,
15.44; Cl, 9.77; Found C = 59.57%, H = 6.45, N = 15.25%, Cl = 9.65%, M.P. = 193-194º
C.
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6-chloro-N-(4-methoxyphenyl)-N,2-dimethyl-5-nitropyrimidin-4-amine (136)
2-methyl-4,6-dichloro-5-nitropyrimdine (1 g, 4.81 mmol), 4-methoxyaniline (792 mg, 5.77
mmol, 1.2 equiv) and catalytic amount of conc. HCl were added to a microwave vial in 15
mL dioxane and heated at 120 ºC for 2 h. The reaction was stopped and dioxane was
stripped off and reaction mixture neutralized to pH 8. Silica gel was added and the solvent
evaporated to obtain a plug. Purification by column chromatography using hexanes and
ethyl acetate (10:1 to 1:2) afforded a yellowish solid in 82 % yield. TLC Rf 0.70 (EtOAc:
Hex; 1:1) 1H NMR (DMSO-d6, 400MHz): δ 2.62 (s, 3H, CH3), 3.53 (s, 3H, 4NCH3), 3.84
(s, 3H, 4’OCH3), 6.86-6.88 (d, 2H, J = 8.8 Hz), 7.07-7.09 (d, 2H, J = 8.8 Hz), Analysis
calculated for C13H13ClN4O3.0.2773CH3(CH2)4CH3 (Hexane was during the purification
step): C, 52.95; H, 5.11; N, 16.84; Cl, 10.65; Found C = 53.04%, H = 4.74, N = 16.87%,
Cl = 10.46%, M.P. = 91-93º C.
N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (137)
The aniline 122 (50 mg, 0.18 mmol) was hydrogenated using 5% Pd/C (10 mg, 20% w/w)
in methanol (10 mL) for 7 h under 50 psi. Palladium was then filtered using Celiteâ and
washed several times with methanol. Methanol was then striped off. Silica gel was added
and the solvent evaporated to obtain a plug. Purification by column chromatography using
hexanes and ethyl acetate (10:1 to 1:2) afforded a light brown solid in 65 % yield. TLC Rf
0.40 (EtOAc: Hex; 1:1) 1H NMR (400 MHz, CDCl3): δ 2.70 (s, 3H, 2CH3), 3.54 (s, 3H,
4NCH3), 3.86 (s, 3H, 4’OCH3), 4.22 (s, 2H, NH2), 6.92-6.94 (d, 2H, J = 8.8 Hz), 7.15-7.17
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(d,2H, J = 8.8 Hz), 8.15 (s, 1H), (C13H16N4O), HPLC –99.2% pure, HRMS calculated for
C13H17N4O [M + H]+ 245.1404, found 245.1404, M.P. = 183-185º C.
N`4-(4-methoxyphenyl)-N4,2,6-trimethylpyrimidine-4,5-diamine (138)
To a solution of 153 in 10 mL THF was added trimethylaluminium (1M solution in THF,
2 equiv, 718 µmol) and tetrakis(triphenylphosphine)palladium (0.1 equiv) and reaction was
run under reflux and inert conditions. THF was then striped off. Silica gel was added and
the solvent evaporated to obtain a plug. Purification by column chromatography using
hexanes and ethyl acetate (10:1 to 1:2) afforded a light brown solid in 65 % yield. TLC Rf
0.6 (EtOAc: Hex; 1:1), 1H NMR (400 MHz, DMSO-d6): δ 2.18 (s, 3H, 6CH3), 2.37 (s, 3H,
2CH3), 3.24 (s, 3H, 4NCH3), 3.75 (s, 3H, 4’OCH3), 3.81(s, 2H, NH2), 6.89 (m, 4H), HPLC
–97.8% pure, C14H19N4O [M + H]+ 259.1561 found 259.1548, M.P. 108-110 ºC.
6-ethyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (139·HCl)
To a solution of 153 in THF was added triethylaluminium (1M solution in THF, 2 equiv,
718 µmol) and tetrakis(triphenylphosphine)palladium (0.1 equiv) and reaction was run
under reflux and inert conditions. THF was then striped off. Silica gel was added and the
solvent evaporated to obtain a plug. Purification by column chromatography using hexanes
and ethyl acetate (10:1 to 1:2) afforded a light brown semisolid in 58 % yield. TLC Rf 0.68
(EtOAc: Hex; 1:1), 1H NMR (400 MHz, DMSO-d6): δ 1.25 (s, 3H), 2.58 (s, 2H), 2.59 (s,
3H, 2CH3), 3.00 (s, 2H, NH2), 3.43 (s, 3H, 4NCH3), 3.82 (s, 3H, 4’OCH3), 6.88-6.90 (d,
2H, J = 8.8 Hz), 6.99-7.01 (d, 2H, J = 8.8 Hz), C15H20N4O, HPLC –99.5% pure, HRMS
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calculated for C15H21N4O [M + H]+ 273.1717, found 273.1729, M.P. for 139·HCl = 200203 ºC.
N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5,6-triamine (140)
6-chloro-2-methylpyrimidine-4,5-diamine (50 mg, 1 equiv, 315 µmol), 4-methoxy aniline
(65 mg, 1.5 equiv, 473 µmol) and catalytic amount of conc. HCl (1-2 drops) were added to
a microwave vial in 15 mL dioxane and heated at 120 ºC for 2 h. The reaction was stopped
and dioxane was stripped off and reaction mixture neutralized to pH 8. The resulting plug
was loaded on to a silica gel column (2 × 12 cm) and eluted with CHCl3 followed by 3%
MeOH in CHCl3 and then 5% MeOH in CHCl3. Fractions containing the product were
pooled and evaporated to afford a white solid in 42 % yield. TLC Rf 0.75 (CH3OH: CHCl3;
1:5), 1H NMR (DMSO-d6, 400MHz): δ 2.22 (s, 3H, CH3), 3.15 (s, 3H, 4NCH3), 3.70 (s,
3H, 4’OCH3), 3.70-3.75 (s, 2H, 5NH2), 6.31 (s, 2H, 6NH2), 6.71-6.73 (d, C’2, 6 aromatic),
6.81-6.83(d, C’3, 5), Analysis calculated for C13H17N5O. 0.23 H2O: C, 60.21; H, 6.61; N,
27.01, Found C = 59.17%, H = 6.41, N = 26.76%, M.P. = 179-181 ºC.
5-amino-6-((4-methoxyphenyl)(methyl)amino)-2-ethylpyrimidine-4-carbonitrile
(141)
Iodopyridine 142 (0.45 g, 1.22 mmol) was dissolved in 10 mL DMF and reaction is heated
to 120 ºC with stirring and copper cyanide (3 equiv, 3.65 mmol) was added. There was
complete conversion in 10 min. The reaction mixture was cooled to room temp. and filtered
using Buchner funnel. Silica gel was added and the solvent evaporated to obtain a plug.
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Purification by column chromatography using hexanes and ethyl acetate (10:1 to 1:2)
afforded 141 in 22% yield as a yellow solid: TLC Rf 0.66 (EtOAc: Hex, 1:1); 1H NMR
(400 MHz, DMSO-d6): δ 2.40 (s, 3H), 3.33 (s, 3H), 3.77 (s, 3H), 4.67 (s, 2H), 6.96-6.98
(d, J = 8.9 Hz, 2H), 7.13-7.15 (d, J = 8.9 Hz, 2H) Anal. calcd. for C14H15N5O. 0.1 H2O: C,
62.02; H, 5.65; N, 25.83, Found C = 61.99%, H = 5.52%, N = 25.58%, M.P. = 126.0-129.0
ºC.
6-iodo-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (142)
Pyrimidine 122 (1g, 3.59 mmol) was added in portions in stirring aqueous HI (57 wt % aq.,
25 mL) at 0 ºC and then stirred overnight. The reaction mixture was then neutralized by
adding 15 mL of ammonium hydroxide and then extracted using ethyl acetate and dried
under magnesium sulfate. Silica gel was added and the solvent evaporated to obtain a plug.
Purification by column chromatography using hexanes and ethyl acetate (10:1 to 1:2)
afforded 0.92 g (65%) as a greenish solid: TLC Rf 0.65 (EtOAc: Hex, 1:1); 1H NMR
(CDCl3) δ 1H NMR (400 MHz, CDCl3) δ 2.56 (s, 3H), 3.43 (s, 3H), 3.83 (s, 3H), 3.90 (s,
2H), 6.88-6.89 (d, J = 8.8 Hz, 2H), 7.02-7.03 (d, J = 8.8 Hz, 2H) Anal. calcd. for
C13H15IN4O: C, 42.18; H, 4.08; N, 15.13; I, 34.28, Found C = 42.48%, H = 4.24%, N =
15.15%, I = 34.15%, M.P. = 88.8-91.0 ºC.
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N4-(4-methoxyphenyl)-N4,2-dimethyl-6-(trifluoromethyl)pyrimidine-4,5-diamine
(143)
Trifluoromethylation was done using phenanthroline−CuCF3 complex reagent (1.3 equiv,
122 mg, 0.389 mmol) and 10 mL DMF as solvent in microwave at 80 ºC in 8 hours. DMF
is then stripped off. Silica gel was added and the solvent evaporated to obtain a plug.
Purification by column chromatography using hexanes and ethyl acetate (10:1 to 1:2)
afforded 143 in 85% yield as a dark brown solid: TLC Rf 0.82 (EtOAc: Hex, 1:1); 1H NMR
(400 MHz, DMSO-d6): δ 2.43 (s, 3H), 3.30 (s, 3H), 3.74 (s, 3H), 4.35 (s, 2H), 6.93-6.96
(dd, J = 3.6Hz, J = 8.8Hz, 2H), 7.06-7.08 (dd, J = 3.5Hz, J = 8.9Hz, 2H) HPLC – 98.8%
pure, HRMS calculated for C14H15F3N4O [M + H]+ 313.1278, found 313.1261, M.P. = 125126 °C.
6-chloro-N4-(4-methoxyphenyl)-N4-methylpyrimidine-4,5-diamine (144)
4,6-dichloropyrimidin-5-amine (80 mg, 1equiv, 485 µmol), 4-methoxyaniline (101 mg,
0.73 mmol, 1.5 equiv) and catalytic amount of conc. HCl were added to a microwave vial
in 15 mL dioxane and heated at 120 ºC for 2 h. The reaction was stopped and dioxane was
stripped off and reaction mixture neutralized to pH 8. Silica gel was added and the solvent
evaporated to obtain a plug. Purification by column chromatography using hexanes and
ethyl acetate (10:1 to 1:2) afforded a grey solid in 68 % yield. TLC Rf 0.39 (EtOAc: Hex;
1:1), 1H NMR (CDCl3, 400MHz): δ 3.46 (s, 3H, 4NCH3), 3.84 (s, 3H, 4’OCH3), 3.5-3.8 (s,
2H, 5NH2), 6.90-6.91 (d, C’2, 6 aromatic), 7.06-7.07 (d, C’3, 5), 8.2 (s, 1H, 2-H), Anal.
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calcd. for C12H13ClN4O: C, 54.45; H, 4.95; N, 21.17; Cl, 13.39, Found C = 54.72%, H =
5.00%, N = 20.93%, Cl = 13.12 %, M.P. = 126.0-129.0 ºC.
6-chloro-2-ethyl-N4-(4-methoxyphenyl)-N4-methylpyrimidine-4,5-diamine
(145·HCl)
2-ethyl-4,6-dichloropyrimdine (100 mg, 0.52 mmol, 1 equiv.) and the N-methyl-4methoxyaniline (0.62 mmol, 1.2 equiv.) were dissolved in butanol (15 mL). To this
solution, was added 37% HCl (cat.). The mixture was heated at 120 ºC in microwave with
stirring for 1.5 h. Then the reaction mixture was cooled to room temperature. Neutralization
was done by the addition of aq. NH4OH. The butanol is then stripped off. Silica gel was
added and the solvent evaporated to obtain a plug. Purification by column chromatography
using hexanes and ethyl acetate (10:1 to 1:2) afforded a grey solid in 68 % yield. TLC Rf
0.75 (EtOAc: Hex; 1:1), 1H NMR (CDCl3, 400MHz): δ 1.35 (s, 3H, 2CH3), 2.84 (s, 2H,
2CH2), 3.48 (s, 3H, 4NCH3), 3.84 (s, 3H, 4’OCH3), 6.92-6.94 (d, 2H, J = 8.8 Hz), 7.077.08 (d, 2H, J = 8.8 Hz), Anal. calcd. for C14H17ClN4O.0.95H2O. 0.95HCl: C, 48.80; H,
5.80; N, 16.26; Cl, 20.07; Found C = 48.92%, H = 5.82%, N = 15.94%, Cl = 20.04 %, M.P.
= 135-136.0 ºC.
6-chloro-2-ethyl-N4-(4-methoxyphenyl)-N4,N5-dimethylpyrimidine-4,5-diamine
(146)
Compound 145 (100 mg, 1 equiv, 0.36 mmol) was taken in a 3 necked round bottom flask
covered with septums, and adapter. NaH (1.1 equiv, 0.39 mmol) was added and was
diluted with 3 mL of DMF. The reaction is kept under argon for the entire time. After 10
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min, methyl iodide (1.1 equiv., 0.39 mmol) was added and remaining DMF (2 mL) was
added. The reaction was allowed to run under argon for 4 hrs at room temperature. DMF
was stripped off using high pressure. The product was then extracted using ethyl acetate
and dried under sodium sulfate. Silica gel was added and the solvent evaporated to obtain
a plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to
1:2) afforded a brown solid in 35 % yield. TLC Rf 0.21 (EtOAc: Hex; 1:1), 1H NMR (400
MHz, DMSO-d6): δ 1.35 (s, 3H, 2CH3), 2.84 (s, 2H, 2CH2), 3.48 (s, 3H, 4NCH3), 3.84 (s,
3H, 4’OCH3), 6.92-6.94 (d, 2H, J = 8.8 Hz), 7.07-7.08 (d,2H, J = 8.8 Hz), Anal. calcd. for
C12H14ClN5O: C, 51.53; H, 5.04; N, 25.04; Cl, 12.67, Found C = 51.70%, H = 5.13%, N
= 24.98%, Cl = 12.53 %, M.P. = 141-142 ºC.
6-chloro-N5,2-diethyl-N4-(4-methoxyphenyl)-N4-methylpyrimidine-4,5-diamine
(147)
Compound 146 (100 mg, 1 equiv, 0.36 mmol) was taken in a 3 necked round bottom flask
covered with septums and an adapter. NaH (1.1 equiv, 0.39 mmol) was added and was
diluted with 3 mL of DMF. The reaction is kept under argon for the entire time. After 10
min, methyl iodide (1.1 equiv., 0.39 mmol) was added and remaining DMF (2 mL) was
added. The reaction was allowed to run under argon for 4 hrs at room temperature. DMF
was stripped off using high pressure. The product was then extracted using ethyl acetate
and dried under sodium sulfate. Silica gel was added and the solvent evaporated to obtain
a plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to
1:2) afforded 147 (65 % yield as a light brown solid). TLC Rf 0.30 (EtOAc: Hex; 1:1), 1H
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NMR (400 MHz, DMSO-d6): δ 1.35 (s, 3H, 2CH3), 2.84 (s, 2H, 2CH2), 3.48 (s, 3H,
4NCH3), 3.84 (s, 3H, 4’OCH3), 6.92-6.94 (d, 2H, J = 8.8 Hz), 7.07-7.08

(d,2H, J = 8.8

Hz), ), Anal. calcd. for C13H16ClN5O: C, 53.15; H, 5.49; N, 23.84, Cl, 12.07, Found C =
53.36%, H = 5.58%, N = 23.56%, Cl = 11.84 %, M.P. = 155-156ºC.
6-chloro-N4-(4-methoxyphenyl)-N4-methylpyrimidine-2,4,5-triamine (148)
4,6-dichloropyrimidine-2,5-diamine (40 mg, 1 equiv, 223 µmol), 4-methoxyaniline (46
mg, 0.34 mmol, 1.5 equiv) and catalytic amount of conc. HCl were added to a microwave
vial in 15 mL dioxane and heated at 120 ºC for 2 h. The reaction was stopped and dioxane
was stripped off and reaction mixture neutralized to pH 8. Silica gel was added and the
solvent evaporated to obtain a plug. Purification by column chromatography using hexanes
and ethyl acetate (10:1 to 1:2) afforded a dark brown solid in 72 % yield. TLC Rf 0.45
(EtOAc: Hex; 1:1) 1H NMR (CDCl3, 400MHz): 2.96 (s, 2H, 2NH2), δ 3.18 (s, 3H, 4NCH3),
3.84 (s, 3H, 4’OCH3), 4.70 (s, 2H, 5NH2), 6.90-6.91 (d, C’2, 6 aromatic), 7.06-7.07 (d,
C’3, 5). Anal. calcd. for C14H18ClN5O: C, 54.63; H, 5.90; N, 22.75; Cl, 11.52, Found C =
54.83%, H = 5.86%, N = 22.55%, Cl = 11.36 %, M.P. = 172-174 ºC.
6-chloro-N4-(4-methoxyphenyl)-N4,N5-dimethylpyrimidine-2,4,5-triamine (149)
Compound 148 (100 mg, 1 equiv, 0.36 mmol) was taken in a 3 necked round bottom flask
covered with septums, and an adapter. NaH (1.1 equiv, 0.39 mmol) was added and was
diluted with 3 mL of DMF. The reaction is kept under argon for the entire time. After 10
min, methyl iodide (1.1 equiv, 0.39 mmol) was added and remaining DMF (2 mL) was
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added. The reaction was allowed to run under argon for 4 hrs at room temperature. DMF
was stripped off using high pressure. The product was then extracted using ethyl acetate
and dried under sodium sulfate. Silica gel was added and the solvent evaporated to obtain
a plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to
1:2) afforded a light brown solid in 22 % yield. TLC Rf 0.6 (EtOAc: Hex; 1:1) 1H NMR
(400 MHz, DMSO-d6): 2.92 (s, 2H, 2NH2), 2.97 (s, 3H, 4NCH3), 3.40 (s, 3H, 4’OCH3),
3.83 (s, 3H, 5NCH3), 4.84 (s, 2H, 5NH), 6.90-6.91 (d, C’2, 6 aromatic), 7.06-7.07 (d, C’3,
5), Anal. calcd. for C13H16ClN5O: C, 53.15; H, 5.49; N, 23.84; Cl, 12.07, Found C =
53.36%, H = 5.58%, N = 23.56%, Cl = 11.84 %, M.P. = 148-150 ºC.
6-chloro-N5-ethyl-N4-(4-methoxyphenyl)-N4-methylpyrimidine-2,4,5-triamine (150)
Compound 148 (100 mg, 1 equiv, 0.36 mmol) was taken in a 3 necked round bottom flask
covered with septums, and an adapter. NaH (1.1 equiv, 0.39 mmol) was added and was
diluted with 3 mL of DMF. The reaction is kept under argon for the entire time. After 10
min, ethyl iodide (1.1 equiv., 0.39 mmol) was added and remaining DMF (2 mL) was
added. The reaction was allowed to run under argon for 4 hrs at room temperature. DMF
was stripped off using high pressure. The product was then extracted using ethyl acetate
and dried under sodium sulfate. Silica gel was added and the solvent evaporated to obtain
a plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to
1:2) afforded a dark brown solid in 53 % yield. TLC Rf 0.6 (EtOAc: Hex; 1:1), 1H NMR
(400 MHz, DMSO-d6): 2.92 (s, 2H, 2NH2), 2.97 (s, 3H, 4NCH3), 3.40 (s, 3H, 4’OCH3),
3.83 (s, 3H, 5NCH3), 4.84 (s, 2H, 5NH), 6.90-6.91 (d, C’2, 6 aromatic), 7.06-7.07 (d, C’3,
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5)., Anal. calcd. for C14H18ClN5O: C, 54.63; H, 5.90; N, 22.75; Cl, 11.52, Found C =
54.83%, H = 5.86%, N = 22.55%, Cl = 11.36 %, M.P. = 90-92 ºC.
6-chloro-N4,2-dimethyl-N4-(4-(methylthio)phenyl)pyrimidine-4,5-diamine (151)
2-methyl-4,6

dichloro-5-aminopyrimdine

(1

g,

5.44

mmol),

N-methyl-4-

(methylthio)aniline (1.1 g, 7.18 mmol, 1.2 equiv) and catalytic amount of conc. HCl were
added to a microwave vial in 15 mL dioxane and heated at 120 ºC for 2 h. The reaction
was stopped and dioxane was stripped off and reaction mixture neutralized to pH 8. Silica
gel was added and the solvent evaporated to obtain a plug. Purification by column
chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded a light brown solid
in 73 % yield. TLC Rf 0.80 (EtOAc: Hex; 1:1) 1H NMR (DMSO-d6, 400MHz): δ 2.39 (s,
3H, CH3), 2.46 (s, 3H, 4NCH3), 3.34 (s, 3H, 4’OCH3), 4.32 (s, 2H, 5NH2), 6.92-6.94 (d,
C’2, 6 aromatic), 7.22-7.25(d, C’3, 5). Anal. calcd. for C13H15ClN4S. 0.2C6H14: C, 54.17;
H, 5.21; N, 18.41; Cl, 11.66; S, 10.54, Found C = 54.54%, H = 5.41%, N = 18.08%, Cl =
11.34 %, S = 10.39 %, M.P. = 93-94 ºC.
4-chloro-6-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylpyrimidin-5-amine
(152)
2-methyl-4,6-dichloro-5-aminopyrimdine

(1

g,

5.62

mmol),

6-methoxy-1,2,3,4-

tetrahydroquinoline (1.1 g, 6.74 mmol, 1.2 equiv) and catalytic amount of conc. HCl were
added to a microwave vial in 15 mL dioxane and heated at 120 ºC for 2 h. The reaction
was stopped and dioxane was stripped off and reaction mixture neutralized to pH 8. Silica
gel was added and the solvent evaporated to obtain a plug. Purification by column
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chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded a solid in 20 %
yield. TLC Rf 0.67 (EtOAc: Hex; 1:1), 1H NMR (DMSO-d6, 400MHz): δ 1.91-1.94 (t, 2H,
CH2), 2.35 (s, 3H, CH3), 2.76-2.79 (t, 2H, CH2), 3.61-3.64 (t, 2H, CH2), 3.70 (s, 3H,
4’OCH3), 4.61 (s, 2H, 5NH2), 6.28-6.31 (d, 1H, C’8 aromatic), 6.60-6.63(dd, 1H, C’7),
6.74 (s, 1H, C’5), Anal. calcd. for C15H17ClN4O: C, 59.11; H, 5.62; N, 18.38; Cl, 11.63,
Found C = 58.82%, H = 5.59%, N = 18.16%, Cl = 11.50 %, M.P. = 107-109 ºC.
6-chloro-N4-(2,3-dihydrobenzofuran-5-yl)-N4,2-dimethylpyrimidine-4,5-diamine
(153)
2-methyl-4,6-dichloro-5-aminopyrimdine (100 mg, 0.562 mmol, 1 equiv) and N-methyl2,3-dihydrobenzofuran-5-amine (0.674 mmol, 1.2 equiv) were dissolved in dioxane (5
mL). To this solution, was added 37 % HCl (cat.). The mixture was heated at 120 º C in
microwave with stirring for 2 h. Then the reaction mixture was cooled to room temperature.
Neutralization was done by the addition of NH4OH. The dioxane is then stripped off. Silica
gel was added and the solvent evaporated to obtain a plug. Purification by column
chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 70 mg (42 %) as a
light brown solid: TLC Rf = 0.45 (EtOAc: Hex, 1:1); M; 1H NMR (400 MHz, DMSO-d6):
δ 2.38 (s, 3H), 3.14-3.19 (t, J = 8.7 Hz, 2H), 3.28 (s, 3H), 3.98 (s, 2H), 4.52-4.56 (t, J = 8.7
Hz, 2H), 6.73-6.75 (d, J = 8.4 Hz, 1H), 6.82-6.84 (dd, J = 2.3 Hz, J = 8.4 Hz, 1H), 7.06 (s,
1H). Anal. calcd. for C14H15ClN4O: C, 57.83; H, 5.20; N, 19.27; Cl, 12.19, Found C =
57.74%, H = 5.20%, N = 19.21%, Cl = 12.03%, M.P. = 101.5-103.7 ºC.
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6-chloro-N4-(4-methoxyphenyl)-2-methylpyrimidine-4,5-diamine (154)
2-methyl-4,6-dichloro-5-aminopyrimdine (2 g, 11.23 mmol, 1 equiv) and the 4-methoxy
aniline (10.11 mmol, 1.25 equiv) were dissolved in butanol (15 mL). To this solution, was
added 37 % HCl (cat.). The mixture was heated at 120 ºC in microwave with stirring for
1.5 h. Then the reaction mixture was cooled to room temperature. Neutralization was done
by the addition of aq. NH4OH. The butanol is then stripped off. Silica gel was added and
the solvent evaporated to obtain a plug. Purification by column chromatography using
hexanes and ethyl acetate (10:1 to 1:2) afforded 154 (75%) as a grey solid: TLC Rf 0.42
(EtOAc: Hex, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 2.27 (s, 3H), 3.75 (s, 3H), 5.11 (s,
2H), 6.90-6.93 (d, J = 9.1 Hz, 2H), 6.59-6.62 (d, J = 9.1 Hz, 2H), 8.40 (s, 1H)
(C12H13ClN4O), Anal. calcd. for C12H13ClN4O: C, 54.45; H, 4.95; N, 21.17; Cl, 13.39;
Found C = 54.49%, H = 5.05%, N = 21.02%, Cl = 13.40%, M.P.= 170.1 °C.
6-chloro-2-methyl-N4-(4-(methylthio)phenyl)pyrimidine-4,5-diamine (155)
2-methyl-4,6-dichloro-5-aminopyrimdine (100 mg, 0.562 mmol, 1 equiv) and the 4(methylthio)aniline (0.674 mmol, 1.2 equiv) were dissolved in butanol (15 mL). To this
solution, was added 37 % HCl (cat.). The mixture was heated at 120 ºC in microwave with
stirring for 1.5 h. Then the reaction mixture was cooled to room temperature. Neutralization
was done by the addition of aq. NH4OH. The butanol is then stripped off. Silica gel was
added and the solvent evaporated to obtain a plug. Purification by column chromatography
using hexanes and ethyl acetate (10:1 to 1:2) afforded 155 (85%) as a grey solid: TLC Rf
= 0.49 (EtOAc: Hex, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 2.31 (s, 3H), 2.46 (s, 3H),
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5.12 (s, 2H), 7.25-7.27 (d, J = 8.8 Hz, 2H), 7.70-7.72 (d, J = 8.8 Hz, 2H), 8.53 (s, 1H),
Anal. calcd. for C12H13ClN4S: C, 51.33%, H, 4.67%, N, 19.95%, Cl, 12.63%, S, 11.42%,
Found C = 51.26%, H = 4.67%, N = 19.80%, Cl = 12.52%, S = 11.32%, M.P. = 209-211
ºC.
N4,N6-bis(4-methoxyphenyl)-N4,N6,2-trimethylpyrimidine-4,5,6-triamine (156)
2-methyl-4,6-dichloro-5-aminopyrimdine (1 g, 5.62 mmol), 4-methoxyaniline (1.55 g,
11.24 mmol, 2 equiv) and catalytic amount of conc. HCl were added to a microwave vial
in 15 mL dioxane and heated at 160 ºC for 3 h. The reaction was stopped and dioxane was
stripped off and reaction mixture neutralized to pH 8. Silica gel was added and the solvent
evaporated to obtain a plug. Purification by column chromatography using hexanes and
ethyl acetate (10:1 to 1:2) afforded a dark brown solid in 60 % yield. TLC Rf 0.18 (EtOAc:
Hex; 1:1) 1H NMR (DMSO-d6, 400MHz): δ 2.39 (s, 2-C 3H), 3.01 (s, NH2 2H), 3.27 (s,
4,6-N- 6H), 3.70 (s, 4’O-CH3, 6H), 6.81-6.86 (m, aromatic, 8H) Anal. calcd. for
C21H25N5O2: C, 66.47; H, 6.64; N, 18.46; Found C = 66.50%, H = 6.59%, N = 18.22%,
M.P. = 101-103 ºC.
N4,N6,2-trimethyl-N4,N6-bis(4-(methylthio)phenyl)pyrimidine-4,5,6-triamine (159)
2-methyl-4,6-dichloro-5-aminopyrimdine (1 g, 5.62 mmol), 4-methoxy N-methylaniline
(1.55 g, 11.24 mmol, 2 equiv) and catalytic amount of conc. HCl were added to a
microwave vial in 15 mL dioxane and heated at 160 ºC for 3 h. The reaction was stopped
and dioxane was stripped off and reaction mixture neutralized to pH 8. Silica gel was added
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and the solvent evaporated to obtain a plug. Purification by column chromatography using
hexanes and ethyl acetate (10:1 to 1:2) afforded a greyish solid in 32 % yield. TLC Rf 0.25
(EtOAc: Hex; 1:1), 1H NMR (DMSO-d6, 400MHz): δ 2.39 (s, 2-C 3H), 2.41 (s, 4,6-N6H), 3.32 (s, 4’O-CH3, 6H), 3.50 (s, NH2 2H), 6.73-6.78 (m, aromatic, 4H), 7.15-7.20 (m,
aromatic, 4H), Analysis calculated for C21H25N5S2: C, 61.28; H, 6.12; N, 17.02; S, 15.58,
Found C = 61.00%, H = 6.09%, N = 17.28%, S = 15.34%, M.P. -117-119 º C.
4,6-bis(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylpyrimidin-5-amine (160)

2-methyl-4,6-dichloro-5-aminopyrimdine (100 mg, 0.562 mmol, 1 equiv) and the 6methoxy-1,2,3,4-tetrahydroquinoline (0.674 mmol, 1.2 equiv) were dissolved in 1,4
dioxane (5 mL). To this solution was added 37 % HCl (2-3 drops). The mixture was heated
at 150 ºC in microwave with stirring for 2 h. Then the reaction mixture was cooled to room
temperature. Neutralization was done by the addition of NH4OH. Solvents are then stripped
off. Silica gel was added and the solvent evaporated to obtain a plug. Purification by
column chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 160 in 65%
yield as an off-white solid: TLC Rf 0.56 (EtOAc: Hex, 1:1); 1H NMR (400 MHz, DMSOd6): δ 1.94-1.97 (p, 4H), 2.32 (s, 3H), 2.79-2.82 (t, J = 6.5Hz, 3H), 3.59-3.62 (t, 4H), 3.69
(s, 6H), 3.73 (s, 2H), 6.25-6.28 (d, J = 8.8Hz, 2H) 6.62-6.65 (dd, J = 2.9Hz, J = 8.8Hz, 2H),
6.69-6.70 (d, J = 2.8Hz, 2H). Analysis calculated for C25H29N5O2. 0.1H2O: C, 69.29; H,
6.79; N, 16.16, Found C = 69.08%, H = 6.57%, N = 16.14%, M.P. = 166.5 °C.

200

N-(2,3-dihydrobenzofuran-5-yl)-N,2-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
(162)
4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine (100 mg, 0.562 mmol, 1 equiv) and Nmethyl-2,3-dihydrobenzofuran-5-amine (0.674 mmol, 1.2 equiv) were dissolved in nbutanol (5 mL). To this solution was added 37 % HCl (2-3 drops). The mixture was heated
at 150 ºC in microwave with stirring for 2 h. Then the reaction mixture was cooled to room
temperature. Neutralization was done by the addition of NH4OH. Solvents are then stripped
off. Silica gel was added and the solvent evaporated to obtain a plug. Purification by
column chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 162 in 65%
yield as an off-white solid: TLC Rf 0.90 (EtOAc: Hex, 1:1; 1H NMR (500 MHz, DMSOd6):) δ 2.44 (s, 3H), 3.18-3.20 (t, J = 8.4 Hz, 2H), 3.43 (s, 3H), 4.58-4.60 (t, J = 8.4 Hz,
2H), 4.58 (s, 1H), 6.73 (s, 1H), 6.81-6.83 (d, J = 8.2 Hz, 1H), 7.01-7.03 (d, J = 7.9 Hz, 1H),
7.20 (s, 1H), 11.26 (s, 1H). Analysis calculated for C16H16N4O: C, 68.55; H, 5.75; N, 19.99,
Found C = 68.34%, H = 5.73%, N = 19.88%, M.P. = 243-245 ºC.
N-(5-methoxypyridin-2-yl)-N,2-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (163)
4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine (100 mg, 0.562 mmol, 1 equiv) and 5methoxy-N-methylpyridin-2-amine (0.674 mmol, 1.2 equiv) were dissolved in butanol. To
this solution was added 37 % HCl (2-3 drops). The mixture was heated at 110 ºC with
stirring for 5 h. Neutralization was done by the addition of NH4OH. Solvents are then
stripped off. The resulting plug was loaded on to a silica gel column (2 × 12 cm) and eluted
with CHCl3 followed by 3% MeOH in CHCl3 and then 5% MeOH in CHCl3. Fractions
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containing the product were pooled and evaporated to afford 163 in 42% yield as a brown
solid: TLC Rf 0.75 (chloroform/methanol: 5:1); 1H NMR (400 MHz, DMSO-d6): δ 2.49
(s, 3H), δ 3.52 (s, 3H), δ 3.88 (s, 3H), 4.75 (s, 1H), 6.88 (s, 1H), 7.30 (d, J = 8.7 Hz, 1H),
7.49 (dd, J = 2.8 Hz, J = 8.7 Hz, 1H), 8.22 (d, J = 2.6Hz, 1H), 11.45 (s, 1H), Analysis
calculated for C14H15N5O. 0.25H2O: C, 61.41; H, 5.71; N, 25.58, Found C = 61.38%, H =
5.65%, N = 25.53%, M.P. = 217 -219 ºC.
N-(5-methoxynaphthalen-1-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (164)
4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine (100 mg, 0.562 mmol, 1 equiv) and 5methoxynaphthalen-1-amine (0.674 mmol, 1.2 equiv) were dissolved in n-butanol. To this
solution was added 37 % HCl (2-3 drops). The mixture was heated at 120 ºC in microwave
with stirring for 2 h. Then the reaction mixture was cooled to room temperature.
Neutralization was done by the addition of NH4OH. Solvents are then stripped off. To the
reaction mixture was added silica gel (1 g), and the solvent was evaporated reduced
pressure. The resulting plug was loaded on to a silica gel column (2 × 12 cm) and eluted
with CHCl3 followed by 3% MeOH in CHCl3 and then 5% MeOH in CHCl3. Fractions
containing the product were pooled and evaporated to afford 164 in 55% yield as a grey
solid: TLC Rf 0.50 (chloroform/methanol: 5:1); 1H NMR (400 MHz, DMSO-d6): 2.50 (s,
3H), 3.60 (s, 3H), 4.01 (s, 3H), 6.53-6.54 (m, 1H), 7.00-7.20 (d, J = 7.6Hz, 1H), 7.25-7.27
(d, J = 8.4Hz, 1H), 7.38-7.42 (m, 1H), 7.57-7.67(m, 2H), 8.29 (dd, J = 1.7Hz, J = 7.9Hz,
1H), 11.23 (s, 1H) Analysis calculated for C18H16N4O .0.105 H2O: C, 70.59; H, 5.34; N,
18.30, Found C = 70.59%, H = 5.36%, N = 18.33%, M.P. = 281-283 ºC.
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5-((2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)naphthalen-1-ol (165)
4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine (100 mg, 0.562 mmol, 1 equiv) and 5aminonaphthalen-1-ol (0.674 mmol, 1.2 equiv) were dissolved in dioxane. To this solution
was added 37 % HCl (2-3 drops). The mixture was heated at 140 ºC in microwave with
stirring for 2 h. Then the reaction mixture was cooled to room temperature. Neutralization
was done by the addition of NH4OH. Solvents are then stripped off. To the reaction mixture
was added silica gel (1 g), and the solvent was evaporated reduced pressure. The resulting
plug was loaded on to a silica gel column (2 × 12 cm) and eluted with CHCl3 followed by
3% MeOH in CHCl3 and then 5% MeOH in CHCl3. Fractions containing the product were
pooled and evaporated to afford 165 in 51% yield as a dark brown solid: TLC Rf 0.30
(chloroform/methanol: 5:1); 1H NMR (400 MHz, DMSO-d6): δ 2.35 (s, 3H), δ 5.90 (s,
1H), 6.88-6.90 (d, J = 7.3 Hz, 1H), 6.94 (s, 1H), 7.26-7.30 (t, J = 7.9 Hz, 1H), 7.45-7.49
(t, 2H), 7.60-7.61 (d, Hz, 1H), 8.06-8.08 (d, J = 8.3 Hz, 1H), 9.27 (s, 1H), 10.19 (s, 1H),
11.39 (s, 1H). Analysis calculated for C17H14N4O. 0.3H2O: C, 69.04; H, 4.98; N, 18.95,
Found C = 68.67%, H = 5.13%, N = 18.61%, M.P. = 293-295 ºC.
N-(5-methoxynaphthalen-2-yl)-N,2-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
(166)
4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine (100 mg, 0.562 mmol, 1 equiv) and 5methoxy-N-methylnaphthalen-2-amine (0.674 mmol, 1.2 equiv) were dissolved in nbutanol. To this solution was added 37 % HCl (2-3 drops). The mixture was heated at 120
ºC in microwave with stirring for 2 h. Then the reaction mixture was cooled to room
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temperature. Neutralization was done by the addition of NH4OH. Solvents are then stripped
off. To the reaction mixture was added silica gel (1 g), and the solvent was evaporated
reduced pressure. The resulting plug was loaded on to a silica gel column (2 × 12 cm) and
eluted with CHCl3 followed by 3% MeOH in CHCl3 and then 5% MeOH in CHCl3.
Fractions containing the product were pooled and evaporated to afford 166 in 65% yield as
a grey solid: TLC Rf 0.55 (chloroform/methanol: 5:1); 1H NMR (400 MHz, DMSO-d6):
2.50 (s, 3H), 3.60 (s, 3H), 4.01 (s, 3H),4.45-4.46(s, 1H), 6.69-7.00 (d, J = 7.6Hz, 1H), 7.007.02 (d, J = 8.4Hz, 1H), 7.42-7.46 (m, 3H), 7.85-7.86 (m, 1H), 8.20 (dd, J = 1.7Hz, J =
7.9Hz, 1H), 11.35 (s, 1H), Analysis calculated for C19H18N4O. 0.2H2O: C, 70.87; H, 5.76;
N, 17.40, Found C = 70.94%, H = 5.78%, N = 17.40%, M.P. = 280-282 ºC.
N,2-dimethyl-N-(4-(methylthio)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (167)
4-Chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine (100 mg, 0.562 mmol, 1 equiv) and Nmethyl-4-(methylthio)aniline (0.674 mmol, 1.2 equiv) were dissolved in n-butanol (5 mL).
To this solution was added 37 % HCl (2-3 drops). The mixture was heated at 120 ºC in
microwave with stirring for 2 h. Then the reaction mixture was cooled to room temperature.
Neutralization was done by the addition of NH4OH. Solvents were then stripped off. Silica
gel was added and the solvent evaporated to obtain a plug. Purification by column
chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 167 in 62% yield
as a white solid: TLC Rf 0.45 (EtOAc:Hex, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 2.47
(s, 3H), 2.53 (s, 3H), 3.48 (s, 3H), 4.64-4.66 (dd, J = 2Hz, J = 3.5Hz, 1H), 6.78-6.80 (dd, J
= 2.4Hz, J = 3.5Hz, 1H), 7.25-7.27 (d, 2H, J = 8.8 Hz), 7.32-7.35 (d, 2H, J = 8.8 Hz), 11.34
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(s, 1H). Analysis calculated for C15H16N4S: C, 63.35; H, 5.67; N, 19.70; S, 11.27, Found
C = 63.44%, H = 5.64%, N = 19.71%, S = 11.28%, M.P. = 155 °C.
2-(tert-butyl)-N-(4-methoxyphenyl)-N,5-dimethyloxazolo[5,4-d]pyrimidin-7-amine
(171)
Compound 122 (50 mg, 1 equiv, 0.18 mmol) was dissolved in pivalic anhydride (6 mL)
and the reaction was run at 150 ºC for 12 h. The solvent was stripped off. Silica gel was
added and the solvent evaporated to obtain a plug. Purification by column chromatography
using hexanes and ethyl acetate (10:1 to 1:2) afforded a grey solid in 60 % yield. TLC Rf
0.25 (EtOAc: Hex; 1:1); 1H NMR (CDCl3, 400MHz): δ 1.34 (s, 9H, CH3), 2.55 (s, 3H,
2CH3), 3.77 (s, 3H, 4NCH3), 3.87 (s, 3H, 4’OCH3), 6.94-6.96 (d,2H, J = 8.8 Hz), 7.22-7.25
(d,2H, J = 8.8 Hz). Analysis calculated for C18H24N4O2: C, 65.83; H, 7.26; N, 17.06; Found
C = 65.96%, H = 6.88, N = 17.08%, M.P. = 120-122 ºC.
N4,N9-bis(4-methoxyphenyl)-N4,N9,2,7-tetramethylpyrimido[4,5-g]pteridine-4,9diamine (172)
Compound 122 (500 mg, 1.79 mmol) was taken and added to benzylpotassium
trifluroboate (355 mg, 1.79 mmol, 1 equiv) in a microwave vial and cesium carbonate (2
equiv) was added in addition to tetrakistriphenylphosphine palladium (0.05 equiv) in
acetonitrile. The reaction was run for 3 hrs at 120 ºC and after the reaction was done,
acetonitrile was stripped off. Silica gel was added and the solvent evaporated to obtain a
plug. Purification by column chromatography using hexanes and ethyl acetate (10:1 to 1:2)
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afforded a red solid in 15 % yield. TLC Rf 0.25 (EtOAc: Hex; 1:1); 1H NMR (CDCl3,
400MHz): δ 2.59 (s, 6H, 2CH3), 3.89 (s, 6H, 4NCH3), 3.98 (s, 6H, 4’OCH3), 6.96-6.98 (d,
4H, J = 8.8 Hz), 7.19-7.21 (d, 4H, J = 8.8 Hz). Analysis calculated for C26H26N8O2.
0.2CH3COOC2H5: C, 64.36; H, 5.56; N, 22.40; Found C = 64.47%, H = 5.54%, N =
22.45%, M.P. = 243-245 ºC.
N4-(2-bromo-4-methoxyphenyl)-6-chloro-2-methylpyrimidine-4,5-diamine (241)
2-Methyl-4,6-dichloropyrimdine (2 g, 11.23 mmol, 1 equiv) and the 2-bromo-4-methoxy
aniline (10.11 mmol, 1.25 equiv) were dissolved in butanol (15 mL). To this solution, was
added 37 % HCl (cat.). The mixture was heated at 120 ºC in microwave with stirring for
1.5 h. Then the reaction mixture was cooled to room temperature. Neutralization was done
by the addition of aq. NH4OH. The butanol is then stripped off. Silica gel was added and
the solvent evaporated to obtain a plug. Purification by column chromatography using
hexanes and ethyl acetate (10:1 to 1:2) afforded 241 (79%) as a grey solid: TLC Rf 0.55
(EtOAc:Hex, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 2.17 (s, 3H), 3.79 (s, 3H), 5.11 (s,
2H), 6.97-7.01 (dd, 1H), 7.25-7.26 (d, J = 9.1 Hz, 2H), 7.41-7.43 (d, J = 9.1 Hz, 2H) Anal.
calcd. for C12H12BrClN4O: C, 41.95; H, 3.52; N, 16.31; Cl, 10.32; Br, 23.25, Found C =
42.08%, H = 3.58%, N = 16.15%, Cl = 10.18%, Br = 23.11%, M.P. = 135-136 ºC.
N-methyl-4-(methylthio)aniline (193)
Aniline 192 (5 g, 1 equiv) was added to a suspension of NaOMe (5 equiv) in MeOH (8-15
mL). The resulting solution was poured into a suspension of paraformaldehyde (1.4 equiv.)
in MeOH (5-10 mL). The reaction was stirred at rt for 4.5 h and then sodium borohydride
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(1.2 equiv.) was added and solution heated to reflux for 2 h. The reaction mixture was
allowed to cool to room temperature and then filtered with methanol washings. Silica gel
was added and the solvent evaporated to obtain a plug. Purification by column
chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 4.90 g (90%) as a
dark red liquid: TLC Rf 0.80 (EtOAc:Hex, 1:1); δ 1H NMR (400 MHz, DMSO-d6) δ 2.34
(s, 3H), 2.64-2.66 (d, J = 5.1 Hz, 3H), 5.72-5.73 (q, 1H), 6.50-6.52 (d, J = 8.6 Hz, 2H),
7.11-7.13 (d, J = 8.6 Hz, 2H).1H NMR matches prior synthesis.248
N-methyl-2,3-dihydrobenzofuran-5-amine (196)
Aniline 195 (1 g, 1 equiv) was added to a suspension of NaOMe (5 equiv.) in MeOH (815 mL). The resulting solution was poured into a suspension of paraformaldehyde (1.4
equiv.) in MeOH (5-10 mL). The reaction was stirred at rt for 5 h and then sodium
borohydride (1.2 equiv.) was added and solution heated to reflux for 2 h. The reaction
mixture was allowed to cool to room temp. and then filtered with methanol washings. Silica
gel was added and the solvent evaporated to obtain a plug. Purification by column
chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 0.93 g (85%) as a
brown liquid: TLC Rf 0.90 (EtOAc:Hex, 1:1; 1H NMR (DMSO-d6) δ 1H NMR (400 MHz,
DMSO-d6) δ 2.61 (s, 3H), 3.04-3.08 (t, J = 8.5 Hz, 2H), 4.36-4.40 (t, J = 8.6 Hz, 2H), 5.09
(s, 1H), 6.25-6.28 (dd, J = 2.4 Hz, J = 8.4 Hz, 1H), 6.48-6.49 (s, 1H), 6.51-6.54 (d, J = 8.5
Hz, 1H). The reaction was carried on without additional characterization.
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5-methoxy-N-methylnaphthalen-1-amine (200)
Aniline 199 (5 g, 1 equiv) was added to a suspension of NaOMe (5 equiv) in MeOH (8-15
mL). The resulting solution was poured into a suspension of paraformaldehyde (1.4 equiv.)
in MeOH (5-10 mL). The reaction was stirred at rt for 4.5 h and then sodium borohydride
(1.2 equiv.) was added and solution heated to reflux for 2 h. The reaction mixture was
allowed to cool to room temperature and then filtered with methanol washings. Silica gel
was added and the solvent evaporated to obtain a plug. Purification by column
chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded (75%) as a grey
solid: TLC Rf 0.15 (EtOAc:Hex, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 1H NMR (400
MHz, DMSO) 2.84 (d, J=4.8Hz, 3H), 3.93 (s, 3H), 6.23-6.25 (q, J = 4.5Hz, 1H), 6.44-6.46
(d, J = 7.1Hz, 1H), 6.90-6.92 (d, J = 7.6Hz, 1H), 7.26-7.33 (m, 2H), 7.37-7.39 (d, 1H),
7.64-7.66 (d, J = 8.6Hz, 1H), M.P. = 195 ºC. The reaction was carried on without additional
characterization.
Ethyl 4-hydroxybenzoate (207a)
4-Hydroxybenzoic acid (1.37 g, 10 mmol) was dissolved in a minimum amount of absolute
ethanol (15 mL). As 1 mL of concentrated sulfuric acid was added, a white suspension
formed which was vigorously stirred and refluxed for 3 h to give a clear solution. The
reaction mixture was cooled to 40 ˚C and poured into a saturated solution of sodium
bicarbonate in water (100 mL). Vigorous effervescence was observed with the precipitation
of a white solid. The precipitate was filtered and dried in air at room temperature to afford
207a (62%) as a white solid: TLC Rf = 0.80 (EtOAc:Hex, 1:1); 1H NMR (400 MHz,
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DMSO-d6): δ 1.31 (t, 3H), 4.28 (q, 2H), 7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J =
1.9 Hz, 2H). M.P. = 131 ºC. M.P. matches prior synthesis.249
Ethyl 4-((6-hydroxyhexyl)oxy)benzoate (208a)
A mixture of 207a (0.3 g, 3.2 mmol), K2CO3 (1.3 g, 9.6 mmol) and 6-bromo-hexanol (0.34
ml, 4.8 mmol) in MeCN (25 mL) was heated for 6 h at 90 ° C. The mixture was cooled to
room temperature and then H2O was added and the mixture was diluted with Et2O. The
organic layer was separated, and the aqueous layer was extracted with Et2O. The combined
organic layers were washed with brine, dried over MgSO4 and concentrated under reduced
pressure. Silica gel was added and the solvent evaporated to obtain a plug. Purification by
column chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 208a (45%)
as a liquid: TLC Rf 0.50 (EtOAc:Hex, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 1.31 (t,
3H), 1.41 (m, 2H), 1.58 (m, 2H), 1.73 (m, 2H), 2.46 (m, 2H), 3.81 (m, 2H), 4.03 (m, 2H),
4.28 (q, 2H), 7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H). Rf matches prior
synthesis.250 The reaction was carried on without additional characterization.
Ethyl 4-((6-oxohexyl)oxy)benzoate (209a)
To a solution of DMP (3.7 g, 14.4 mmol) in CH2Cl2 (14 mL) was added a solution of
208a (1.85 g, 12 mmol) in CH2Cl2 (60 mL) at 0 ° C, and the mixture was stirred for 4 hours
at room temperature. The aldehyde product was extracted with organic solvent CH2Cl2,
and the combined extracts were washed with brine, dried over anhydrous Na2SO4, and
concentrated under reduced pressure. Silica gel was added and the solvent evaporated to
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obtain a plug. Purification by column chromatography using hexanes and ethyl acetate
(10:1 to 1:2) afforded aldehyde 209a (1.64 g, 10.8 mmol) in 90% yield as a transparent oil.
TLC Rf=0.40 (10% EtOAc/hexanes).251 Fractions containing the product were pooled and
evaporated to afford (75%) as a liquid: TLC Rf 0.70 (EtOAc:Hex, 1:1); 1H NMR (400
MHz, DMSO-d6): δ 1.31 (t, 3H), 1.41 (m, 2H), 1.58 (m, 2H), 1.73 (m, 2H), 2.46 (m, 2H),
3.81 (m, 2H), 4.28 (q, 2H), 7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H),
9.67 (s, IH). The reaction was carried on without additional characterization.
Ethyl-4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)butoxy)benzoate (211a)252
To a solution of bromine (0.1 mL) –dioxane (0.3 mL) solution, 1 mL DCM was added. The
viscous solution was stirred for 10 min at 0 ° C, and then a solution of 209a (5.00 g, 37.26
mmol) in DCM was added dropwise to it at 0 ° C. The mixture was stirred at 25°C for 1 h.
After 1 h, the mixture was poured into water and extracted with DCM. The combined
organic layers were washed with brine, dried (Na2SO4) and evaporated to give the crude
title product, which was used directly in the next step reaction. To a suspension of 2,4diamino-6-hydroxypyrimidine (4.7 g, 37.26 mmol) and sodium acetate (6.11 g, 74.53
mmol) in water was added methyl 4-((5-bromo-6-oxohexyl)oxy)benzoate (210a, 7.94 g,
37.26 mmol) in DMF The reaction mixture was stirred at 40 °C for 12 h. Silica gel was
added and the solvent evaporated to obtain a plug. Purification by column chromatography
using hexanes and ethyl acetate (10:1 to 1:2) afforded 211a. (20%) as a solid: TLC Rf 0.65
(chloroform: methanol, 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.31 (t, 3H), 1.61 (m, 2H),
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1.72 (m, 2H), 2.6 (m, 2H), 3.1 (m, 2H), 4.28 (q, 2H), 7.38-7.40 (d, J = 1.9 Hz, 2H), 7.847.86 (d, J = 1.9 Hz, 2H), 8.58(s, IH), 10.3 (s, 2H), M.P. = 220-222 ºC. The reaction was
carried on without additional characterization.
4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)butyl)thio)benzoic acid (212a)
The ethyl ester of 211a (0.5 g, 0.37 mmol was hydrolyzed using 5 mL 1N sodium
hydroxide solution at room temperature for 5 hours to produce acid 212a. The pH of the
reaction mixture was reduced to 2 (acidic) using 1N HCl solution. The precipitates formed
were filtered and dried to yield 212a (88%) as a solid: TLC Rf 0.65 (chloroform: methanol,
5:1); 1H NMR (DMSO-d6) δ 1.61 (m, 2H), 1.72 (m, 2H), 2.6 (m, 2H), 3.1 (m, 2H), 7.387.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H), 8.58(s, IH), 12.5 (s, 2H), M.P. =
225-227 ºC. The reaction was carried on without additional characterization.
Diethyl(4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)butyl)thio)benzoyl)-L-glutamate (213a)
The acid 212a was coupled with commercially available L-glutamate-diethylester in the
presence of the base NMM, and CDMT to give coupled product 213a.The solvents were
stripped off, the silica was added and the resulting plug was loaded on to a silica gel column
(2 × 12 cm) and eluted with CHCl3 followed by 3% MeOH in CHCl3 and then 5% MeOH
in CHCl3.Fractions containing the product were pooled and evaporated to afford 213a
(85%) as a solid: TLC Rf = 0.5 (chloroform: methanol, 5:1); 1H NMR (400 MHz, DMSO-
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d6): δ 1.2 ( 1.61 (m, 2H), 1.72 (m, 2H), 2.6 (m, 2H), 3.1 (m, 2H), 4.0-4.01 (m, 4H), 4.394.41 (m, 1H), 7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H), 8.58(s, IH), 12.5
(s, 2H), Decomposes above 250 ºC. The reaction was carried on without additional
characterization.
(4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)butyl)thio)benzoyl)-L-glutamic acid (173)
The ethyl ester of 213a was hydrolyzed using 1 N sodium hydroxide solution at room
temperature for 5 hours to produce acid 173. The pH of the reaction mixture was reduced
to pH = 2 (acidic) using 1N HCl solution. The precipitates formed were filtered and dried
to yield final compound 173 (75%) as a solid: TLC Rf 0.5 (chloroform: methanol, 5:1); 1H
NMR (DMSO-d6) δ 1.70-1.80 (m, 4H, CH2), 1.95-1.97 (m, 1H, CH2), 2.07-2.09 (m, 1H,
CH2), 2.35 (m, 2H, CH2), 2.63 (m, 2H, CH2), 4.04 (t, 2H, OCH2), 4.39 (t, 1H, CH), 5.98
(d, 2H, 2-NH2, exch), 6.38 (s, 1H, 6-CH), 6.98-7.00 (d, 2H, Ar-CH, J = 8 Hz), 7.84−7.86
(d, 2H, Ar-CH, J = 8 Hz), 8.44-8.46 (d, 1H, Ar-CONH, J = 8 Hz, exch), 10.12 (s, 1H, 3NH, exch), 10.65 (s, 1H, 7-NH, exch), 12.38-12.41 (s, 2H, COOH, exch). Analysis
calculated for C22H25N5O7. 1.43H2O: C, 53.14; H, 5.65; N, 14.08; Found C = 53.22%, H
= 5.37%, N = 13.69%, decomposes above 250 ºC.
Ethyl 4-mercaptobenzoate (207b)
4-Mercaptobenzoic acid (1.1 g, 10 mmol was dissolved in a minimum amount of absolute
ethanol (15 mL). As 1 mL of concentrated sulfuric acid was added, a white suspension
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formed which was vigorously stirred and refluxed for 3 h to give a clear solution. The
reaction mixture was cooled to 40 ˚C and poured into a saturated solution of sodium
bicarbonate in water (100 mL). Vigorous effervescence was observed with the precipitation
of a white solid. The precipitate was filtered and dried in air at room temperature to afford
a white solid in 62 % yield. TLC Rf 0.6 (EtOAc: Hex; 1:1) TLC Rf 0.6 (CH3OH: CHCl3;
1:10) 1H NMR (400 MHz, DMSO-d6) δ7.79-7.81 (2H, d), δ7.41-7.43 (2H, d), 5.99 (1H, s),
4.29 (2H, q), 1.30 (3H, t). M.P. = 220-221 ºC. 1H NMR matches prior synthesis.253
Ethyl 4-((6-hydroxyhexyl)thio)benzoate (208b) 254

A mixture of 207a (0.3 g, 3.2 mmol), Cs2CO3 (1.3 g, 9.6 mmol) and 6-bromo-hexanol (0.34
mL, 4.8 mmol) in DMF (25 mL) was heated for 6 h at 90 ° C. The mixture was cooled to
room temperature and then H2O was added and the mixture was diluted with Et2O. The
organic layer was separated, and the aqueous layer was extracted with Et2O. The combined
organic layers were washed with brine, dried over MgSO4 and concentrated under reduced
pressure. Silica gel was added and the solvent evaporated to obtain a plug. Purification by
column chromatography using hexanes and ethyl acetate (10:1 to 1:2) afforded 208b (75%)
as a liquid: TLC Rf 0.50 (EtOAc:Hex, 1:1); 1H NMR (DMSO-d6) δ 1.31 (t, 3H), 1.41 (m,
2H), 1.58 (m, 2H), 1.73 (m, 2H), 2.46 (m, 2H), 3.81 (m, 2H), 4.03 (m, 2H), 4.28 (q, 2H),
7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H). The reaction was carried on
without additional characterization.
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Ethyl 4-((6-oxohexyl)thio)benzoate (209b)
To a solution of DMP (3.7 g, 14.4 mmol) in CH2Cl2 (14 mL) was added a solution of
208b (1.85 g, 12 mmol) in CH2Cl2 (60 mL) at 0 ° C, and the mixture was stirred for 4 hours
at room temperature. The aldehyde product was extracted with organic solvent CH2Cl2,
and the combined extracts were washed with brine, dried over anhydrous Na2SO4, and
concentrated under reduced pressure. Silica gel was added and the solvent evaporated to
obtain a plug. Purification by column chromatography using hexanes and ethyl acetate
(10:1 to 1:2) afforded aldehyde 209b (1.64 g, 10.8 mmol) in 65% yield as a transparent oil.
TLC Rf=0.40 (10% EtOAc:Hex).251 (75%) as a liquid: TLC Rf 0.70 (EtOAc:Hex, 1:1); 1H
NMR (400 MHz, DMSO-d6): δ 1.31 (t, 3H), 1.41 (m, 2H), 1.58 (m, 2H), 1.73 (m, 2H),
2.46 (m, 2H), 3.81 (m, 2H), 4.28 (q, 2H), 7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J =
1.9 Hz, 2H), 9.67 (s, IH). The reaction was carried on without additional characterization.
Ethyl-4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5l)butyl)thio)benzoate (211b) 252
To a solution of bromine (0.1 mL) –dioxane (0.3 mL) solution, 1 mL DCM was added. The
viscous solution was stirred for 10 min at 0 °C, and then a solution of 209b in DCM was
added dropwise to it (5.00 g, 37.26 mmol) at 0 °C. The mixture was stirred at 25 °C for 1
h. After 1 h, the mixture was poured into water and extracted with DCM. The combined
organic layers were washed with brine, dried (Na2SO4) and evaporated to give the crude
title product, which was used directly in
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the next step reaction. To a suspension of 2,4-diamino-6-hydroxypyrimidine (4.7 g, 37.26
mmol) and sodium acetate (6.11 g, 74.53 mmol) in water was added ethyl 4-((5-bromo-6oxohexyl)thio)benzoate (210b, 7.94 g, 37.26 mmol) in DMF The reaction mixture was
stirred at 40 °C for 12 h. To the reaction mixture was added silica gel, and the solvent was
evaporated under reduced pressure. The resulting plug was loaded on to a silica gel column
(2 × 12 cm) and eluted with CHCl3 followed by 3% MeOH in CHCl3 and then 5% MeOH
in CHCl3 afforded 211b (35%) as a solid: TLC Rf 0.65 (chloroform: methanol, 5:1); 1H
NMR (400 MHz, DMSO-d6): δ 1.31 (t, 3H), 1.61 (m, 2H), 1.72 (m, 2H), 2.6 (m, 2H), 3.1
(m, 2H), 4.28 (q, 2H), 7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H), 8.58(s,
IH), 10.3 (s, 2H). M.P. = 241-243 ºC. The reaction was carried on without additional
characterization.
4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)butyl)thio)benzoic acid (212b)
The ethyl ester of 211b was hydrolyzed using 1N sodium hydroxide solution at room
temperature for 5 hours to produce acid 212b. The pH of the reaction mixture was reduced
to 2 (acidic) using 1N HCl solution. The precipitates formed were filtered and dried to yield
final product (93%) as a solid: TLC Rf = 0.65 (chloroform: methanol, 5:11H NMR (400
MHz, DMSO-d6): δ 1.61 (m, 2H), 1.72 (m, 2H), 2.6 (m, 2H), 3.1 (m, 2H), 7.38-7.40 (d, J
= 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H), 8.58(s, IH), 12.5 (s, 2H). The reaction was
carried on without additional characterization.
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Diethyl(4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)butyl)thio)benzoyl)-L-glutamate (213b)
The acid 212b was coupled with L-glutamate-diethylester in the presence of the base
NMM, and CDMT to give coupled product 213b.The solvents were stripped off and the
plug was made using silica powder. The resulting plug was loaded on to a silica gel column
(2 × 12 cm) and eluted with CHCl3 followed by 3% MeOH in CHCl3 and then 5% MeOH
in CHCl3. Fractions with desired Rf (TLC) were pooled and evaporated to afford 213b
(65%) as a solid: TLC Rf 0.5 (chloroform: methanol, 5:1); 1H NMR (DMSO-d6) δ 1.2 (
1.61 (m, 2H), 1.72 (m, 2H), 2.6 (m, 2H), 3.1 (m, 2H), 4.0-4.01 (m, 4H), 4.39-4.41 (m, 1H),
7.38-7.40 (d, J = 1.9 Hz, 2H), 7.84-7.86 (d, J = 1.9 Hz, 2H), 8.58(s, IH), 12.5 (s, 2H).
Decomposes above 250 ºC.

The reaction was carried on without additional

characterization.
(4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)butyl)thio)benzoyl)-L-glutamic acid (174)
The ethyl ester of 213b was hydrolyzed using 1 N sodium hydroxide solution at room
temperature for 5 hours to produce acid 174. The pH of the reaction mixture was reduced
to 2 (acidic) using 1N HCl solution. The precipitates formed were filtered and dried to yield
final 174 (92%) as a solid: TLC Rf 0.5 (chloroform: methanol, 5:1); 1H NMR (DMSO-d6)
δ 1.59-1.62 (m, 1H, CH2), 1.73-1.76 (m, 1H, CH2), 1.95-1.97 (m, 1H, CH2), 2.08-2.10 (m,
1H, CH2), 2.35 (m, 2H, CH2), 2.63 (m, 2H, CH2), 3.04 (t, 2H, SCH2), 4.39 (t, 1H, CH),
6.00 (d, 2H, 2-NH2, exch), 6.36 (s, 1H, 6-CH), 7.34-7.36 (d, 2H, Ar-CH, J = 8 Hz),
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7.82−7.84 (d, 2H, Ar-CH, J = 8 Hz), 8.56-8.58 (d, 1H, Ar-CONH, J = 8 Hz, exch), 10.14
(s, 1H, 3-NH, exch), 10.65 (s, 1H, 7-NH, exch), 12.35-12.65 (s, 2H, COOH, exch).
Analysis calculated for C22H25N5O6S. 1.38H2O: C, 52.14; H, 5.39; N, 12.28; S, 5.62;
Found C = 52.10%, H = 5.48%, N = 12.17%, S = 5.93%, calculated MW = 497.23,
Decomposes above 250 ºC.
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VI. SUMMARY
This dissertation describes the design and synthesis of pyrimidine-based heterocycles as
single agents with combination chemotherapy potential. These efforts led to the
identification of structural features that are necessary for inhibition of tubulin
polymerization. Structural modifications also led to the identification of antiangiogenic
agents which inhibit one or more of the receptor tyrosine kinases (RTKs)- vascular
endothelial growth factor receptor-2, platelet derived growth factor receptor-β and
epidermal growth factor receptor. Single agents with both antiangiogenic activities as well
as cytotoxicity would afford single entities that circumvent pharmacokinetic problems of
multiple agents, avoid drug-drug interactions, could be used at lower doses to alleviate
toxicity, devoid of overlapping toxicities, and delay or prevent tumor cell resistance. This
dissertation also describes selective tumor targeting with 5-substituted pyrrolo[2,3d]pyrimidines with heteroatom bridge substitution as GARFTase inhibitors circumventing
both dose-limiting toxicity and tumor resistance associated with most prescribed antitumor
agents like pemetrexed.

The novel target compounds synthesized as part of this study are listed below:

1. 6-chloro-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (122)
2. 6-chloro-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (123)
3. 6-chloro-N4-(4-methoxyphenyl)-N4,N5,N5,2-tetramethylpyrimidine-4,5-diamine
(124)
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4. 6-chloro-N5-ethyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine
(125)
5. 6-chloro-N4-(4-methoxyphenyl)-N4,2-dimethyl-N5-propylpyrimidine-4,5-diamine
(126)
6. N5-butyl-6-chloro-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine
(127)
7. 6-chloro-N5-isobutyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine
(128)
8. 6-benzyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (130)
9. N4-(4-methoxyphenyl)-N4,2-dimethyl-6-phenethylpyrimidine-4,5-diamine (131)
10. N4-(4-methoxyphenyl)-N4,2-dimethyl-6-(phenylethynyl)pyrimidine-4,5-diamine
(132)
11. N-(4-chloro-6-((4-methoxyphenyl)(methyl)amino)-2-methylpyrimidin-5yl)acetamide (133)
12. N-acetyl-N-(4-chloro-6-((4-methoxyphenyl)(methyl)amino)-2-methylpyrimidin-5yl)acetamide (134)
13. N-(4-chloro-6-((4-methoxyphenyl)(methyl)amino)-2-methylpyrimidin-5yl)pivalamide (135)
14. 6-chloro-N-(4-methoxyphenyl)-N,2-dimethyl-5-nitropyrimidin-4-amine (136)
15. N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (137)
16. N`4-(4-methoxyphenyl)-N4,2,6-trimethylpyrimidine-4,5-diamine (138)
17. 6-ethyl-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (139)
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18. N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5,6-triamine (140)
19. 5-amino-6-((4-methoxyphenyl)(methyl)amino)-2-ethylpyrimidine-4-carbonitrile
(141)
20. 6-iodo-N4-(4-methoxyphenyl)-N4,2-dimethylpyrimidine-4,5-diamine (142)
21. N4-(4-methoxyphenyl)-N4,2-dimethyl-6-(trifluoromethyl)pyrimidine-4,5-diamine
(143)
22. 6-chloro-N4-(4-methoxyphenyl)-N4-methylpyrimidine-4,5-diamine (144)
23. 6-chloro-2-ethyl-N4-(4-methoxyphenyl)-N4-methylpyrimidine-4,5-diamine (145)
24. 6-chloro-2-ethyl-N4-(4-methoxyphenyl)-N4,N5-dimethylpyrimidine-4,5-diamine
(146)
25. 6-chloro-N5,2-diethyl-N4-(4-methoxyphenyl)-N4-methylpyrimidine-4,5-diamine
(147)
26. 6-chloro-N4-(4-methoxyphenyl)-N4-methylpyrimidine-2,4,5-triamine (148)
27. 6-chloro-N4-(4-methoxyphenyl)-N4,N5-dimethylpyrimidine-2,4,5-triamine (149)
28. 6-chloro-N5-ethyl-N4-(4-methoxyphenyl)-N4-methylpyrimidine-2,4,5-triamine
(150)
29. 6-chloro-N4,2-dimethyl-N4-(4-(methylthio)phenyl)pyrimidine-4,5-diamine (151)
30. 4-chloro-6-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylpyrimidin-5-amine
(152)

31. 6-chloro-N4-(2,3-dihydrobenzofuran-5-yl)-N4,2-dimethylpyrimidine-4,5-diamine
(153)
32. 6-chloro-N4-(4-methoxyphenyl)-2-methylpyrimidine-4,5-diamine (154)
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33. 6-chloro-2-methyl-N4-(4-(methylthio)phenyl)pyrimidine-4,5-diamine (155)
34. N4,N6-bis(4-methoxyphenyl)-N4,N6,2-trimethylpyrimidine-4,5,6-triamine (156)
35. N4,N6-bis(4-methoxyphenyl)-N4,N6,2-trimethylpyrimidine-4,5,6-triamine (157)
36. N4,N6,2-trimethyl-N4,N6-bis(4-(methylthio)phenyl)pyrimidine-4,5,6-triamine (158)
37. N4,N6,2-trimethyl-N4,N6-bis(4-(methylthio)phenyl)pyrimidine-4,5,6-triamine (159)
38. 4,6-bis(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylpyrimidin-5-amine (160)
39. N-(2,3-dihydrobenzofuran-5-yl)-N,2-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
(162)
40. N-(5-methoxypyridin-2-yl)-N,2-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (163)
41. N-(5-methoxynaphthalen-1-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (164)
42. 5-((2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)naphthalen-1-ol (165)
43. N-(5-methoxynaphthalen-2-yl)-N,2-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
(166)
44. N,2-dimethyl-N-(4-(methylthio)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (167)

45. N-(4-methoxyphenyl)-N,2,5-trimethyloxazolo[5,4-d]pyrimidin-7-amine (170)

46. 2-(tert-butyl)-N-(4-methoxyphenyl)-N,5-dimethyloxazolo[5,4-d]pyrimidin-7-amine
(171)

47. N4,N9-bis(4-methoxyphenyl)-N4,N9,2,7-tetramethylpyrimido[4,5-g]pteridine-4,9diamine (172)
48. N4-(2-bromo-4-methoxyphenyl)-6-chloro-2-methylpyrimidine-4,5-diamine
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49. (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)butoxy)benzoyl)-L-glutamic acid (173)
50. (4-((4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)butyl)thio)benzoyl)-L-glutamic acid (174)
51. (4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5yl)ethoxy)benzoyl)-L-glutamic acid (175)
52. 6-chloro-N4-(4-methoxyphenyl)-N4,N5,N5-trimethylpyrimidine-2,4,5-triamine
(188)
53. 6-chloro-N4-(4-methoxyphenyl)-N2,N4,N5,N5-tetramethylpyrimidine-2,4,5triamine (189)

7-Benzyl-pyrrolo[3,2-d]pyrimidine 129 maintained the cytotoxic antitubulin activity of
pyrrolo[3,2-d]pyrimidine 121, but also showed improved activity against VEGFR2 and 9fold improvement of antiangiogenic effects over 121. These observations are consistent
with combination chemotherapeutic potential in a single agent.180, 199
Compounds 130 and 131 were designed as open chain analogs of 129, to explore dual
antiangiogenic and microtubule properties with the potential for multikinase inhibition.
The compounds turned out to be inactive in tubulin assays. They are currently being tested
for their multikinase inhibition properties. Compound 122 is an open chain
conformationally flexible analog of 121. This was an intermediate in the synthesis of 130
and 131. Compound 122 showed potent activity against bovine tubulin assembly (IC50 =
2.1 ± 0.04 µM), and in a VEGFR2 expressing cell line, it was determined that 122 (IC50
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=33.2 nM) was 5-fold more active than 121 in this assay. Importantly, this is only 2-fold
less potent than the standard sunitinib. These results are remarkable as VEGFR2 is the
principal mediator of angiogenesis. Compound 122, an open chain monocyclic flexible
pyrimidine displayed increased dual potency in both tubulin assays.
There could be multiple reasons why 122 is more active than pyrrolo[2,3-d]pyrimidine
121. Electron withdrawing 6-chloro group in 122 is an obvious place to start an analysis.
Any electron donating group at 6-position such as OH, NH2 or an alkyl group was not
tolerated. But replacement with electron withdrawing groups at the 6-position like
trifluoromethyl or iodo, was tolerated. Another reason might be the size of the chloro
group. However, replacement of Cl with a methyl moiety was not tolerated. A third reason
might be the availability of lone pair of 5-NH2 in 122. Compared to the 121, the lone pair
of electrons at 5-NH2 in 122 may be available for hydrogen bonding as either a hydrogen
bond donor and/or acceptor. The nitrogen lone pair of compound 121 are unavailable due
to conjugation. The equivalent lone pair of 122 NH2 might be involved in conjugation with
the pyridine ring but could still form hydrogen bonds.
So, it is likely the electron withdrawing nature of the Cl, or the hydrogen bonding acceptor
properties of 5-NH2 results in improved activity compared to 121.
The effect of homologation at the N5 position of 122 on tubulin and RTK activity was
examined. Optimum chain length of the N5-substituent was determined. Compound 125
was found to be 18 nM (IC50) in β-III overexpressing HeLa cells, and 22.2 nM (IC50) in Pgp overexpressing NC/DR-Res cells. Increased lipophilicity of 125 may also permit better
penetration across cell membranes, and produce better cellular activity. Compound 125
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displayed more effective interactions with Ala316, Val315, Val181 in the tubulin site,
Leu840 and Leu1035 in the VEGFR site, Ala719 in the EGFR site, and Val665 and Phe845
in the PDGFR homology model.
Compound 125 displayed combination chemotherapeutic properties in a single agent. The
next goals could examine changes at other positions keeping the 6-Cl substitution
unchanged. Substituted anilines could be introduced at the 4-position of the pyrimidine
ring of 125 replacing the 4´-OMe aniline. The 4ʹ-thiomethyl group was the best tolerated,
and so should be examined.
Compound 125 could also be substituted with other halogens. Exploration of other electron
withdrawing groups at other positions could have favorable effects in the biological assays
examined.
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VIII. APPENDIX
APPENDIX-1
The biological evaluations of were performed by Dr. Michael Ihnat (Department of
Pharmaceutical Sciences, University of Oklahoma College of Pharmacy, Oklahoma City,
OK 73117), Dr. Ernest Hamel (Screening Technologies Branch, Developmental
Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National
Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21702), Dr.
Susan Mooberry (Department of Pharmacology, University of Texas Health Science
Center at San Antonio, San Antonio, TX 78229), National Cancer Institute (Developmental
Therapeutics Program) and Luceome Biotechnologies (1775 S. Pantano Rd, Suite 100,
Tucson, AZ 85710)
Biological evaluations
The EC50 (concentration required to cause 50% loss of cellular microtubules) was
determined in A-10 cells1. The effects of the compounds on interphase and mitotic
microtubules were evaluated using indirect immunofluorescence techniques, and the EC50
values were calculated from a minimum of three experiments.
Antiproliferative effects were evaluated against the drug sensitive MDA-MB-435
melanoma cells using sulforhodamine B assay and the IC50 values (concentration required
to cause 50% inhibition of proliferation) were calculated.
In experiments with purified tubulin, the control compound was combretastatin A4 (CSA4), a potent colchicine site agent generously supplied by Dr. G. R. Pettit, Arizona
State University, Tempe AZ. Tubulin polymerization was measured by turbidimetry at 350
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nm in Beckman DU7400 and DU7500 recording spectrophotometers equipped with
temperature controllers. In brief, 10 µM bovine brain tubulin, purified as described
previously 2, was preincubated for 15 min in a 0.24 mL volume at 30°C containing 0.75 M
monosodium glutamate (adjusted to pH 6.6 with HCl in a 2 M stock solution), varying
compound concentrations, and 4% (v/v) dimethyl sulfoxide (compound solvent).
Following the preincubation, which permits detection of activity in slow binding
compounds such as colchicinoids 3, samples were chilled on ice, and 10 µL of 10 mM GTP
was added (0.4 mM). The addition of GTP is an absolute requirement for assembly under
these reaction conditions. All concentrations refer to the final 0.25 mL reaction volume.
Samples were transferred to cuvettes held at 0°C in the recording spectrophotometers, and
the temperature was jumped to 30°C, which takes less than a minute. Assembly at 30°C
was followed for 30 min, and the compound concentration to inhibit extent of assembly
after 30 min was determined by interpolation of data obtained with individual compound
concentrations. After determining the likely range for the IC50 value, 2-4 individual
determinations were made, and the average from these determinations are presented in
Table 1.
The binding of [3H]colchicine to tubulin was performed by the DEAE-cellulose
filter technique 4 with a stack of two filters, as described in detail previously 5. In brief,
reaction mixtures contained, in a 0.10 mL volume, 1.0 µM purified tubulin, 5.0 µM
[3H]colchicine, potential inhibitor at 5.0 µM, 5% (v/v) dimethyl sulfoxide (the compound
solvent), and other components previously found to stabilize the colchicine binding activity
of tubulin for prolonged periods at 37°C 6. Incubation was at 37°C for 10 min, at which
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time samples were diluted with 2 mL of ice-cold water and poured over the DEAE-filters
under mild suction, with several rinses of the reaction vessel and of the filtration chamber.
The amount of radiolabel bound to the filters was determined by liquid scintillation
counting, and samples containing test compounds were compared to reaction mixtures
without compound. The percent inhibition relative to the control was determined for each
compound in 2-4 independent experiments.

Table 1. Effects in cellular assays and on purified tubulin
Inhibition of
Lab

% Colchicine
MDA-

Record

EC50 Microtubule

Tubulin

Binding

Assembly

inhibited at

IC50±SD

5µM

(µM)

compound

MB-435
Compd.

book
no.

Depolymerization
IC50±SD

(nM)

(nM)

concentration
130

284

-

-

>20

17 ± 0.4

131

281

-

-

>20

11 ± 3

132

280

-

-

>20

122

46

3800

160 ± 32

2.1 ± 0.04

81 ± 0.3

123

65

169

30.3 ± 4.0

1.6 ± 0.3

91 ± 0.04

124

61

-

-

2.4 ± 0.3

63 ± 1
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125

70

45

17.3 ± 1.1

1.5 ± 0.2

95 ± 2

126

90

46 ± 4

82

1.4 ± 0.2

93 ± 0.4

127

109

-

-

2.0 ± 0.2

89 ± 0.6

128

112

-

-

1.2 ± 0.05

87 ± 4

133

114

-

-

> 20

-

134

115

-

-

> 20

-

135

84

-

-

> 20

136

136

-

-

4.0 ± 0.2

137

66

-

-

11 ± 0

138

89

9400

580 ± 71

18 ± 2

139

88

> 10000

830 ± 90

> 20

140

231

-

-

> 20

141

203

-

-

> 20

142

157

5100

220 ± 15

3.4 ± 0.07

273
143

238.2 ±
6.5 µM

6.0 ± 0.1
21.4

144

140

-

-

11 ± 0.2

145

159

-

-

4.9 ± 0.6

146

159b

-

-

Inactive

147

159c

-

-

Inactive

148

142

> 10 µM

-

Inactive
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149

147

-

-

Inactive

150

149

-

--

Inactive

151

223

-

-

2.6 ± 0.03

65 ± 0.4

152

234

-

-

3.0 ± 0.2

51 ± 4

153

215

-

-

8.8 ± 0.5

154

235

-

-

> 20

155

236

-

-

16 ± 0.5

156

29

-

-

> 20

159

209

-

-

> 20

160

224

6400

195 ± 18

> 20

162

228

8 µM

550 ± 86

163

249

> 10 µM

-

164

275

> 10 µM

165

259

> 10 µM

-

166

295

365

37.1 ± 9.4

167

222

8.1 µM

198 ± 23

170

93

-

-

12 ± 0.6

172

79

-

-

> 20

0.0131

3.47 ± 0.6

1.2 ± 0.01

CSA4

247

-

98 ± 0.3

Antibodies
The PY-HRP antibody was from BD Transduction Laboratories (Franklin Lakes, NJ).
Antibodies against VEGFR-2 were purchased from Cell Signaling Technology (Danvers,
MA).

Phosphotyrosine ELISA
Cells used were tumor cell lines naturally expressing high levels of VEGFR-2 (U251).
Expression levels at the RNA level were derived from the NCI Developmental
Therapeutics Program (NCI-DTP) web site public molecular target information. Briefly,
cells at 60–75% confluence are placed in serum-free medium for 18 h to reduce the
background phosphorylation. Cells were always >98% viable by trypan blue exclusion.
Cells were then pretreated for 60 min with a dose-response relation of 100-1.4 µM
compound followed in ⅓ Log increments by 100 ng/mL VEGF for 10 min. The reaction
was stopped and cells permeabilized by quickly removing the media from the cells and
adding ice-cold Tris-buffered saline (TBS) containing 0.05% Triton X-100, protease
inhibitor cocktail and tyrosine phosphatase inhibitor cocktail. The TBS solution was then
removed and cells fixed to the plate for 30 min at 60 °C with a further incubation in 70%
ethanol for an additional 30 min. Cells were exposed to a blocking solution (TBS with 1%
BSA) for 1 h, washed, and then a horseradish peroxidase (HRP)-conjugated
phosphotyrosine (PY) antibody was added overnight. The antibody was removed, and the
cells were washed again in TBS, exposed to an enhanced luminol ELISA substrate (Pierce
Chemical EMD, Rockford, IL) and light emission was measured using a UV Products
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(Upland, CA) BioChemi digital darkroom. Data were graphed as a percent of cells
receiving growth factor alone, and IC50 values were calculated from two to three separate
experiments (n = 8–24) using non-linear regression dose-response relation analysis.

OVCAR-8, NCI/ADR-RES and HeLa cells
The OVCAR-8 and the Pgp overexpressing NCI/ADR-RES cell lines were generously
provided by the Drug Screening group of the Developmental Therapeutics Program, NCI.
The wild-type and β-III overexpressing HeLa cells were generous gifts, respectively, of
Dr. Richard F. Ludueña and Dr. Susan L. Mooberry. The OVCAR-8 and NCI/ADR-RES
cells were grown in RPMI 1640 medium with 5% fetal bovine serum at 37 °C in a 5% CO2
atmosphere for 96 h in the presence of varying compound concentrations. The HeLa cells
were grown in MEM supplemented with Earle’s salts, nonessential amino acids, 2 mM Lglutamine, and 10% fetal bovine serum at 37 °C in a 5% CO2 atmosphere for 96 h in the
presence of varying compound concentrations. In all cultures, the DMSO concentration
was 0.5%. Protein was the parameter measured by the sulforhodamine B technique,8 and
the IC50 was defined as the compound concentration causing a 50% reduction in the
increase in cell protein as compared with cultures without compound addition.

Chorioallantoic membrane assay of angiogenesis
The CAM assay is a standard assay for testing antiangiogenic agents. The CAM assay used
in these studies was modified from a procedure by Sheu and Brooks and as published
previously. Briefly, fertile leghorn chicken eggs (CBT Farms, Chestertown, MD) were
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allowed to grow until 10 days of incubation. The proangiogenic factors human VEGF-165
and bFGF (100 ng each) were then added at saturation to a 6 mm microbial testing disk
(BBL, Cockeysville, MD) and placed onto the CAM by breaking a small hole in the
superior surface of the egg. Antiangiogenic compounds were added 8 h after the
VEGF/bFGF at saturation to the same microbial testing disk and embryos allowed to
incubate for an additional 40 h. After 48 h, the CAMs were perfused with 2%
paraformaldehyde/3% glutaraldehyde containing 0.025% Triton X-100 for 20 sec, excised
around the area of treatment, fixed again in 2% paraformaldehyde/3% glutaraldehyde for
30 min, placed on Petri dishes, and a digitized image taken using a dissecting microscope
(Wild M400; Bannockburn, IL) at 7.5X and a SPOT enhanced digital imaging system
(Diagnostic Instruments, Sterling Heights, MI). A grid was then added to the digital CAM
images and the average number of vessels within 5–7 grids counted as a measure of
vascularity. Sunitinib and semaxanib were used as a positive control for antiangiogenic
activity. Data were graphed as a percent of CAMs receiving bFGF/VEGF only and IC50
values calculated from two to three separate experiments (n = 5–11) using non-linear
regression dose-response relation analysis.
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Table 2. Inhibitory data for multiple kinases
Compd.(Lab
EGFR
record book Inhibition
no)
123 (65)
335.3 ±
4.0
124 (61)
146.2 ±
18.9
125 (70)
255.6 ±
30.2
156 (29)
100.3 ±
14.8
122 (46)
415.4 ±
50.1
137 (66)
356.3 ±
52.3
139 (88)
288.4 ±
39.0
126 (90)
152.6 ±
20.4
172 (79)
23.2 ± 4.6
135 (84)
189.2 ±
23.6
127
58.2 ±
(109·HCl)
10.5
128 (112)
18.6 ± 2.1
133 (114)
134 (115)
PD153035

198.6 ±
16.6
26.0 ±
3.8
0.21 ±
0.002

Cisplatin
SU5416

Erlotinib

24.5 ±
4.0
18.5 ±
3.1
30.1 ±
4.3
10.3 ±
1.9
20.6 ±
3.1
36.2 ±
5.0
16.4 ±
2.1
19.9 ±
2.8

±

VEGFR- PDGFRA431
MDA2
β
cytotoxicity MBinhibition inhibition
231
34.2 ± 4.0
137.0
100.2
>1000
15.4 ± 2.1
193.2
98.5
40.2 ± 8.2
± 30.2
32.5 ± 5.0
227.2
193.1
47.2 ± 5.9
± 4.1
7.9 ± 1.8
227.2
108.5
33.2 ± 5.8
± 30.3
33.2 ± 4.1
121.0 ±
343.3
183.2
19.9
± 42.1
21.6 ±
109.5 ±
209.2
>1000
3.81
22.2
21.8 ± 3.6
283.1
89.4 ± 15.0 >1000
15.2 ± 2.5

183.3

30.1 ± 5.7

52.1 ± 8.2
>200

>200
>200

7.8 ± 0.9

26.3 ± 4.1

70.6 ±
10.2
103.2 ±
14.0
326.3 ±
50.3

22.7 ± 3.1
17.7±5.5

208.6 ±
28.5
32.6 ± 4.1

40.6 ± 5.0

650 ± 79.3
80.8 ± 10.7
7.6 ± 0.51
626.7 ±
105.1
8.2 ± 0.76

7.65 ± 1.4

DOX
Suntinib

CAM

172.1 ±
19.4µM
1.2 ±
0.2µM

0.041 ±
0.009
0.04 ±
0.0031
1.3 ±
0.07
29.1 ±
1.9

12.9
1.35 ± 0.03
18.9 ± 2.7
124.7 ±
18.2
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83.1 ±
10.1
12.2 ± 1.9

292.4
± 39.1

Table 3: Inhibition of growth of β-III and P-gp overexpressing cells.
Lab

β-III
WT

Record

overexpressing
HeLa

book
no.

P-gp
Parental
overexpressing
OVCAR-8

HeLa
IC50 (nM)

IC50 (nM)

NCI/DR-RES
IC50 (nM)

IC50 (nM)

130

284

-

-

> 5,000

4,400 ± 900

131

281

-

-

> 5,000

> 5,000

122

46

123

65

124

61

125

70

188 ± 24

186 ± 20

27.3 ± 3.3

35.1 ± 0.6

610 ± 20

610 ± 20

16.5 ± 2.2

18.0 ± 0.6

16.5 ± 2.2

18.0 ± 0.6

59.8 ±
17.7

60.3 ± 1.9

311 ± 15

516 ± 98

47.2 ± 8.9

67.3 ± 13.0

20.5 ± 2.7

22.2 ± 3.8

90
126
127

109

128

112

133

114

134

115

135

84

136

136
66

> 5,000

> 5,000

5000

5000

1700 ±

137

2500 ± 0
500
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20.5 ± 2.7

22.2 ± 3.8

70.4 ± 9.2

87.0 ± 3.7

63 ± 6

37 ± 10

> 10,000

> 10,000

> 10,000

> 10,000

138

89
88

2,200 ± 500

610 ± 20

> 5000

> 5000

1600 ±

139

2500 ± 0
300

140

231

141

203

142

157

144

140

145

159

151

223

152

234

153

215

154

5000

4,400 ± 900

2,300 ± 400

450 ± 70

250 ± 70

1,250 ± 0

700 ± 300

5000

310 ± 100
500 ± 100

170 ± 7
210 ± 10

3,100 ± 900

630 ± 40

235

> 5000

> 5000

155

236

> 5000

> 5000

156

29

159

209

160

224

167

222

170

93

172

79

CSA4
Paclitaxel

> 10,000

> 10,000
> 5,000
> 5,000

190 ± 19

151 ± 14

> 5,000

> 5,000

5.6 ± 0.3
1.9 ± 0.3

> 5,000
> 5,000

260 ± 26
> 5,000

440 ± 56
> 5,000

5.7 ± 0.4

6.9 ± 0.1

3.0 ± 0.3

32.9 ± 5.8

6.3 ± 0.4

1,187.2 ±
265.2
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Tubulin immunofluorescence assay
MDA-MB-435 cells were plated in chamber slides at ~30% confluency and allowed to
attach overnight. Cells were then treated with drug at the IC50 concentration for 2 h in
serum free media. After 2 h, drug was removed, cells were washed and then fixed in 3.7%
buffered formalin for 10 min. Fixed cells were then washed 3x with PBS, permeabilized
with 0.5% Triton 100-X in PBS for 10 min at RT then blocked in 10% goat serum for 30
min at RT. Slides were washed again with PBS 3x and then incubated with anti-alphatubulin Alexa Fluor® 488 (Invitrogen, Carlsbad CA) in PBS containing 10% goat serum
at a concentration of 2.5 µg/mL for 1 h at RT in the dark. After incubation, cells were
washed, chambers removed, SlowFade Gold (Molecular Probes/Invitrogen, Carlsbad CA)
added and a cover slip applied. Slides were imaged using a fluorescent microscope, Leica
DM4000 B (Wetzlar, Germany) at EX488 nm/EM519 nm.

Maximum tolerated dose in mice
To determine the maximum tolerated dose (MTD) of compounds and drugs, a dose finding
study was performed using BALBc/J mice (Jackson Laboratories, Bar Harbor, ME). Drugs
were first dissolved at 50 mg/mL in DMSO and frozen in aliquots at -80 °C. Solutol-15
(BASF, Ludwigshafen, Germany) was melted at 60 °C for 5-10 min, then mixed in a ratio
of 1 part DMSO/drug to 1.8 parts solutol-15 to 7.2 parts sterile dextrose 5% in water (D5W).
This solvent mixture was used for all drugs. Starting at 10 mg/kg and 15 mg/kg body weight
(n = 2 mice per treatment), mice were weighed and doses increased in 10 mg/kg increments
every other day until weight loss was observed. At this point the MTD was estimated to be
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the approximate dose of first weight loss. The MTD of docetaxel was found to be 35 mg/kg,
sunitinib 30 mg/kg and 126 [RM/AG-90·HCl] 50 mg/kg, temozolomide 30 mg/kg.

U251 flank xenograft model
Human U251 glioblastoma cells (500,000) in media were implanted into the lateral flank
of 8 wk old male NCr athymic nu/nu nude mice (Charles River, Wilmington, DE). Tumor
sizes (length, width, depth) were measured twice weekly. When volumes reached 75-100
mm3 (day 8 after implantation), treatment with drugs at their MTD (above) was begun and
animal weights and tumor volumes measured twice weekly. At the end of the experiment,
animals were humanely euthanized using the AALAC approved method of carbon dioxide
asphyxiation. Tumors were removed, fixed in neutral buffered formalin, paraffin
embedded, sectioned and sections stained against CD31/PECAM-1 using an antibody from
Abcam (ab28364) and staining done using a Vectastain ABC kit (Vector Laboratories,
Burlingame, CA Vessel density was assessed by counting the number of CD31-positive
vessels in a 200x microscope field in a blinded fashion and graphed as a percent vessel
density of carrier treated animals.
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Figure 1: Treatment with 126 [RM/AG-90·HCl] decreased primary tumor growth and
tumor vascular density in U251 flank xenograft mouse model. * P<0.05, ** P<0.01, ***
P<0.001 by one way ANOVA with Neuman-Keuls post test. U251 human glioma cells
were implanted into the lateral flank of NCr athymic nu/nu nude mice at 500,000 cells, and
the mice were treated with carrier temozolomide or 126 [RM/AG-90·HCl] twice weekly at
their MTD’s until the end of the experiment. Data is representative of 6-8 animals. (A)
Tumor size was determined as described in the legend of Figure 3. Statistics on this graph
were two way ANOVA with repeated measures post test. (B) Graphical representation of
percent change in animal weight as determined by measuring animal weight at the
beginning and end of experiment.
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Table 4. Cancer cell growth inhibitory activity (GI50, nM) of 126 (RM/AG-90.HCl) (NCI
60 cell line panel)
Panel/ Cell

GI50

Panel/ Cell

GI50

Panel/ Cell

line

(nM)

line

(nM)

line

GI50

Panel/

GI50

(nM) Cell line (nM)
Renal

Leukemia

Colon Cancer

Melanoma
Cancer

CCRF-CEM

43.5

COLO 205

24.8

LOX IMVI

55.6

786-0

36.5

HL-60(TB)

2.7.2

HCC-2998

35.2

M14

21.4

A498

28.8

MOLT-4

62.8

HCT-116

32.6

16.7

ACHN

83.9

66.5

CAKI-1

40.4

MDA-MB435
RPMI-8226
SR

47.7

HCT-15

31.0

SK-MEL-2

42.0

KM12

40.0

SK-MEL-28 76.5 RXF 393 25.5

SW-620

39.2

SK-MEL-5

NSCLC

33.9

SN12C

88.1

TK-10

78.3

UO-31

427

34.9
A549/ATCC

39.7

CNS Cancer

UACC-257
(µM)

HOP-62

43.6

SF-268

67.3

UACC-62

31.7

Ovarian
HOP-92

80.0

SF-295

24.6
cancer
Breast

NCI-H226

SF-539

27.3

IGROVI

168
Cancer
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NCI-H23

61.8

SNB-19

51.3

OVCAR-3

33.3

SNB-75

22.3

OVCAR-4

98.1

U251

43.3

OVCAR-5

44.6 HS 578T 36.7

OVCAR-8

46.3

BT-549

32.7

35.6

T-47D

71.7

100
NCI-H322M
(µM)
NCI-H460

36.8

MCF7

31.0

MDA40.4
MB-231/
ATCC

Prostate
NCI-H522

53.3
Cancer

NCI/ADRPC-3

44.6
RES

MDADU-145

44.8

SK-OV-3

41.0

26.4
MB-468
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APPENDIX-2
The biological evaluations of the analogs listed in the following tables were performed
by Dr. Larry H. Matherly (Developmental Therapeutics Program, Barbara Ann Karmanos
Cancer Institute and the Cancer Biology Program and Department of Pharmacology,
Wayne State University School of Medicine) against GARFTase, RFC-expressing PC4310 cells, FRα-expressing RT16 cells, FRβ-expressing D4 cells and hPCFT-expressing
R2/hPCFT4 cells.

Cell Lines and Assays of Antitumor Drug Activities. RFC- and FRR-null
MTXRIIOuaR2-4 (R2) CHO cells were gifts from Dr. Wayne Flintoff (University of
Western Ontario) and were cultured in R-minimal essential medium (MEM) supplemented
with 10% bovine calf serum (Invitrogen, Carlsbad, CA), penicillin- streptomycin solution
and L-glutamine at 37 °C with 5% CO2. PC43-10 cells are R2 cells transfected with hRFC.
RT16 cells are R2 cells transfected with human FRα, and D4 cells are R2 cells transfected
with human FRβ. R2/hPCFT4 cells were prepared by transfection of R2 cells with an
hPCFT cDNA, epitope tagged at the C-terminus with Myc-His6 (hPCFTMyc-His6) and
cloned in pCDNA3.1. All the R2 transfected cells (PC43- 10, RT16, D4, R2/hPCFT4) were
routinely cultured in R-MEM plus 1.5 mg/mL G418. Prior to the cytotoxicity assays (see
below), RT16 and D4 cells were cultured in complete folate-free RPMI1640 (without
added folate) for 3 days. KB human cervical cancer cells were purchased from the
American Type Culture Collection (Manassas, VA), whereas IGROV1 ovarian carcinoma
cells were a gift of Dr. Manohar Ratnam (Medical University of Ohio). Cells were routinely
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cultured in folate-free RPMI1640 medium, supplemented with 10% fetal bovine serum,
penicillin-streptomycin solution, and 2 mM L-glutamine at 37 °C with 5% CO2. For growth
inhibition assays, cells (CHO, KB, or IGROV1) were plated in 96 well dishes (∼25005000 cells/well, total volume of 200 µL medium) with a broad range of antifolate
concentrations. The medium was RPMI1640 (contains 2.3 µM folic acid) with 10%
dialyzed serum and antibiotics for experiments with R2 and PC43-10 cells. For RT16, D4,
KB, and IGROV1 cells, the cells were cultured in folate-free RPMI media with 10%
dialyzed fetal bovine serum (Invitrogen) and antibiotics supplemented with 2 nM LCV.
The requirement for FR mediated drug uptake in these assays was established in a parallel
incubation including 200 nM folic acid. For R2/hPCFT4 cells, the medium was folate-free
RPMI1640 (pH 7.2) containing 25 nM LCV, supplemented with 10% dialyzed fetal bovine
serum (Invitrogen) and antibiotics. Cells were routinely incubated for up to 96 h, and
metabolically active cells (a measure of cell viability) were assayed with Cell Titer-blue
cell viability assay (Promega, Madison, WI), with fluorescence measured (590 nm
emission, 560 nm excitation) using a fluorescence plate reader. Raw data were exported
from Softmax Pro software to an Excel spreadsheet for analysis and determinations of
IC50s, corresponding to the drug concentrations that result in 50% loss of cell growth. For
some of the in vitro growth inhibition studies, the inhibitory effects of the antifolate
inhibitors on de novo thymidylate biosynthesis (i.e., TS) and de novo purine biosynthesis
(GARFTase and AICARFTase) were tested by coincubations with thymidine (10 µM) and
adenosine (60 µM), respectively. For de novo purine biosynthesis, additional protection
experiments used AICA (320 µM) as a means of distinguishing inhibitory effects at
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GARFTase from those at AICARFTase. For assays of colony formation in the presence of
the antifolate drugs, KB cells were harvested and diluted, and 200 cells were plated into
60mmdishes in folate-free RPMI1640 medium supplemented with 2 nM LCV, 10%
dialyzed fetal bovine serum, penicillin-streptomycin, and 2 mM L-glutamine in the
presence of antifolate drugs. The dishes were incubated at 37 °C with 5% CO2 for 10-14
days. At the end of the incubations, the dishes were rinsed with Dulbecco’s phosphatebuffered saline (DPBS), 5%trichloroacetic acid, and borate buffer (10 mM, pH 8.8),
followed by 30 min incubation in 1% methylene blue in the borate buffer. The dishes were
rinsed with the borate buffer, and colonies were counted for calculating percent colonyforming efficiency normalized to control.

FR Binding Assay. [3H]Folic acid binding was used to assess levels of surface FRs.
Briefly, cells (e.g., RT16 or D4; ∼1.6 × 106) were rinsed twice with Dulbecco’s phosphatebuffered saline (DPBS) followed by two washes in acidic buffer (10 mM sodium acetate,
150 mM NaCl, pH 3.5) to remove FR-bound folates. Cells were washed twice with icecold HEPES-buffered saline (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, 5
mM glucose, pH 7.4; HBS), then incubated in HBS with [3H]folic acid (50 nM, specific
activity 0.5 Ci/mmol) in the presence and absence of a range of concentrations of unlabeled
folic acid or antifolate for 15 min at 0 °C. The dishes were rinsed three times with ice-cold
HBS, after which the cells were solubilized with 0.5 N sodium hydroxide and aliquots
measured for radioactivity and protein contents. Protein concentrations were measured
with Folin phenol reagent. Bound [3H]folic acid was calculated as pmol/mg protein.

261

Relative binding affinities for assorted folate/antifolate substrates were calculated as the
inverse molar ratios of unlabeled ligands required to inhibit [3H]folic acid binding by 50%.
By definition, the relative affinity of folic acid is 1.

Transport Assays. For transport assays, R2/hPCFT4, PC43- 10, and R2(VC) CHO cells
grown as monolayers were used to seed spinner flasks. For experiments to determine the
inhibitions of transport by antifolate substrates, cells were collected and washed with DPBS
and resuspended in 2 mL of physiologic Hank’s balanced salts solution (HBSS) for PC4310 cells and in HBS adjusted to pH 7.2 or 6.8 or 4-morpholinepropanesulfonic acid (MES)buffered saline (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 mM
glucose) adjusted to pH 6.5, 6.0, or 5.5 for R2/hPCFT4 cells. In either case, uptakes of
[3H]MTX (0.5 µM) were measured over 2 min at 37 °C in the presence and absence of
unlabeled antifolates (10 µM). Uptakes of [3H]MTX were quenched with ice-cold DPBS.
Cells were washed with icecold DPBS (3×) and solubilized with 0.5 N NaOH. Levels of
intracellular radioactivity were expressed as pmol/mg protein, calculated from direct
measurements of radioactivity and protein contents of cell homogenates. Protein
concentrations were measured with Folin phenol reagent. Percent MTX transport inhibition
was calculated by comparing level of [3H]MTX uptake in the presence and absence of the
inhibitors. Kinetic constants (Kt, Vmax) and Kis were calculated from Lineweaver-Burke and
Dixon plots, respectively.
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In Vitro GARFTase Enzyme Inhibition Assay. Purified recombinant mouse GARFTase
enzyme was a gift from Dr. Richard Moran (Virginia Commonwealth University,
Richmond, VA). Briefly, enzyme activity was assayed spectrophotometrically at 37 °C
using GARFTase (0.75 nM), α,β-GAR (11 µM), and coenzyme 10-formyl-5,8-dideazafolic
acid (10 µM) in HEPES buffer (75 mM, pH 7.5) with or without antifolate inhibitor (1030 000 nM). The absorbance of the reaction product, 5,8-dideazafolic acid, was monitored
at 295 nM over the first minute as a measure of the initial rate of enzyme activity. IC50s
were calculated as the concentrations of inhibitors that resulted in a 50% decrease in the
initial velocity of the GARFTase reaction.

In Situ GARFT Enzyme Inhibition Assay. Incorporation of [14C]glycine into
[14C]FGAR, as an in situ measure of endogenous GARFTase activity, was described by
Beardsley et al. and modified by Deng et al. For these experiments, KB cells were seeded
in 4 mL of complete folate-free RPMI1640 plus 2 nM LCVin 60 mm dishes at a density of
2 × 106 cells per dish. On the next day, the medium was replaced with 2 mL of fresh
complete folate-free RPMI1640 plus 2 nM LCV (without supplementing glutamine).
Azaserine (4 µM final concentration) was added in the presence and absence of the
antifolate inhibitors (0.1, 1, 10, 100, or 1000 nM). After 30 min, L-glutamine (final
concentration, 2 mM) and [14C]glycine (tracer amounts; final specific activity 0.1 mCi/L)
were added. Incubations were at 37 °C for 15 h, at which time cells were washed (onetime) with ice-cold folate-free RPMI1640 plus serum. Cell pellets were dissolved in 2mL
of 5% trichloroacetic acid at 0 °C. Cell debris was removed by centrifugation (the cell
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protein contents in the pellets were measured), and the supernatants were extracted twice
with 2 mL of ice-cold ether. The aqueous layer was passed through a 1 cm column of AG1
× 8 (chloride form), 100-200 mesh (Bio-Rad), washed with 10 mL of 0.5 N formic acid
and then 10 mL of 4 N formic acid, and finally eluted with 8 mL of 1 N HCl. The elutants
were collected and determined for radioactivity. The accumulation of radioactive FGAR
was calculated as pmol per mg protein over a range of inhibitor concentrations. IC50s were
calculated as the concentrations of inhibitors that resulted in a 50% decrease in FGAR
synthesis.

Antifolate

KB

PC43-

(nM)

10

R2

RFC/FR

(nM)

(nM)

/PCFT

RFC

Null

68

138

7.94

56.6
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R2/

RT16

D4

(nM)

(nM)

FR

FR

894

42

60

13.2

>1000

8.57

6.99

840

PCFT4
(nM)
PCFT

20.1

194.6

>1000

33.5

-

4.63

768

>1000

40.3

0.13

199.8

29.3

319

>1000

9.61

3.32

30.7

>1000

Table 1. IC50 values (nM) for 5-substituted pyrrolo[2,3-d]pyrimidine antifolates and the
clinically used classical antifolate PMX in RFC-, PCFT-, and FR-expressing Chinese
hamster ovary (CHO) cell lines and KB human tumor cells. The data shown summarize
results from 3 to 10 experiments. The results are presented as mean IC50 values
corresponding to the concentrations that inhibit growth by 50% relative to cells incubated
without drug.
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Fig. 1 Protection studies for compounds
173 (RM/AG-293) and 174 (RM/AG-306)
APPENDIX-3
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The synthetic strategy required the substituted indole 30 which was synthesized in two steps from
3-bromo-2-chloronitrobenzene 28 by a potassium t-butoxide induced displacement with
cyanoacetate to 29, followed by Zn-dust catalyzed reduction. Cyclocondensation of 30 with
chloroformamidine in methylsulfone at 120 °C for 5 h or guanidine hydrochloride in DMF under
reflux conditions did not afford 31.7
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Intermediate 3 was synthesized from commercially available 2,4-diamino-6-hydroxypyrimidine
2 and chloroacetaldehyde in sodium acetate-water solution. The cyclocondensation was
regiospecific and afforded 3 in 82% yield. The 2-amino group was pivaloyated and then
chloromercuration of 4 was carried out by adding mercuric acetate in glacial acetic acid, followed
by the addition of saturated sodium chloride solution. The precipitated white solid was
filtered and washed thoroughly with water to give a 10:1 mixture of 6chloromercuri derivative 5 and 5-chloromercuri derivative in 50% overall yield. The
resulting mixture of c h l o r o m e r c u r i d e r i v a t i v e s w a s t r e a t e d w i t h i o d i n e
i n dichloromethane to afford the corresponding 6-iodo and 5-iodo derivatives from which the
desired 6-iodo 6 was readily separated by column chromatography in 64% yield.8
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Compound 8 were readily prepared from 7 using the Vilsmeier reagent with DMF/POCl3 in 70%
yield.9 5-Arylthiophene-2-carboxylate 9 were then synthesized by reacting β-chlorovinyl aldehyde
8 with mercaptoacetate in the presence of potassium carbonate.

10

Then, two step, one pot

palladium catalyzed borylation/Suzuki coupling reaction11 was attempted with iodo 6 tilizing bisboronic acids but did not provide the desired compound 12.

The aldehyde 6 was alpha-brominated using bromine to yield 7 which was then cyclized using
commercially available 2,4-diamino-6-hydroxypyrimidine to furnish 8 which was then pivylated
to afford 9. Bromination of 9 was then attempted but did not give the desired product 10.
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Commercially available acid 2 was esterified with ethanol to afford 3 which was then alkylated
with 3-bromo-1-propanol to afford alkylated intermediate 4. The intermediate 4were then oxidized
using Dess-Martin Oxidation but gave a series of side products which could not be isolated.
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Gangjee et al. reported12 the synthesis of the pivaloyl-protected pyrrolo[2,3-d]pyrimidine 2 beore.
A Mannich reaction was carried out on 2.13 The Mannich reagent 3 was prepared by the slow
addition of 37% aqueous formaldehyde to a cold (0 °C) solution of N,N-dimethylamine in glacial
acetic acid. Compound 4 was added to the cold reagent solution, and the mixture was heated to 50
°C for 48 h to afford 5 as a crude product in 55 % yield. Compound 5 was not purified and directly
taken to next step which was hydrolysis using 1 N NaOH to afford 6. The peptide with (L)-diethyl
glutamate esters using N-methylmorpholine and 6-chloro-2,4-dimethoxytriazine as the activating
agents did not afford the final product 7.
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